fluorouracil has been researched along with Invasiveness, Neoplasm in 595 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluorouracil plus cisplatin and radiation twice a day (FCT) is an established chemoradiation (CRT) regimen for selective bladder-sparing treatment of muscle-invasive bladder cancer." | 9.30 | Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. ( Coen, JJ; Efstathiou, JA; Jani, AB; Kucuk, O; Lautenschlaeger, T; Lee, CT; Parker, W; Rodgers, JP; Sandler, HM; Saylor, PJ; Shipley, WU; Souhami, L; Wu, CL; Zhang, P; Zietman, AL, 2019) |
| "Docetaxel, cisplatin, and fluorouracil (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma and is associated with significant toxicity." | 9.20 | Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. ( Capanu, M; Henderson, C; Janjigian, YY; Kelsen, DP; Kemeny, M; Krishnamurthi, S; Mehrotra, B; Ocean, A; Ritch, P; Shah, MA; Shibata, S; Stoller, R; Su, YB, 2015) |
| "We assessed effectiveness, safety, and tolerability of paclitaxel or fluorouracil when added to radiation plus cisplatin followed by adjuvant chemotherapy in a programme of selected bladder preservation for patients with muscle invasive bladder cancer." | 9.17 | Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase ( Buyyounouski, MK; Hunt, D; Kaufman, DS; Mitin, T; Sandler, H; Shipley, WU; Uzzo, R; Wu, CL; Zietman, AL, 2013) |
| " A randomized phase 2b screening trial in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer demonstrated a significant improvement in progression-free survival (PFS) when sorafenib was added to capecitabine versus placebo (median 6." | 9.17 | A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. ( Baselga, J; Costa, F; Gomez, H; Gradishar, WJ; Hudis, CA; Petrenciuc, O; Rapoport, B; Roche, H; Schwartzberg, LS; Shan, M, 2013) |
| " A randomized, double-blind, placebo-controlled phase IIB trial assessed sorafenib with capecitabine for locally advanced or metastatic human epidermal growth factor receptor 2 (HER2) -negative breast cancer." | 9.16 | Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. ( Baselga, J; Bermejo, B; Ciruelos, EM; Costa, F; de Moraes, AA; Del Giglio, A; Durán, MÁ; Espié, M; Filho, SC; Garicochea, B; Gil Gil, M; Gómez, P; Hoff, PM; Kwon Ro, S; Li, S; Llombart, A; Mathias, C; Morales, J; Ojeda, B; Pinczowski, H; Ribeiro, RA; Roché, H; Segalla, JG; Van Eyll, B, 2012) |
| "To compare the efficacy of cediranib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor [VEGFR TKI]) with that of bevacizumab (anti-VEGF-A monoclonal antibody) in combination with chemotherapy as first-line treatment for advanced metastatic colorectal cancer (mCRC)." | 9.16 | Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). ( Barker, P; Bodoky, G; Bondarenko, I; Cunningham, D; Karapetis, CS; Kocakova, I; Koski, SL; Mainwaring, P; Mookerjee, B; Robertson, J; Rougier, P; Salazar, R; Schmoll, HJ; Sobrero, A; Van Cutsem, E, 2012) |
| " HORIZON II [Cediranib (AZD2171, RECENTIN) in Addition to Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer] assessed infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (FOLFOX/CAPOX) with or without cediranib in patients with previously untreated metastatic colorectal cancer (mCRC)." | 9.16 | Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). ( Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B, 2012) |
| "Our data indicate that second-line neoadjuvant treatment with radiation therapy and capecitabine is feasible, well tolerated, and effective in patients with locally advanced breast cancer refractory to primary anthracycline-based treatment." | 9.12 | A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer. ( Amorim, G; Arcuri, RA; Biasoli, I; Djahjah, C; Gaui, MF; Moreira, D; Pereira, G; Spector, N, 2007) |
| "A phase I/II study was performed to determine the safety and activity of a capecitabine plus oxaliplatin and irinotecan (COI) regimen using capecitabine concurrently with oxaliplatin and irinotecan in previously untreated patients with metastatic colorectal cancer." | 9.12 | Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. ( Bajetta, E; Bajetta, R; Celio, L; Colombo, A; Denaro, A; Di Bartolomeo, M; Dotti, K; Ferrario, E; Mancin, M; Pusceddu, S, 2007) |
| "We studied the usefulness of the oral 5-FU anti-cancer drug 1-hexylcarbamoyl-5-fluorouracil (HCFU) + cyclophosphamide (CPM) + tamoxifen (TAM) (HCT group) in comparison with CMF + TAM (CMFT group) in adjuvant therapy for breast cancer by a non-inferiority study based on a multi-institutional joint study." | 9.11 | 1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial. ( Abe, R; Aoyama, H; Asaga, T; Awane, H; Danno, M; Ikeda, T; Kimura, M; Koyama, H; Mitsuyama, S; Nishi, T; Ogita, M; Sano, M; Takashima, S; Takatsuka, Y; Toi, M; Tominaga, T; Wada, T; Yoshida, M, 2004) |
| "The objective of this pilot trial was to evaluate the safety and activity profile of epidoxorubicin, docetaxel and oral capecitabine plus pegfilgrastim (TEX+P) as preoperative first-line treatment for patients with breast cancer." | 9.11 | Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer. ( Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC, 2005) |
| "In a phase III trial, combining bevacizumab (BV)--a recombinant, humanized, monoclonal antibody targeting vascular endothelial growth factor--with irinotecan, bolus fluorouracil (FU), and leucovorin (LV; IFL) increased survival compared with IFL alone in first-line treatment of patients with metastatic colorectal cancer (CRC)." | 9.11 | Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. ( Berlin, J; Fehrenbacher, L; Hainsworth, JD; Hambleton, J; Heim, W; Holmgren, E; Hurwitz, HI; Kabbinavar, F; Novotny, WF, 2005) |
| "Patients with clinical stage I-IIIA breast cancer were randomly assigned to receive PST of paclitaxel doses administered either weekly (for a total of 12 doses of paclitaxel) or once every 3 weeks (four cycles), followed by four cycles of fluorouracil/doxorubicin/cyclophosphamide (FAC) in standard doses every 3 weeks." | 9.11 | Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. ( Booser, DJ; Buzdar, AU; Carter, C; Cristofanilli, M; Frye, D; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Pusztai, L; Rivera, E; Rosales, MF; Sahin, AA; Sikov, W; Smith, T; Strom, EA; Symmans, WF; Theriault, RL; Valero, V, 2005) |
| "We randomized 1,475 premenopausal women with node-positive breast cancer to three, six, or nine courses of "classical" CMF (cyclophosphamide, methotrexate, and fluorouracil)." | 9.11 | Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Ca ( Bonetti, M; Carbone, A; Castiglione-Gertsch, M; Coates, AS; Collins, J; Crivellari, D; Fey, MF; Gelber, RD; Goldhirsch, A; Golouh, R; Gruber, G; Holmberg, SB; Lindtner, J; Nasi, ML; Price, KN; Rudenstam, CM; Simoncini, E; Thürlimann, B, 2005) |
| "Capecitabine is a rationally designed oral, tumor-activated fluoropyrimidine carbamate with high activity in metastatic breast cancer." | 9.10 | Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. ( Jänicke, F; Jonat, W; Kaufmann, M; Kieback, DG; Kölbl, H; Kuhn, W; Lück, HJ; Mohrmann, S; Reichardt, P; Schindler, AE; Thuss-Patience, PC; Von Minckwitz, G, 2003) |
| "The purpose of this study was to compare the objective response rate, duration of remission, and survival of 5-fluorouracil (5-FU) versus those of 5-FU plus levamisole in metastatic colorectal cancer using the same dose and schedule of these agents as in the North Central Cancer Treatment Group and intergroup studies of adjuvant therapy." | 9.08 | Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Bandealy, MT; Einhorn, LH; Gonin, R; Loehrer, PJ; Monaco, F, 1998) |
| "Based on improved safety and efficacy results, advanced colorectal cancer (CRC) treatment has recently shifted from intravenous bolus 5-fluorouracil (5-FU) monotherapy to standard combinations of prolonged intravenous 5-FU infusion with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI)." | 8.84 | Capecitabine plus oxaliplatin for the treatment of colorectal cancer. ( Carrato, A; Gallego-Plazas, J; Guillén-Ponce, C, 2008) |
| "5-Fluorouracil (5-FU) resistance has been long considered as an obstacle to the efficacy of chemotherapy in colorectal cancer (CRC)." | 8.02 | Syndecan-2, negatively regulated by miR-20b-5p, contributes to 5-fluorouracil resistance of colorectal cancer cells via the JNK/ERK signaling pathway. ( Hua, R; Li, X; Ni, Q; Tang, D; Wang, D; Yan, X; Zhang, Y; Zhu, J, 2021) |
| "5-Fluorouracil (5-FU) is one of the most effective drugs for the treatment of colorectal cancer (CRC)." | 7.96 | Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. ( Cai, J; Li, W; Liu, Y; Ma, L; Xu, Y; Yang, Y; Zhang, Y, 2020) |
| "The first-line chemotherapy of colorectal cancer (CRC), besides surgery, comprises administration of 5-Fluorouracil (5FU)." | 7.91 | Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo. ( Cumova, A; Galanova, N; Horak, J; Hucl, T; Kostovcikova, K; Kozics, K; Macinga, P; Opattova, A; Rejhova, A; Sliva, D; Turnovcova, K; Vodenkova, S; Vodicka, P; Vodickova, L, 2019) |
| "A total of 132 women with non-metastatic breast cancer receiving FEC (5-fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), cyclophosphamide 500 mg/m(2)) were prospectively enrolled." | 7.83 | A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. ( Au, HJ; Bies, RR; Carandang, D; Cass, CE; Clemons, M; Damaraju, S; Damaraju, VL; Hanson, J; Joy, AA; King, K; Koski, S; Kuzma, M; Mackey, JR; Pituskin, E; Prado, CM; Sawyer, MB; Scarfe, AG; Smylie, M; Tonkin, K; Vos, LJ, 2016) |
| "The use of PORT was associated with improved local control in the gemcitabine era for patients with resected, node-positive, pancreatic adenocarcinoma." | 7.81 | Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. ( Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE, 2015) |
| " Herein, we investigated an alginate-based 3D scaffold for screening of 5-fluorouracil (5-FU) or/and curcumin on malignancy of colorectal cancer cells (CRC)." | 7.81 | Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. ( Buhrmann, C; Goel, A; Kraehe, P; Popper, B; Shakibaei, M; Shayan, P, 2015) |
| "To establish and characterize the gemcitabine-resistant cholangiocarcinoma (CCA) cell lines, CCA KKU‑M139 and KKU‑M214 cell lines were exposed stepwisely to increasing gemcitabine (GEM)." | 7.81 | Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. ( Boonmars, T; Hahnvajanawong, C; Jearanaikoon, P; Kanchanawat, S; Leelayuwat, C; Namwat, N; Seubwai, W; Techasen, A; Wattanawongdon, W, 2015) |
| "Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI)." | 7.81 | Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K, 2015) |
| "5-Fluorouracil (5-FU) is commonly used to treat breast cancer; however, it becomes increasingly ineffective with tumor progression." | 7.78 | Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. ( Chen, Y; Feng, M; He, Z; Pen, B; Wang, X; Yin, J; Yu, Y; Zhang, W; Zheng, G, 2012) |
| "Inhibition of TP may be beneficial in decreasing angiogenesis-dependent growth and migration of cholangiocarcinoma but may diminish the response to 5-fluorouracil chemotherapy." | 7.76 | Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. ( Jearanaikoon, P; Limpaiboon, T; Miwa, M; Pairojkul, C; Sripa, B; Tantimavanich, S; Thanasai, J, 2010) |
| "We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy." | 7.74 | [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008) |
| "A 67-year-old male diagnosed as having inoperable advanced hepatocellular carcinoma with portal invasion was able to undergo resection after continuous intra-arterial chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP)." | 7.71 | [A case of advanced hepatocellular carcinoma with portal invasion resected after treatment by continuous intra-arterial chemotherapy with cisplatin and 5-fluorouracil]. ( Furutani, S; Hara, F; Ikeda, E; Kashiyama, Y; Matsumoto, H; Mitunaga, S; Moriyama, S; Naitoh, M; Nawa, S; Ohtuka, K; Tuji, T, 2001) |
| "A 53-year-old female patient was treated with combined radiochemotherapy with 5-fluorouracil (5-FU) because of adenocarcinoma of the lung." | 7.69 | [5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?]. ( Härle, M; Jungius, KP; Maurer, U, 1996) |
| "A combined pancreatic cancer multimodality approach using CIT and radiosensitized radiotherapy is feasible and safe; delivery of immunotherapy can lead to T-cell immunity." | 6.90 | Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. ( Are, C; Berim, LD; Grem, JL; Hollingsworth, MA; Lazenby, A; Lin, C; Ly, QP; Madiyalakan, M; Meza, JL; Nicodemus, CF; Padussis, J; Schwarz, JK; Verma, V, 2019) |
| " We aimed to assess the safety, efficacy, biomarkers, and pharmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine (ECX) in patients with advanced gastric or oesophagogastric junction cancer." | 6.79 | Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. ( Anderson, A; Davidenko, I; Deptala, A; Donehower, RC; Dubey, S; Harrison, M; Iveson, T; Jiang, Y; Lakshmaiah, K; Loh, E; Nirni, S; Oliner, KS; Tang, R; Thomas, A; Tjulandin, S; Zhu, M, 2014) |
| "A total of 64 invasive breast cancer patients were recruited in the N001 Phase II, multicenter, open-label, single-arm study to receive four cycles of FEC (500, 100, 500 mg/m(2)) followed by four cycles of T (100 mg/m(2)) with concurrent CXB (200 mg b." | 6.78 | Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. ( Chow, LW; Glück, S; Im, SA; Lee, MH; Ng, TY; Toi, M; Tung, SY; Yip, AY, 2013) |
| "Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection." | 6.75 | Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. ( Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z, 2010) |
| " This study was performed to determine the efficacy and safety of irinotecan (CPT-11) in combination with fluorouracil (FU) administered as a 48-hour continuous infusion twice a month in elderly patients." | 6.71 | Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Gil, S; Maestu, I; Marcuello, E; Masutti, B; Maurel, J; Navarro, M; Sastre, J; Valladares, M; Vicent, JM, 2005) |
| "The prognosis of hepatocellular carcinoma(HCC) invading the major branches of the portal vein(Vp3 or 4) is extremely poor." | 6.41 | [Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy]. ( Monden, M; Nagano, H; Sakon, M, 2002) |
| "Chemoresistance in breast cancer is a major obstacle, especially in p53 mutation types." | 5.46 | l-arginine alters the effect of 5-fluorouracil on breast cancer cells in favor of apoptosis. ( Azadbakht, M; Jahani, M; Mansouri, K; Norooznezhad, F, 2017) |
| "Oesophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer-associated death in the world and novel therapeutic alternatives are urgently warranted." | 5.43 | Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. ( Bai, L; Chen, DL; Chen, LZ; Ju, HQ; Lu, YX; Mo, HY; Sheng, H; Wang, DS; Wang, F; Wu, QN; Xie, D; Xu, RH; Yu, HE; Yun, JP; Zeng, ZL, 2016) |
| "Because the serum concentration of 5-FU fluctuates and displays various patterns, the dosage should not be based on body surface area." | 5.42 | Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. ( Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A, 2015) |
| "The prognosis in advanced hepatocellular carcinoma (HCC) with multiple intrahepatic metastases is extremely poor." | 5.39 | Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study. ( Endo, I; Kumamoto, T; Matsuo, K; Nakagawa, K; Taguri, M; Tanaka, K; Yabushita, Y, 2013) |
| "We encountered a case of colorectal cancer with pelvic abscess treated with radical surgery following colostomy and chemotherapy." | 5.39 | [A case of locally advanced colorectal cancer with abscess responding to 5-fluorouracil, leucovorin, and oxaliplatin plus bevacizumab]. ( Goseki, N; Kuwabara, H; Liu, B; Mitsuoka, A; Nakajima, K; Sanada, T; Watanabe, S, 2013) |
| "Endoscopic findings showed Type 3 gastric cancer with pyloric stenosis." | 5.34 | [A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil]. ( Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E, 2007) |
| "Microsatellite instability is a recognised pathway of colorectal carcinogenesis responsible for about 15% of all sporadic colorectal cancers." | 5.33 | 5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer. ( Kaufman, A; Ramanathan, P; Robinson, BG; Schnitzler, M; Warusavitarne, J, 2006) |
| "Fluorouracil plus cisplatin and radiation twice a day (FCT) is an established chemoradiation (CRT) regimen for selective bladder-sparing treatment of muscle-invasive bladder cancer." | 5.30 | Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. ( Coen, JJ; Efstathiou, JA; Jani, AB; Kucuk, O; Lautenschlaeger, T; Lee, CT; Parker, W; Rodgers, JP; Sandler, HM; Saylor, PJ; Shipley, WU; Souhami, L; Wu, CL; Zhang, P; Zietman, AL, 2019) |
| "Patients with metastatic adenocarcinoma of the pancreas or biliary tract, previously untreated or having received 1 cytotoxic regimen for advanced disease, were treated with gemcitabine 1000 mg/m intravenously (IV) over 100 minutes, cisplatin 35 mg/m IV over 30 minutes, and 5-FU 2400 mg/m IV over 48 hours on day 1 of a 14-day cycle." | 5.27 | A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. ( Davis, EJ; Griffith, KA; Kim, EJ; McDonnell, KJ; Ruch, JM; Zalupski, MM, 2018) |
| "This was a randomized controlled trial of 155 patients with stage pT3-4p N1-3c M0 or pAnyT pN2-3c M0 breast cancer undergoing 5-fluorouracil+epirubicin+cyclophosphamide followed by docetaxel (FEC-D) chemotherapy after mastectomy and axillary dissection." | 5.24 | Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer. ( Chen, D; Huang, H; Lu, Y; Yang, H, 2017) |
| "Docetaxel, cisplatin, and fluorouracil (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma and is associated with significant toxicity." | 5.20 | Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. ( Capanu, M; Henderson, C; Janjigian, YY; Kelsen, DP; Kemeny, M; Krishnamurthi, S; Mehrotra, B; Ocean, A; Ritch, P; Shah, MA; Shibata, S; Stoller, R; Su, YB, 2015) |
| "Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (FOLFIRI) is unknown." | 5.19 | FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. ( Al-Batran, SE; Decker, T; Heinemann, V; Heintges, T; Hielscher, J; Höffkes, HG; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerchenmüller, C; Lindig, RU; Link, H; Modest, DP; Moehler, M; Müller, S; Niederle, N; Rossius, L; Rost, A; Scheithauer, W; Scholz, M; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF, 2014) |
| "We assessed effectiveness, safety, and tolerability of paclitaxel or fluorouracil when added to radiation plus cisplatin followed by adjuvant chemotherapy in a programme of selected bladder preservation for patients with muscle invasive bladder cancer." | 5.17 | Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase ( Buyyounouski, MK; Hunt, D; Kaufman, DS; Mitin, T; Sandler, H; Shipley, WU; Uzzo, R; Wu, CL; Zietman, AL, 2013) |
| " A randomized phase 2b screening trial in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer demonstrated a significant improvement in progression-free survival (PFS) when sorafenib was added to capecitabine versus placebo (median 6." | 5.17 | A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. ( Baselga, J; Costa, F; Gomez, H; Gradishar, WJ; Hudis, CA; Petrenciuc, O; Rapoport, B; Roche, H; Schwartzberg, LS; Shan, M, 2013) |
| "Sequential doxorubicin/paclitaxel (AT) followed by CMF treatment was shown to be an active neoadjuvant chemotherapy regimen in the first European Cooperative Trial in Operable Breast Cancer (ECTO I trial)." | 5.16 | Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). ( Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M, 2012) |
| " A randomized, double-blind, placebo-controlled phase IIB trial assessed sorafenib with capecitabine for locally advanced or metastatic human epidermal growth factor receptor 2 (HER2) -negative breast cancer." | 5.16 | Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. ( Baselga, J; Bermejo, B; Ciruelos, EM; Costa, F; de Moraes, AA; Del Giglio, A; Durán, MÁ; Espié, M; Filho, SC; Garicochea, B; Gil Gil, M; Gómez, P; Hoff, PM; Kwon Ro, S; Li, S; Llombart, A; Mathias, C; Morales, J; Ojeda, B; Pinczowski, H; Ribeiro, RA; Roché, H; Segalla, JG; Van Eyll, B, 2012) |
| "Synchronous chemotherapy with fluorouracil and mitomycin C combined with radiotherapy significantly improved locoregional control of bladder cancer, as compared with radiotherapy alone, with no significant increase in adverse events." | 5.16 | Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. ( Crundwell, M; Hall, E; Hendron, C; Huddart, RA; Hussain, SA; James, ND; Jenkins, P; Lewis, R; Rawlings, C; Sizer, B; Sreenivasan, T; Tremlett, J; Waters, R, 2012) |
| "To compare the efficacy of cediranib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor [VEGFR TKI]) with that of bevacizumab (anti-VEGF-A monoclonal antibody) in combination with chemotherapy as first-line treatment for advanced metastatic colorectal cancer (mCRC)." | 5.16 | Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). ( Barker, P; Bodoky, G; Bondarenko, I; Cunningham, D; Karapetis, CS; Kocakova, I; Koski, SL; Mainwaring, P; Mookerjee, B; Robertson, J; Rougier, P; Salazar, R; Schmoll, HJ; Sobrero, A; Van Cutsem, E, 2012) |
| " HORIZON II [Cediranib (AZD2171, RECENTIN) in Addition to Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer] assessed infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (FOLFOX/CAPOX) with or without cediranib in patients with previously untreated metastatic colorectal cancer (mCRC)." | 5.16 | Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). ( Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B, 2012) |
| "Patients suffering from locally-advanced (T3-4 any N M0 or any T N1-3 M0) gastric carcinoma, staged with endoscopic ultrasound, bone scan, computed tomography, and laparoscopy, were assigned to receive four 21 d/cycles of TCF (docetaxel 75 mg/m(2) day 1, cisplatin 75 mg/m(2) day 1, and fluorouracil 300 mg/m(2) per day for days 1-14), either before (Arm A) or after (Arm B) gastrectomy." | 5.14 | Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. ( Andreoni, B; Biffi, R; Bonomo, G; Chiappa, A; Crosta, C; Fazio, N; Fiori, G; Huber, O; Luca, F; Orsi, F; Roth, A; Schuller, JC; Zampino, MG, 2010) |
| "Patients with nonkeratinizing nasopharyngeal carcinoma staged T1-4N2-3M0 were randomly assigned to RT (176 patients) or to CRT (172 patients) using cisplatin (100 mg/m(2)) every 3 weeks for three cycles in concurrence with radiotherapy, followed by cisplatin (80 mg/m(2)) plus fluorouracil (1000 mg per m(2) per day for 4 days) every 4 weeks for three cycles." | 5.14 | Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. ( Au, GK; Au, JS; Chappell, R; Choi, CW; Chua, DT; Fung, KK; Lau, JT; Lau, WH; Law, SC; Lee, AW; Leung, TW; Ng, WT; Ngan, RK; O'Sullivan, B; Siu, L; Sze, WK; Sze, WM; Tung, R; Tung, SY; Yau, TK, 2010) |
| "Our data indicate that second-line neoadjuvant treatment with radiation therapy and capecitabine is feasible, well tolerated, and effective in patients with locally advanced breast cancer refractory to primary anthracycline-based treatment." | 5.12 | A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer. ( Amorim, G; Arcuri, RA; Biasoli, I; Djahjah, C; Gaui, MF; Moreira, D; Pereira, G; Spector, N, 2007) |
| "A phase I/II study was performed to determine the safety and activity of a capecitabine plus oxaliplatin and irinotecan (COI) regimen using capecitabine concurrently with oxaliplatin and irinotecan in previously untreated patients with metastatic colorectal cancer." | 5.12 | Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. ( Bajetta, E; Bajetta, R; Celio, L; Colombo, A; Denaro, A; Di Bartolomeo, M; Dotti, K; Ferrario, E; Mancin, M; Pusceddu, S, 2007) |
| "We conducted a phase I/II study investigating synchronous chemoradiotherapy with mitomycin C and infusional 5-fluorouracil (5-FU) in muscle invasive bladder cancer." | 5.11 | Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Peake, DR; Stocken, DD; Wallace, DM; Zarkar, A, 2004) |
| "We studied the usefulness of the oral 5-FU anti-cancer drug 1-hexylcarbamoyl-5-fluorouracil (HCFU) + cyclophosphamide (CPM) + tamoxifen (TAM) (HCT group) in comparison with CMF + TAM (CMFT group) in adjuvant therapy for breast cancer by a non-inferiority study based on a multi-institutional joint study." | 5.11 | 1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial. ( Abe, R; Aoyama, H; Asaga, T; Awane, H; Danno, M; Ikeda, T; Kimura, M; Koyama, H; Mitsuyama, S; Nishi, T; Ogita, M; Sano, M; Takashima, S; Takatsuka, Y; Toi, M; Tominaga, T; Wada, T; Yoshida, M, 2004) |
| "The objective of this pilot trial was to evaluate the safety and activity profile of epidoxorubicin, docetaxel and oral capecitabine plus pegfilgrastim (TEX+P) as preoperative first-line treatment for patients with breast cancer." | 5.11 | Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer. ( Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC, 2005) |
| "In a phase III trial, combining bevacizumab (BV)--a recombinant, humanized, monoclonal antibody targeting vascular endothelial growth factor--with irinotecan, bolus fluorouracil (FU), and leucovorin (LV; IFL) increased survival compared with IFL alone in first-line treatment of patients with metastatic colorectal cancer (CRC)." | 5.11 | Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. ( Berlin, J; Fehrenbacher, L; Hainsworth, JD; Hambleton, J; Heim, W; Holmgren, E; Hurwitz, HI; Kabbinavar, F; Novotny, WF, 2005) |
| "Patients with clinical stage I-IIIA breast cancer were randomly assigned to receive PST of paclitaxel doses administered either weekly (for a total of 12 doses of paclitaxel) or once every 3 weeks (four cycles), followed by four cycles of fluorouracil/doxorubicin/cyclophosphamide (FAC) in standard doses every 3 weeks." | 5.11 | Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. ( Booser, DJ; Buzdar, AU; Carter, C; Cristofanilli, M; Frye, D; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Pusztai, L; Rivera, E; Rosales, MF; Sahin, AA; Sikov, W; Smith, T; Strom, EA; Symmans, WF; Theriault, RL; Valero, V, 2005) |
| "We randomized 1,475 premenopausal women with node-positive breast cancer to three, six, or nine courses of "classical" CMF (cyclophosphamide, methotrexate, and fluorouracil)." | 5.11 | Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Ca ( Bonetti, M; Carbone, A; Castiglione-Gertsch, M; Coates, AS; Collins, J; Crivellari, D; Fey, MF; Gelber, RD; Goldhirsch, A; Golouh, R; Gruber, G; Holmberg, SB; Lindtner, J; Nasi, ML; Price, KN; Rudenstam, CM; Simoncini, E; Thürlimann, B, 2005) |
| "Capecitabine is a rationally designed oral, tumor-activated fluoropyrimidine carbamate with high activity in metastatic breast cancer." | 5.10 | Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. ( Jänicke, F; Jonat, W; Kaufmann, M; Kieback, DG; Kölbl, H; Kuhn, W; Lück, HJ; Mohrmann, S; Reichardt, P; Schindler, AE; Thuss-Patience, PC; Von Minckwitz, G, 2003) |
| "The purpose of this study was to compare the objective response rate, duration of remission, and survival of 5-fluorouracil (5-FU) versus those of 5-FU plus levamisole in metastatic colorectal cancer using the same dose and schedule of these agents as in the North Central Cancer Treatment Group and intergroup studies of adjuvant therapy." | 5.08 | Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Bandealy, MT; Einhorn, LH; Gonin, R; Loehrer, PJ; Monaco, F, 1998) |
| "Based on improved safety and efficacy results, advanced colorectal cancer (CRC) treatment has recently shifted from intravenous bolus 5-fluorouracil (5-FU) monotherapy to standard combinations of prolonged intravenous 5-FU infusion with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI)." | 4.84 | Capecitabine plus oxaliplatin for the treatment of colorectal cancer. ( Carrato, A; Gallego-Plazas, J; Guillén-Ponce, C, 2008) |
| "5-Fluorouracil (5-FU) resistance has been long considered as an obstacle to the efficacy of chemotherapy in colorectal cancer (CRC)." | 4.02 | Syndecan-2, negatively regulated by miR-20b-5p, contributes to 5-fluorouracil resistance of colorectal cancer cells via the JNK/ERK signaling pathway. ( Hua, R; Li, X; Ni, Q; Tang, D; Wang, D; Yan, X; Zhang, Y; Zhu, J, 2021) |
| "5-Fluorouracil (5-FU) is one of the most effective drugs for the treatment of colorectal cancer (CRC)." | 3.96 | Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. ( Cai, J; Li, W; Liu, Y; Ma, L; Xu, Y; Yang, Y; Zhang, Y, 2020) |
| "Metronomic chemotherapy using the 5-FU prodrug uracil-tegafur (UFT) and cyclophosphamide (CTX) was previously shown to only modestly delay primary tumor growth, but nevertheless markedly suppressed the development of micro-metastasis in an orthotopic breast cancer xenograft model, using the metastatic variant of the MDA-MB-231 cell line, 231/LM2-4." | 3.91 | Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. ( Cruz-Muñoz, W; Hileeto, D; Kerbel, RS; Man, S; Muñoz, R; Viloria-Petit, A; Wood, GA; Xu, P, 2019) |
| "The first-line chemotherapy of colorectal cancer (CRC), besides surgery, comprises administration of 5-Fluorouracil (5FU)." | 3.91 | Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo. ( Cumova, A; Galanova, N; Horak, J; Hucl, T; Kostovcikova, K; Kozics, K; Macinga, P; Opattova, A; Rejhova, A; Sliva, D; Turnovcova, K; Vodenkova, S; Vodicka, P; Vodickova, L, 2019) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic agent commonly used to treat esophageal squamous cell carcinoma (ESCC), but acquisition of chemoresistance frequently occurs and the underlying mechanisms are not fully understood." | 3.91 | MicroRNA-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id-1. ( Chan, KT; Chan, KW; Cheung, ALM; Cui, D; Guan, XY; Han, L; Lam, AKY; Law, SYK; Lee, NPY; Li, B; Ma, S; Qin, YR; Tsao, SW; Xu, WW; Zhu, Y, 2019) |
| "To investigate the possibility of enhancing an anti-metastatic effect of 5-fluorouracil (5-FU) on colorectal cancer (CRC) cells by combining it with continuous calcium supplementation." | 3.85 | Synergistically Anti-metastatic Effect of 5-Flourouracil on Colorectal Cancer Cells via Calcium-mediated Focal Adhesion Kinase Proteolysis. ( Jeong, KY; Kim, HM; Park, M; Sim, JJ; Sundaramoorthy, P, 2017) |
| "A total of 132 women with non-metastatic breast cancer receiving FEC (5-fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), cyclophosphamide 500 mg/m(2)) were prospectively enrolled." | 3.83 | A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. ( Au, HJ; Bies, RR; Carandang, D; Cass, CE; Clemons, M; Damaraju, S; Damaraju, VL; Hanson, J; Joy, AA; King, K; Koski, S; Kuzma, M; Mackey, JR; Pituskin, E; Prado, CM; Sawyer, MB; Scarfe, AG; Smylie, M; Tonkin, K; Vos, LJ, 2016) |
| "First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA) compared with gemcitabine." | 3.81 | FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. ( Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I, 2015) |
| " Herein, we report that NPs conjugated with antibody against GRP78 (mAb GRP78-NPs) inhibit the adhesion, invasion, and metastasis of hepatocellular carcinoma (HCC) and promote drug delivery of 5-fluorouracil into GRP78 high-expressed human hepatocellular carcinoma cells." | 3.81 | Nanoparticles inhibit cancer cell invasion and enhance antitumor efficiency by targeted drug delivery via cell surface-related GRP78. ( Li, H; Liu, L; Shi, Y; Su, C; Su, R; Wang, G; Zhao, L, 2015) |
| "The use of PORT was associated with improved local control in the gemcitabine era for patients with resected, node-positive, pancreatic adenocarcinoma." | 3.81 | Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. ( Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE, 2015) |
| " Herein, we investigated an alginate-based 3D scaffold for screening of 5-fluorouracil (5-FU) or/and curcumin on malignancy of colorectal cancer cells (CRC)." | 3.81 | Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. ( Buhrmann, C; Goel, A; Kraehe, P; Popper, B; Shakibaei, M; Shayan, P, 2015) |
| "To establish and characterize the gemcitabine-resistant cholangiocarcinoma (CCA) cell lines, CCA KKU‑M139 and KKU‑M214 cell lines were exposed stepwisely to increasing gemcitabine (GEM)." | 3.81 | Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. ( Boonmars, T; Hahnvajanawong, C; Jearanaikoon, P; Kanchanawat, S; Leelayuwat, C; Namwat, N; Seubwai, W; Techasen, A; Wattanawongdon, W, 2015) |
| "Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI)." | 3.81 | Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K, 2015) |
| "Despite the use of 5-fluorouracil (5-FU)-based adjuvant treatments, a large proportion of patients with high-risk stage II/III colorectal cancer will relapse." | 3.80 | AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. ( Arthur, K; Blayney, JK; Dunne, PD; Greer, S; Johnston, PG; Kalimutho, M; Longley, DB; Loughrey, M; McArt, DG; Ong, CW; Redmond, K; Salto-Tellez, M; Srivastava, S; Van Schaeybroeck, S; Wang, T, 2014) |
| " We examined the effects of celecoxib, a COX-2 inhibitor, in enhancing the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma (ESCC) by reducing the COX-2 activity." | 3.80 | A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. ( Akanuma, N; Akutsu, Y; Hanari, N; Hoshino, I; Hu, X; Isozaki, Y; Komatsu-Akimoto, A; Matsubara, H; Mori, M; Mutallip, M; Qin, W; Yusup, G, 2014) |
| "5-Fluorouracil (5-FU) is commonly used to treat breast cancer; however, it becomes increasingly ineffective with tumor progression." | 3.78 | Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. ( Chen, Y; Feng, M; He, Z; Pen, B; Wang, X; Yin, J; Yu, Y; Zhang, W; Zheng, G, 2012) |
| "Inhibition of TP may be beneficial in decreasing angiogenesis-dependent growth and migration of cholangiocarcinoma but may diminish the response to 5-fluorouracil chemotherapy." | 3.76 | Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. ( Jearanaikoon, P; Limpaiboon, T; Miwa, M; Pairojkul, C; Sripa, B; Tantimavanich, S; Thanasai, J, 2010) |
| " This study aimed to assess the range of gene copies per nucleus of thymidylate synthase (TYMS), thymidine phosphorylase (TP) and dihydrofolate reductase (DHFR) in colorectal cancer, and to evaluate its prognostic significance following adjuvant chemotherapy, since these enzymes are closely related to efficacy of 5-fluorouracil (5FU)." | 3.74 | Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer. ( Jensen, SA; Jørgensen, JT; Sørensen, JB; Vainer, B; Witton, CJ, 2008) |
| " We used a fibrin-thrombin clot-based angiogenesis model to evaluate the angiogenic response of human breast cancer to various cytotoxic agents commonly used in its treatment." | 3.74 | A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer. ( Anthony, CT; Lyons, JM; Thomson, JL; Woltering, EA, 2008) |
| "We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy." | 3.74 | [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008) |
| "A 67-year-old male diagnosed as having inoperable advanced hepatocellular carcinoma with portal invasion was able to undergo resection after continuous intra-arterial chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP)." | 3.71 | [A case of advanced hepatocellular carcinoma with portal invasion resected after treatment by continuous intra-arterial chemotherapy with cisplatin and 5-fluorouracil]. ( Furutani, S; Hara, F; Ikeda, E; Kashiyama, Y; Matsumoto, H; Mitunaga, S; Moriyama, S; Naitoh, M; Nawa, S; Ohtuka, K; Tuji, T, 2001) |
| "Gemcitabine and capecitabine are nucleoside analogues used in chemotherapy strategies for the treatment of breast cancer." | 3.71 | Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. ( Baldwin, SA; Cass, CE; Clarke, ML; Coupland, RW; Dabbagh, L; Jennings, LL; Koski, SL; Mackey, JR; Santos, CL; Vsianska, M; Young, JD, 2002) |
| " We examined TP expression using immunohistochemistry (654-1 Mab) in 182 invasive breast carcinomas (67 N0 and 115 N1/2; median follow-up 78 months [range, 3-177]; 51 patients treated with adjuvant systemic cyclophosphamide, methotrexate and 5-fluorouracil [CMF] chemotherapy and 82 with tamoxifen)." | 3.71 | Prognostic value of thymidine phosphorylase expression in breast carcinoma. ( Barbareschi, M; Caffo, O; Dalla Palma, P; Galligioni, E; Kakudo, K; Mauri, F; Mori, I; Muscarà, M; Nakamura, M; Nakamura, Y; Sakurai, T; Yang, Q; Yoshimura, G, 2002) |
| "Sixteen patients with rectal adenocarcinoma up to 3 cm above the pectineal line with initial indications for abdominoperineal resection (APR) were submitted to a 5040-cGy (28 x 180 cGy) radiotherapy dose and chemotherapy during the first 3 and last 3 days of radiotherapy, using 425 mg/m2/day of 5-fluorouracil (5FU) and 20 mg/m2/day of folinic acid." | 3.70 | Radiation and chemotherapy instead of surgery for low infiltrative rectal adenocarcinoma: a prospective trial. ( Filho, WD; Lopes, A; Nakagawa, WT; Novaes, PE; Rossi, BM, 1998) |
| "Concurrent 2-drug chemoradiotherapy with cisplatin and 5-fluorouracil is feasible without major toxicity and offers a potentially curative and conservative treatment for patients with localized muscle-invasive bladder cancer." | 3.70 | [Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study]. ( Berger, C; Chauvet, B; Davin, JL; Félix-Faure, C; Reboul, F; Vincent, P, 1998) |
| "A 53-year-old female patient was treated with combined radiochemotherapy with 5-fluorouracil (5-FU) because of adenocarcinoma of the lung." | 3.69 | [5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?]. ( Härle, M; Jungius, KP; Maurer, U, 1996) |
| "To improve the results obtained by cystectomy alone and to determine the possibilities of conservative treatment in invasive bladder cancer, we designed a prospective study using a combination of fluorouracil (5-FU) plus cisplatin and concomitant radiation therapy, followed by either cystectomy or additional chemoradiotherapy." | 3.68 | Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. ( Baillet, F; Brunel, P; Chretien, Y; Colardelle, F; Delanian, S; Dufour, B; Housset, M; Huart, J; Maulard, C, 1993) |
| "We report 5 cases of invasive squamous cell bladder cancer treated with preoperative mitomycin C and 5-fluorouracil in combination with preoperative external beam radiation therapy (the Nigro regimen), and the subsequent apparent cure of 3 of the 5 patients." | 3.67 | A new treatment for invasive squamous cell bladder cancer: the Nigro regimen: preoperative chemotherapy and radiation therapy. ( Gee, WF; Medina, WD; Mendiondo, OA; Patterson, JM; Ray, EH, 1988) |
| " Adenocarcinoma related to diethylstilbestrol exposure in utero is a recently recognized type of vaginal lesion, and melanoma and sarcoma occur rarely in the vagina." | 3.66 | Malignant tumors of the vagina. Classification and approach to treatment. ( Gerbie, MV, 1983) |
| "Patients with locally advanced rectal cancer will be randomized to receive PCRT followed by TME and adjuvant chemotherapy (arm A) or upfront radical surgery with TME followed by adjuvant FOLFOX chemotherapy (arm B)." | 2.94 | Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. ( Ahn, JB; Baek, JH; Beom, SH; Chang, JS; Hur, H; Jeong, SY; Jung, I; Kim, HS; Kim, NK; Kim, SH; Kim, TI; Koom, WS; Lee, JB; Lee, KY; Lim, JS; Min, BS; Park, S; Shin, SJ, 2020) |
| "A combined pancreatic cancer multimodality approach using CIT and radiosensitized radiotherapy is feasible and safe; delivery of immunotherapy can lead to T-cell immunity." | 2.90 | Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. ( Are, C; Berim, LD; Grem, JL; Hollingsworth, MA; Lazenby, A; Lin, C; Ly, QP; Madiyalakan, M; Meza, JL; Nicodemus, CF; Padussis, J; Schwarz, JK; Verma, V, 2019) |
| "A radical rectal cancer surgery was performed 6 to 8 weeks after the simultaneous chemoradiotherapy." | 2.90 | Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer. ( Chen, J; Dai, G; Du, X; Feng, L; Jia, B; Liu, H; Liu, Q; Wang, Y; Wen, K; Yang, Y; Zeng, M; Zhu, Y, 2019) |
| "3%), and 201 completed the treatment (early discontinuation was mainly due to intercurrent adverse events [AEs], 7." | 2.87 | Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. ( Bengala, C; Bisagni, G; Brandes, AA; Cagossi, K; Gianni, L; Gori, S; Iannacone, C; Montemurro, F; Morandi, P; Stell, A; Zamagni, C; Zambetti, M, 2018) |
| "Inoperable oral cavity squamous cell carcinoma (SCC) is a highly invasive disease associated with the extensive destruction of locoregional tissues and a dismal prognosis." | 2.84 | Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study. ( Chang, PM; Chen, MH; Chu, PY; Lu, HJ; Tai, SK; Wang, LW; Yang, MH, 2017) |
| "To compare acute adverse events (AE) and postoperative complication rates in a randomized trial of short-course (SC) versus long-course (LC) preoperative radiotherapy." | 2.84 | Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04). ( Ackland, S; Ansari, N; Burmeister, B; Fisher, RJ; Heriot, A; Joseph, D; Mackay, J; McClure, B; McLachlan, SA; Ngan, SY; Solomon, MJ, 2017) |
| "In patients with muscle invasive bladder cancer (MIBC), necrosis is prognostic for survival following surgery or radiotherapy and predicts benefit from hypoxia modification of radiotherapy." | 2.84 | The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). ( Choudhury, A; Denley, H; Hall, E; Hendron, C; Huddart, R; Hussain, SA; James, N; Lewis, R; Porta, N; West, CM, 2017) |
| "Given the proven prognostic value of circulating tumor cells (CTCs) in EBC, we compared the prevalence of CTCs after chemotherapy between both treatment arms for a preliminary efficacy assessment." | 2.84 | Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. ( Alunni-Fabbroni, M; Andergassen, U; Camara, O; de Gregorio, N; Decker, T; Fasching, PA; Fehm, TN; Friedl, TWP; Heinrich, G; Jaeger, B; Janni, W; Mahner, S; Ober, A; Pantel, K; Rack, BK; Schneeweiss, A; Schochter, F; Schramm, A; Trapp, E, 2017) |
| " We aimed to assess the safety, efficacy, biomarkers, and pharmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine (ECX) in patients with advanced gastric or oesophagogastric junction cancer." | 2.79 | Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. ( Anderson, A; Davidenko, I; Deptala, A; Donehower, RC; Dubey, S; Harrison, M; Iveson, T; Jiang, Y; Lakshmaiah, K; Loh, E; Nirni, S; Oliner, KS; Tang, R; Thomas, A; Tjulandin, S; Zhu, M, 2014) |
| "We consider that our observations in gastric cancer patients in our clinic can be useful in the future randomised trials to point the way to improved outcomes." | 2.79 | Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution. ( Coskun-Breuneval, M; Demirkasimoglu, T; Elgin, Y; Guney, Y; Kara, SP; Kucukpilakci, B; Misirlioglu, HC; Ozgen, A; Sanri, E; Ugur, VI, 2014) |
| "A total of 64 invasive breast cancer patients were recruited in the N001 Phase II, multicenter, open-label, single-arm study to receive four cycles of FEC (500, 100, 500 mg/m(2)) followed by four cycles of T (100 mg/m(2)) with concurrent CXB (200 mg b." | 2.78 | Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. ( Chow, LW; Glück, S; Im, SA; Lee, MH; Ng, TY; Toi, M; Tung, SY; Yip, AY, 2013) |
| " Maintenance chemotherapy started 4-8 weeks later, three courses repeated every 21 days, using 5-FU/CDDP doses above, with MMC reduced to 7 mg/m(2) and administered with the first and third cycles." | 2.77 | Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. ( Cunningham, D; Davidson, N; Glynne-Jones, R; Grieve, R; Hurman, DC; Levine, E; Meadows, HM; Plowman, PN; Sebag-Montefiore, D, 2012) |
| "In patients with locally advanced rectal cancer (LARC), preoperative chemoradiation is known to improve local control, and down-staging of the tumor serves as a surrogate for survival." | 2.76 | Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study. ( Devries, AF; Eisterer, W; Fastner, G; Gnant, M; Greil, R; Jäger, R; Kapp, KS; Keil, F; Offner, F; Ofner, D; Rabl, H; Schaberl-Moser, R; Thaler, J; Tschmelitsch, J; Zitt, M, 2011) |
| "Capecitabine was administered at 850 mg/m twice daily every day with 5 days per week radiotherapy (1." | 2.75 | Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. ( Choi, DW; Choi, SH; Heo, JS; Jun, HJ; Kang, WK; Kim, HS; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS; Yi, SY, 2010) |
| "Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection." | 2.75 | Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. ( Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z, 2010) |
| " The primary toxicity outcome measure was toxicity-induced delay or dose reduction; the secondary outcome was Common Terminology Criteria of Adverse Events grade >or= 3 toxicity." | 2.74 | Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. ( Adlard, JW; Allan, JM; Braun, MS; Daly, CL; Meade, AM; Parmar, MK; Quirke, P; Richman, SD; Seymour, MT; Thompson, L, 2009) |
| "2004, 256 cases with stage III colorectal cancer randomized received de Gramont, modified FOLFOX4 (mFOLFOX4) and XELOX regimens." | 2.73 | [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer]. ( Cheng, RC; Diao, C; Liu, QY; Su, YJ; Wei, XP; Xu, JB; Zhang, JM, 2008) |
| "From January 1998 to January 2003, 400 gastric cancer patients at high risk for recurrence including patients with serosal invasion (stage pT3 N0) and/or lymph node metastasis (stage pT2 or pT3 N1, N2, or N3), were enrolled in a trial of adjuvant chemotherapies; 201 patients were randomly assigned to receive the PELFw regimen, consisting of eight weekly administrations of cisplatin (40 mg/m2), LV (250 mg/m2), epidoxorubicin (35 mg/m2), 5-FU (500 mg/m2), and glutathione (1." | 2.73 | Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. ( Aitini, E; Ardizzoia, A; Arnoldi, E; Barni, S; Barone, C; Beretta, GD; Bertetto, O; Carnaghi, C; Cascinu, S; Cassano, A; Catalano, V; Chiara, S; Cortesi, E; Floriani, I; Foa, P; Frontini, L; Gasparini, G; Giordani, P; Labianca, R; Mansutti, M; Mosconi, S; Nardi, M; Piazza, E; Pozzo, C; Pucci, F; Rabbi, C; Ravaioli, A; Rimassa, L; Rota, S; Santoro, A; Silva, RR; Sobrero, A; Torri, V, 2007) |
| "Our data suggest that esophageal cancers with activated NF-kappaB have aggressive clinical biology and poor treatment outcome." | 2.72 | Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. ( Aggarwal, BB; Ajani, JA; Chao, KS; Ensor, J; Hittelman, WN; Izzo, JG; Lee, JH; Liao, Z; Luthra, R; Malhotra, U; Swisher, SG; Wu, TT, 2006) |
| "Four hundred three women with cervical cancer were randomly assigned to receive either EFRT or CTRT." | 2.71 | Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. ( Cooper, J; Eifel, PJ; Gershenson, D; Grigsby, PW; Levenback, C; Morris, M; Mutch, DG; Rotman, M; Winter, K, 2004) |
| " This study was performed to determine the efficacy and safety of irinotecan (CPT-11) in combination with fluorouracil (FU) administered as a 48-hour continuous infusion twice a month in elderly patients." | 2.71 | Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Gil, S; Maestu, I; Marcuello, E; Masutti, B; Maurel, J; Navarro, M; Sastre, J; Valladares, M; Vicent, JM, 2005) |
| "Thirty patients with squamous cell carcinoma of the esophagus received CRT followed by surgery." | 2.71 | Chemoradiotherapy for T3 and T4 squamous cell carcinoma of the esophagus using low-dose FP and radiation: a preliminary report. ( Fujiwara, M; Fujiwara, Y; Inoue, T; Kamikonya, N; Koishi, K; Kojima, S; Nakagawa, K; Nakao, K; Nishiwaki, M; Yagyu, R; Yamamura, T; Yoshikawa, R, 2005) |
| "The management of locally advanced bladder cancer remains controversial with poor local control with radiotherapy alone." | 2.70 | A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Moffitt, DD; Peake, D; Wallace, DM, 2001) |
| " Dosage in subsequent cycles was adjusted according to toxicity." | 2.69 | A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. ( Kantoff, PW; Loughlin, KR; Manola, J; Oh, WK; Richie, JP, 1999) |
| "The regimens for colon cancer were, Arm I: mitomycin C [intraoperative portal vein bolus (12 mg/m2) + postoperative, twice weekly and then three times bimonthly for six months intermittent i." | 2.68 | Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan. ( , 1995) |
| "5-FU; and arm III was surgery only." | 2.68 | Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy. ( Hamano, K; Kato, T; Kodaira, S; Koyama, Y; Ogawa, N; Sakabe, T; Takahashi, T; Tominaga, T; Yasutomi, M, 1996) |
| "Some 978 patients with colon cancer and 713 patients with rectal cancer were enrolled in the study, 85 (5." | 2.68 | [Prospective controlled study on the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancer]. ( Hojo, K; Ichihashi, H; Kato, T; Kikuchi, K; Kodaira, S; Kunii, Y; Ogawa, M; Takahashi, T; Tamada, R; Tominaga, T; Yasutomi, M, 1997) |
| "Fifty-seven Dukes C colorectal cancer patients were given 5-fluorouracil-interferon-alpha 2b adjuvant treatment from October 1986 to September 1990." | 2.67 | 5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer. ( Cremone, L; Espinosa, A; Faiella, F; Frasci, G; Leone, F; Monaco, M; Persico, G; Sapio, U, 1994) |
| "From 23 patients with advanced non-Hodgkin lymphomas of a high malignancy 11 received a therapy with CVPP scheme; 2 of them came into a complete remission and 3 of them into a partial one." | 2.65 | [The so-called partial synchronization in the treatment of malignant lymphomas. A clinical study]. ( Anger, G; Fink, R; Höche, D, 1980) |
| "Sinonasal undifferentiated carcinoma (SNUC) represents less than 1% of all malignancies." | 2.53 | Management of sinonasal undifferentiated carcinoma with intracerebral invasion: Clinical experience at a single institution and review of the literature. ( Clauditz, T; Knecht, R; Laban, S; Muenscher, A; Schafhausen, P; Tribius, S; Veldhoen, S; Zielinski, V, 2016) |
| "Colorectal cancer is the third most common cancer worldwide." | 2.50 | Use of microRNAs in directing therapy and evaluating treatment response in colorectal cancer. ( Andreoli, SC; de Andrade, RV; de Carvalho, GP; Garicochea, B; Gasparini, NJ; Pogue, RE, 2014) |
| "Treatment of locally advanced pancreatic cancer is palliative, based on chemotherapy and according to response, chemoradiotherapy can be applied." | 2.49 | Locally advanced pancreatic cancer. ( Huber, KE; Oikonomopoulos, GM; Saif, MW; Syrigos, KN, 2013) |
| "For cT2 N0 esophageal cancer patients, the benefit of neoadjuvant therapy is still unclear." | 2.48 | Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. ( Brock, MV; Franco, N; Hooker, CM; How, R; Hulbert, A; Lee, S; Prevas, H; Shin, J; Yang, SC; Zhang, JQ, 2012) |
| "From a global perspective, gastric cancer including cancer of the esophago-gastric junction is the fourth most common malignant tumor and the second-most common cause of cancer-related death." | 2.46 | [Diagnosis and treatment of gastric cancer]. ( Ebert, M; Grenacher, L; Lordick, F; Moehler, M; Röcken, C; Schumacher, G, 2010) |
| "Gallbladder cancer is an aggressive tumor." | 2.46 | [Chemotherapy in gallbladder carcinoma]. ( Abahssain, H; Afchain, P; Errihani, H; Ismaili, N; Melas, N; Rabti, HM; Rahali, R, 2010) |
| "The successful management of rectal cancer requires a multidisciplinary approach, with treatment decisions based on precise patient evaluations by a group of clinicians, including surgeons, gastroenterologists, medical and radiation oncologists, radiologists, and pathologists." | 2.45 | The multidisciplinary management of rectal cancer. ( Hoffe, SE; Meredith, KL; Shibata, D, 2009) |
| "Although a decrease in distant metastases has frequently been observed, an improvement in survival from induction has been difficult to demonstrate." | 2.43 | Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? ( Adelstein, DJ; Leblanc, M, 2006) |
| "The prognosis of hepatocellular carcinoma(HCC) invading the major branches of the portal vein(Vp3 or 4) is extremely poor." | 2.41 | [Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy]. ( Monden, M; Nagano, H; Sakon, M, 2002) |
| "An integrated program of skin cancer awareness, sun protection, and prophylactic approaches is critical." | 2.41 | Nonmelanoma skin cancer. ( Ho, DQ; Nguyen, TH, 2002) |
| "Pancreatic cancer is one of the deadliest malignancies and is fatal in more than 95% of affected individuals." | 2.41 | Management of locally advanced adenocarcinoma of the pancreas. ( Ryan, DP; Willett, CG, 2002) |
| "Advanced esophageal cancer, which invades into neighboring organs are classified as T4 esophageal cancer." | 2.40 | [Esophagectomy combined resection of invaded neighboring organs for T4 esophageal carcinoma]. ( Ayabe, H, 1997) |
| "Use of the conservative approach in bladder cancer now appears to be a tangible reality for selected patients, but these combined modalities have not yet been tested in randomized trials." | 2.40 | [Concurrent radio-chemotherapy in infiltrating cancer of the bladder: a new therapeutic approach?]. ( Baillet, F; Chrétien, Y; Dufour, B; Durdux, C; Housset, M; Méjean, A, 1998) |
| "Despite of improvement of results in rectum cancer treatment after systematical introduction of total mesorectal excision as a standard procedure to control the compartment disease, surgical radicality may be limited in cases with large tumours in ventral position because of eccentric location of the rectum in the perirectal fat." | 2.40 | [Rectal carcinoma. Optimizing treatment by neoadjuvant and adjuvant therapy?]. ( Fasolini, F, 1999) |
| "However, their roles in gastric cancer (GC) remain poorly characterized." | 1.62 | Distinctive Prognostic Value and Cellular Functions of Osteopontin Splice Variants in Human Gastric Cancer. ( Cui, Y; Hao, C; Ji, J; Jia, S; Jiang, WG; Lane, J, 2021) |
| "This study examined the inhibition and mechanism of natural product pentagalloyl glucose (PGG) against HepG2 cells and determined the effects of its combination with the clinical chemotherapeutic drug, 5-FU." | 1.62 | Inhibitory effects and molecular mechanisms of pentagalloyl glucose in combination with 5-FU on aggressive phenotypes of HepG2 cells. ( Ding, XQ; Ma, CM; Wang, JY; Zhao, S; Zheng, HC, 2021) |
| "Three patients (25%) developed anastomotic leakage." | 1.56 | Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer. ( Fujiwara, T; Hashimoto, M; Katsui, K; Maeda, N; Nishizaki, M; Noma, K; Sakurama, K; Shirakawa, Y; Tanabe, S, 2020) |
| " Particularly, the expression of tumour-suppressing gene Ccdc80 was induced by vactosertib and further induced by vactosertib in combination with nal-IRI/5-FU/LV." | 1.56 | Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models. ( An, H; Heo, JS; Hong, CP; Hong, E; Kang, JM; Kim, SJ; Lee, S; Ooshima, A; Park, J; Park, JO; Park, S; Park, SH, 2020) |
| "Unresectable pancreatic cancer (UR-PC) has a poor prognosis." | 1.56 | Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy. ( Endo, I; Kumamoto, T; Matsuyama, R; Murakami, T; Sawada, Y; Tsuchiya, N; Yabushita, Y, 2020) |
| "When treating invasive basal cell carcinoma (BCC) with Mohs micrographic surgery (MMS), including infiltrative and nodular subtypes, the goal is complete surgical removal of the tumor." | 1.56 | Topical Fluorouracil Therapy for Residual Superficial Basal Cell Carcinoma Following Mohs Micrographic Surgery. ( Housewright, C; Pederson, H; Staples, CJ, 2020) |
| "ARID1A was expressed at low levels in breast cancer cells." | 1.56 | Role of ARID1A in epithelial‑mesenchymal transition in breast cancer and its effect on cell sensitivity to 5‑FU. ( Gao, S; Gao, X; Jiang, T; Liu, P; Shi, X; Wang, T; Zhou, K; Zuo, X, 2020) |
| "BACKGROUND Liver cancer is one of the most common malignancies around the world and one of the major causes of cancer related mortality." | 1.51 | Anticancer Action of Psilostachyin-A in 5-Fluorouracil-Resistant Human Liver Carcinoma are Mediated Through Autophagy Induction, G2/M Phase Cell Cycle Arrest and Inhibiting Extracellular-Signal-Regulated Kinase/Mitogen Activated Protein Kinase (ERK/MAPK) ( Huang, J; Huang, L; Liu, J; Liu, Y; Shi, C; Wang, G; Wang, J; Xu, X, 2019) |
| "Patients with recurrence or metastasis within 6 months after cisplatin administration were considered platinum-resistant and those with no recurrence or metastasis within 6 months were considered platinum-sensitive." | 1.51 | Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients. ( Fushimi, C; Hanyu, K; Katsube, Y; Kondo, T; Miura, K; Okada, T; Okamoto, I; Sato, H; Shimizu, A; Tsukahara, K, 2019) |
| "Survival benefits after synchronous metastasectomy have been reported for selected patients." | 1.51 | CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. ( Büchler, MW; Hackert, T; Heckler, M; Heger, U; Klaiber, U; Mihaljevic, AL; Sun, H; Tanaka, M, 2019) |
| " Dosing and completion of prescribed chemotherapy were assessed on the subset of patients who received all therapy at MSK." | 1.48 | Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. ( Cercek, A; Crane, CH; Garcia-Aguilar, J; Gollub, MJ; Gonen, M; Guillem, JG; Nash, GM; Paty, PB; Reidy, DL; Roxburgh, CSD; Saltz, LB; Segal, NH; Seier, K; Shia, J; Smith, JJ; Stadler, ZK; Strombom, P; Temple, LKF; Vakiani, E; Varghese, A; Weiser, MR; Wu, AJ; Yaeger, R, 2018) |
| "Esophageal fistula was observed in 28 patients (24%)." | 1.48 | Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study. ( Fukutomi, A; Hamauchi, S; Kawakami, T; Kito, Y; Machida, N; Ogawa, H; Omae, K; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T; Yoshida, Y, 2018) |
| "The prognosis of hepatocellular carcinoma (HCC) with tumor thrombus in the major portal vein (PV) is extremely poor." | 1.48 | Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Jap ( Hatano, E; Uemoto, S; Yamamoto, M; Yamaue, H, 2018) |
| "5-Fluorouracil (5-FU) has been identified as one of the standard first-line chemotherapy drugs for locally advanced or metastatic gastric cancer." | 1.46 | Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells. ( Cao, G; Gao, Q; Sun, X; Xing, Y; Zhang, D; Zhang, L, 2017) |
| "Of 216 stage IIIB cervical cancer patients, 114 of them had no LTI and 72 had LTI." | 1.46 | Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion. ( Katanyoo, K, 2017) |
| "Two human gastric cancer cell lines (AGS and SGC-7901) were xenografted into zebrafish embryos, their sensitivity to 5-FU were tested both in vitro and in vivo." | 1.46 | Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer. ( He, MF; Li, CY; Shen, LZ; Tan, AM; Wei, P; Wu, JQ; Zhai, J, 2017) |
| "Perineural invasion (PNI) in colon cancer (CC) has been associated with poorer prognosis even in stage II disease (T3-4 N0 M0)." | 1.46 | Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer. ( Baixauli, J; Beorlegui, C; Cienfuegos, JA; Hernández-Lizoáin, JL; Martínez, P; Rodríguez, J; Rosenstone, S; Sola, JJ, 2017) |
| "Chemoresistance in breast cancer is a major obstacle, especially in p53 mutation types." | 1.46 | l-arginine alters the effect of 5-fluorouracil on breast cancer cells in favor of apoptosis. ( Azadbakht, M; Jahani, M; Mansouri, K; Norooznezhad, F, 2017) |
| "PTBP3 mRNA levels in human gastric cancer and adjuvant non-tumour tissues were detected." | 1.46 | Inhibition of polypyrimidine tract-binding protein 3 induces apoptosis and cell cycle arrest, and enhances the cytotoxicity of 5- fluorouracil in gastric cancer cells. ( Li, J; Liang, X; Lin, S; Liu, J; Qi, Y; Qiu, C; Shi, H; Yang, L; Zhao, A, 2017) |
| "Metastatic and refractory gastric cancer (GC) are associated with a poor prognosis; therefore, the identification of prognostic factors and chemosensitivity markers is extremely important." | 1.43 | Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients. ( Altan, B; Asao, T; Bai, T; Bao, P; Hara, K; Ide, M; Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Nishiyama, M; Ogata, K; Oyama, T; Suzuki, M; Toyomasu, Y; Yokobori, T, 2016) |
| "Esophageal squamous cell carcinoma (ESCC) contains genomic alterations of undefined clinical significance." | 1.43 | Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China. ( Bi, Y; Chen, X; Chen, Y; Cheng, C; Cheng, X; Cui, H; Cui, Y; Guo, J; Guo, S; Hu, X; Jia, J; Jia, Z; Kong, P; Li, G; Li, H; Li, Q; Li, Y; Liang, J; Liu, H; Liu, J; Qian, Y; Shi, R; Song, B; Wang, C; Wang, F; Wang, J; Wang, T; Xi, Y; Xu, E; Yan, T; Yang, B; Yang, J; Zhan, Q; Zhang, L; Zhang, Y; Zhao, Z; Zhou, Y, 2016) |
| "We reviewed 21 patients diagnosed with HNSCC of the PNSNC who were treated with IC." | 1.43 | Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. ( Hah, JH; Han, DH; Heo, DS; Keam, B; Kim, DW; Kim, DY; Kim, TM; Kwon, TK; Lee, SH; Ock, CY; Rhee, CS; Sung, MW; Won, TB; Wu, HG, 2016) |
| "RanBPM expression in human gastric cancer tissue samples was analyzed using real-time polymerase chain reaction." | 1.43 | Reduced RanBPM Expression Is Associated with Distant Metastasis in Gastric Cancer and Chemoresistance. ( Feng, YI; Gao, X; Ji, J; Ji, KE; Jia, Y; Jiang, WG; Satherley, LK; Shao, S; Sun, PH; Ye, L, 2016) |
| "Here, we present a case of rectal cancer that became curatively resectable after preoperative chemotherapy with mFOLFOX6 plus c-mab." | 1.43 | [A Case of an Unresectable Locally Advanced Rectal Cancer with Surrounding Organ Invasion Successfully Resected after Chemotherapy with mFOLFOX6 plus Cetuximab]. ( Ariake, K; Doi, T; Takagi, H; Takemura, S, 2016) |
| "This study suggests that exposure of colon cancer cells to butyrate results in development of resistance to butyrate, which may play a role in the acquisition of chemoresistance in colon cancer." | 1.43 | Butyrate-mediated acquisition of chemoresistance by human colon cancer cells. ( Choi, HG; Jeon, CK; Kang, HR; Kim, SH; Lim, SJ, 2016) |
| "To determine the function of WEE1 in gastric cancer cells, we determined that WEE1 ablation decreased the proliferation, migration, and invasion, while overexpression of WEE1 increased these effects in gastric cancer cells." | 1.43 | Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. ( Cho, Y; Chun, KH; Kang, H; Kim, HY; Kim, SJ; Song, J; Yim, YS, 2016) |
| "Oesophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer-associated death in the world and novel therapeutic alternatives are urgently warranted." | 1.43 | Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. ( Bai, L; Chen, DL; Chen, LZ; Ju, HQ; Lu, YX; Mo, HY; Sheng, H; Wang, DS; Wang, F; Wu, QN; Xie, D; Xu, RH; Yu, HE; Yun, JP; Zeng, ZL, 2016) |
| "The anti-tumour effects and adverse events were evaluated in 163 MIBC patients who received systemic chemotherapy (SC, n = 34), intra-arterial chemotherapy (IAC, n = 50), or combined IAC and radiotherapy (IAC + R, n = 79)." | 1.42 | Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: a single-centre study of 163 patients. ( Hayashi, N; Matsuo, T; Miyata, Y; Nomata, K; Ohba, K; Sakai, H; Sakamoto, I; Uetani, M, 2015) |
| " The purpose of this study was to determine the treatment effect of irradiation in combination with hepatic arterial infusion chemotherapy (HAIC) for these patients." | 1.42 | Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. ( Kanazawa, S; Katsui, K; Kobayashi, Y; Kuwaki, K; Miyahara, K; Miyake, Y; Morimoto, Y; Nakamura, S; Nouso, K; Onishi, H; Sakaguchi, K; Shiraha, H; Takaki, A; Takeuchi, Y; Wada, N; Yamamoto, K; Yasunaka, T, 2015) |
| "5-fluorouracil (5-FU) is a principal first-line therapy, but treatment only extends survival modestly and is seldom curative." | 1.42 | Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment. ( Dembinski, JL; Krauss, S; Lund, K; Mills, IG; Solberg, N; Urbanucci, A, 2015) |
| "Treatment of T3 laryngeal cancer in the Netherlands is generally comparable, with CT-RT for voluminous T3N0 and most T3N+ tumors, but there are some differences between the centers in the use of chemotherapy and the dose-fractionation schemes." | 1.42 | Treatment of T3 laryngeal cancer in the Netherlands: a national survey. ( Doornaert, P; Kaanders, JH; Terhaard, CH, 2015) |
| "For different stages of colorectal cancer, expression of VMP1 had a negative correlation with the malignancy of the cancer." | 1.42 | Downregulation of VMP1 confers aggressive properties to colorectal cancer. ( Cai, YJ; Che, XH; Chen, F; Guo, XZ; Liu, XJ; Wei, XN; Xiao, WZ; Ye, XL; You, QH; Yu, MH; Yuan, H, 2015) |
| "Because the serum concentration of 5-FU fluctuates and displays various patterns, the dosage should not be based on body surface area." | 1.42 | Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. ( Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A, 2015) |
| "Transfection of miR-125b sensitizes gastric cancer cells to 5-FU-induced apoptosis." | 1.42 | miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer. ( He, X; Liu, F; Lv, X; Peng, Y; Wu, S; Xie, L; Zhang, Z; Zhu, Y, 2015) |
| "This was a rare case of rectal cancer with submucosal invasion that showed recurrence in the bone and lymph nodes 78 months after the additional resection." | 1.42 | [Recurrence of Rectal Cancer with Submucosal Invasion in the Bone and Lymph Nodes 89 Months after Surgery--A Case Report]. ( Amikura, K; Asayama, M; Fukuda, T; Ishikawa, H; Kawashima, Y; Kazama, S; Kurozumi, M; Mori, Y; Nishimura, Y; Nishizawa, Y; Sakamoto, H; Takano, M; Takenoya, T; Tanaka, Y, 2015) |
| "Human colorectal cancer specimens (n=94) and human colorectal cancer cell lines HRT18 and HT115 were used." | 1.40 | Death associated protein 1 is correlated with the clinical outcome of patients with colorectal cancer and has a role in the regulation of cell death. ( Davies, ML; Hargest, R; Ji, J; Ji, K; Jia, Y; Jiang, WG; Ruge, F; Toms, AM; Ye, L, 2014) |
| "5-Fluorouracil (5-FU) is a classic chemotherapeutic drug that has been widely used for colorectal cancer treatment, but colorectal cancer cells are often resistant to primary or acquired 5-FU therapy." | 1.40 | Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. ( Deng, J; Fu, JC; Lei, W; Li, JH; Xiong, JP; Zhang, L, 2014) |
| "Between 1998 and 2012, 56 patients with squamous cell carcinoma were treated at our institution and included in the analysis." | 1.40 | [Results of definitive radiotherapy for squamous cell carcinomas of the larynx patients with subglottic extension]. ( Blanchard, P; Bourhis, J; Daly-Schveitzer, N; Janot, F; Lévy, A; Tao, Y; Temam, S, 2014) |
| "Surgery is the standard treatment for colorectal cancer (CRC), and adjuvant chemotherapy has been shown to be effective in stage III but less so in stage II." | 1.40 | Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines. ( Artells, R; Cordeiro, A; Diaz, T; Ferrer, G; Hernandez, R; Monzo, M; Moreno, I; Navarro, A; Tapia, G; Tejero, R, 2014) |
| "Hepatic resection of metastatic colorectal cancer (CRC) has become the treatment of choice for patients after resection of the primary CRC." | 1.40 | Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases. ( Araki, K; Asao, T; Fujii, T; Kubo, N; Kuwano, H; Suzuki, H; Tsukagoshi, M; Tsutsumi, S; Wada, S; Watanabe, A, 2014) |
| "MELK expression levels in human gastric cancer were determined by quantitative-PCR and immunohistochemistry." | 1.40 | Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway. ( Du, T; Li, C; Li, H; Li, J; Liu, B; Qu, Y; Su, L; Yan, M; Zhou, Q; Zhu, Z, 2014) |
| "The human colon cancer cell lines SW480, Lovo and HCT116 contain 1." | 1.40 | Characterization of side population cells isolated from the colon cancer cell line SW480. ( Cheng, Y; Hu, X; Ma, L; Xiong, B; Zhang, C, 2014) |
| "Both breast cancer cell lines and tissues displayed increased expression of Axl, and it over expressed in highly metastatic breast cancer." | 1.40 | Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma. ( Gong, Y; Jia, L; Li, Y; Liu, C; Ren, D; Wang, N; Zhang, X; Zhao, Y, 2014) |
| " A c-myc antisense oligodeoxynucleotide can increase the sensitivity of liver cancer cells to 5-fluorouracil and decrease the dosage of the agent necessary for efficacy, providing an experimental basis for the clinical therapy of liver cancer." | 1.40 | Liposome-mediated induction of apoptosis of human hepatoma cells by c-myc antisense phosphorothioate oligodeoxynucleotide and 5-fluorouracil. ( Cai, H; Chen, YR; Guo, TK; He, J; Li, W; Yang, XJ; Yuan, Y, 2014) |
| "We examined Sdc-1 shedding in colorectal cancer by enzyme-linked immunosorbent assay (ELISA), Dot blot, reverse transcription-PCR (RT-PCR), immunohistochemistry and so on, its impact on chemotherapeutic sensitivity by collagen gel droplet embedded culture-drug sensitivity test (CD-DST) and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), and potential mechanisms of action by Dot blot, western blot and immunofluorescence." | 1.40 | Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer. ( Ba, Y; Chen, Y; Deng, T; He, Y; Li, W; Liu, R; Ren, L; Wang, X; Ying, G; Zhou, L; Zuo, D, 2014) |
| "Docetaxel and cisplatin in combination with fluorouracil (DCF) regimen is accepted to be one of the standard regimens in the treatment of advanced gastric cancer." | 1.40 | Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. ( Bilici, A; Demir, N; Dikilitas, M; Oven Ustaalioglu, BB; Selcukbiricik, F; Yildiz, O, 2014) |
| "Biliary tract cancers are rare, and surgical resection is the standard treatment at early stages." | 1.40 | Prognostic factors and adjuvant treatments for surgically treated cancers of the biliary tract: a multicentre study of the Anatolian Society of Medical Oncology (ASMO). ( Aktas, B; Balakan, O; Berk, V; Cinkir, Hy; Demirci, U; Helvaci, K; Kos, T; Kucukoner, M; Oztop, I; Sevinc, A; Tonyali, O; Turan, N; Unal, OU; Yildiz, R; Yilmaz, AU, 2014) |
| "Herein, we present a case of advanced rectal cancer surgically resected after chemotherapy." | 1.40 | [Surgical resection after chemotherapy for advanced rectal cancer - report of a case]. ( Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Minagawa, M; Nogami, H; Sakata, J; Shimada, Y; Suda, K; Wakai, T, 2014) |
| "A colonoscopy detected KRAS wild-type rectal cancer." | 1.40 | [A case of stage IV rectal cancer successfully resected after chemotherapy (mFOLFOX6 plus panitumumab)]. ( Aisu, Y; Ando, Y; Asao, Y; Furuyama, H; Honda, K; Kadokawa, Y; Kato, S; Machimoto, T; Nishino, H; Nishiuchi, A; Yoshimura, T, 2014) |
| "A 62-year-old man presented with type 3 gastric cancer (tub1, HER2 positive) in the cardia, with 10-cm direct invasion into the lower esophagus, and extensive lymph node metastasis (Virchow and paraaortic nodes)." | 1.40 | [A case of HER2-positive advanced gastric cancer with extensive lymph node metastasis treated via chemotherapy with a trastuzumab-containing regimen followed by conversion surgery]. ( Asaoka, T; Fujitani, K; Fukuda, Y; Haraguchi, N; Hirao, M; Ikeda, M; Miyake, M; Miyamoto, A; Nakamori, S; Nishikawa, K; Omiya, H; Sekimoto, M; Takami, K; Tsujinaka, T; Yamamoto, K, 2014) |
| "The prognosis of hepatocellular carcinoma (HCC) with macroscopic vascular invasion is extremely poor even after hepatic resection." | 1.39 | Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. ( Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Imai, K; Nitta, H, 2013) |
| "Sixty-one patients with muscle-invasive bladder cancer who underwent CCRT between January 1996 and March 2011 were eligible for evaluation." | 1.39 | Prognostic value of complete response in patients with muscle-invasive bladder cancer undergoing concurrent chemoradiotherapy. ( Chuang, CK; Hong, JH; Liaw, CC; Lin, YC; Pang, ST; Wu, CE, 2013) |
| "The prognosis in advanced hepatocellular carcinoma (HCC) with multiple intrahepatic metastases is extremely poor." | 1.39 | Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study. ( Endo, I; Kumamoto, T; Matsuo, K; Nakagawa, K; Taguri, M; Tanaka, K; Yabushita, Y, 2013) |
| "A 69-year-old man diagnosed with lower rectal cancer was referred to our hospital." | 1.39 | [A case of pathological complete response with neoadjuvant mFOLFOX6 chemotherapy for advanced lower rectal cancer]. ( Fujiwara, Y; Gotoh, K; Ishikawa, O; Kishi, K; Marubashi, S; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Shingai, T; Sueda, T; Takahashi, H; Tomita, Y; Yano, M, 2013) |
| "We encountered a case of colorectal cancer with pelvic abscess treated with radical surgery following colostomy and chemotherapy." | 1.39 | [A case of locally advanced colorectal cancer with abscess responding to 5-fluorouracil, leucovorin, and oxaliplatin plus bevacizumab]. ( Goseki, N; Kuwabara, H; Liu, B; Mitsuoka, A; Nakajima, K; Sanada, T; Watanabe, S, 2013) |
| "Although squamous cell carcinoma was diagnosed by biopsy of the SMT-like tumor in the gastric cardia, gastric involvement was suspected via metastasis to the perigastric lymph nodes or direct invasion of the gastric wall by the ESCC, because the primary lesion of ESCC could not be identified during the examinations." | 1.39 | [A case of esophageal squamous cell carcinoma with submucosal tumor-like tumor due to direct invasion of the gastric wall]. ( Fujiwara, H; Ichikawa, D; Ikoma, H; Komatsu, S; Konishi, H; Kubota, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Nako, Y; Okamoto, K; Otsuji, E; Sakakura, C; Shiozaki, A, 2013) |
| "For the 83 patients with HPV 16-cancer of the cervix (cervical cancer) I-III stages it was performed a comparative analysis of primary tumor response to therapy, the clinical outcome of the disease for 3-5 years after radical treatment and an evaluation of the possible contribution in these rates of the physical status of the virus." | 1.39 | [The significance of physical status of human papillomavirus type 16 for predicting the effectiveness of invasive cervical cancer treatment]. ( Beziaeva, GP; Kiseleva, VI; Krikunova, LI; Liubina, LV; Mkrtchian, LS; Panarina, LV; Saenko, AS; Zamulaeva, IA, 2013) |
| "By this stage of esophageal cancer, surgery, although very invasive, is the standard radical therapy for the patients." | 1.39 | Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer. ( Kameda, Y; Ohkawa, S; Tamai, S; Yoshii, T, 2013) |
| "We showed a higher risk of breast cancer occurrence for the Trp allele and the Arg194Trp genotype of the XRCC1 gene." | 1.39 | Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer. ( Kordek, R; Kusinska, R; Majsterek, I; Przybylowska-Sygut, K; Stanczyk, M, 2013) |
| "Patients with small residual tumors (≤3 cm) radiologically staged ycT0-2N0 were treated by transanal endoscopic microsurgery." | 1.39 | Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution. ( Bianchi, R; Gama-Rodrigues, J; Habr-Gama, A; Lynn, PB; Perez, RO; Proscurshim, I; São Julião, GP, 2013) |
| "Carcinomas were categorized by MRI as mucinous (mucin proportion >50% within the tumor volume), and as nonmucinous." | 1.38 | Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation. ( Düber, C; Hansen, T; Heintz, A; Hötker, AM; Junginger, T; Kreft, A; Kreitner, KF; Menig, M; Oberholzer, K; Schmidberger, H; Schneider, A, 2012) |
| "Between 1990 and 2010, 110 cervical cancer patients with 2 or more intermediate risk factors (deep stromal invasion, lymphovascular space invasion, and large tumor size) underwent adjuvant RT (n=56) or CCRT (n=54) following radical surgery." | 1.38 | 20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy. ( Ha, SW; Kang, SB; Kim, HJ; Kim, JH; Kim, JW; Park, NH; Song, C; Song, S; Song, YS; Wu, HG, 2012) |
| "A total of 182 breast carcinoma specimens were included." | 1.38 | Clinicopathological significance of mesothelin expression in invasive breast cancer. ( Li, F; Liu, X; Niu, Z; Wang, L; Wang, X; Wang, Y; Zhang, L, 2012) |
| "A total of 45 patients with primary squamous cell carcinoma of the tongue were included in the study." | 1.38 | Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer. ( Asakawa, T; Furusaka, T; Ikeda, M; Matsuda, H; Tanaka, A, 2012) |
| "Head and neck squamous cell carcinoma (HNSCC) is one prevalent human cancer worldwide." | 1.37 | Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma. ( Chang, SY; Chang, YC; Chu, PY; Hsieh, SL; Li, WY; Tai, SK; Tsai, TL; Wang, YF; Yang, MH, 2011) |
| "Pelvic schwannomas are rare; it is even more rare for a pelvic schwannoma to occur concurrently with a colon cancer." | 1.37 | Synchronous colonic adenocarcinoma and pelvic schwannoma. ( Bai, J; Kleyser-Sugrue, K; Nerenstone, SR; Welch, JP, 2011) |
| "SIRT1 was overexpressed in pancreatic cancer tissues at both the mRNA and protein levels, with increased SIRT1 positivity associated with tumors from patients over 60 years old, tumors larger than 4 cm, higher TNM (extent of tumor (T), the extent of spread to lymph nodes (N), and presence of distant metastasis (M)) stage or the presence of lymph node or hepatic metastases." | 1.37 | SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. ( Chen, Q; Cui, J; Deng, SC; Liu, L; Liu, Y; Qin, Q; Tian, K; Wang, B; Wang, CY; Wang, GB; Yin, T; Zhang, JG; Zhao, G, 2011) |
| "He was diagnosed as advanced rectal cancer with an invasion of prostate, and we conducted neoadjuvant capecitabine, oxaliplatin, bevacizumab and radiation therapy." | 1.37 | [A resected case of locally invasive rectal cancer successfully treated with neoadjuvant capecitabine, oxaliplatin, bevacizumab and radiation therapy]. ( Arima, N; Shigaki, N; Sugita, H; Suzuki, S; Yamashita, H; Yokoyama, S, 2011) |
| "However, its roles in clear cell renal cell carcinoma (RCC) are unclear." | 1.37 | The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma. ( Cao, K; Chen, J; Guo, S; Huang, B; Li, X; Mao, X; Mo, C; Pan, J; Qiu, S; Wang, Z; Zhuang, J, 2011) |
| "BACKGROUND Survival in rectal cancer remains unchanged despite improved treatment modalities." | 1.37 | Molecular changes consistent with increased proliferation and invasion are common in rectal cancer. ( Beynon, J; Hughes, R; Jenkins, G; Parry, J, 2011) |
| "Two years later, he was diagnosed for rectal cancer and bilateral lung metastases by TBLB." | 1.37 | [A case of colon cancer with long-term survival treated by resection of recurrence on the rectum and chemotherapy for lung metastasis]. ( Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Kurokawa, T; Nagahama, T; Nakamura, M; Okada, Y; Tei, S; Watayo, Y, 2011) |
| "We established 2 HIF-1alpha knockdown gastric cancer cell lines in order to clarify the role of HIF-1alpha in chemo-resistance against 5-FU." | 1.36 | HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy. ( Hashiguchi, K; Hiraki, M; Kai, K; Kitajima, Y; Miyazaki, K; Nakamura, J; Noshiro, H, 2010) |
| "Patients with deeply invading (T3-T4) oesophageal cancers usually receive chemoradiotherapy with or without surgery." | 1.36 | Pre- and post-therapy nodal status equally affects survival of patients with oesophageal squamous cell carcinoma receiving preoperative chemoradiation. ( Doki, Y; Fujiwara, Y; Miyata, H; Mori, M; Nakajima, K; Takiguchi, S; Yamasaki, M, 2010) |
| "However, the role of CSCs in colorectal cancer metastasis is unclear." | 1.36 | A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. ( Cheung, LW; Chow, AK; Chu, AC; Lam, CS; Lan, HY; Lan, XR; Law, WL; Ng, L; Pang, R; Poon, JT; Poon, RT; Tan, VP; Wong, BC; Yau, TC, 2010) |
| "Patients with gallbladder cancer at T2N0M0, T2N1M0, T3N0M0, and T3N1M0 stages were enrolled in this study." | 1.36 | Adjuvant chemoradiation therapy in gallbladder cancer. ( Cho, SY; Han, SS; Kim, SH; Kim, TH; Kim, YK; Lee, KW; Lee, WJ; Park, SJ; Woo, SM, 2010) |
| "Twenty men with primary rectal cancer clinically involving the lower urinary tract organs underwent extended colorectal resection combined with radical prostatectomy." | 1.36 | Preliminary experience with bladder preservation for lower rectal cancers involving the lower urinary tract. ( Ito, M; Kobayashi, A; Minagawa, N; Nishizawa, Y; Saito, N; Sugito, M; Suzuki, T; Tanaka, T; Watanabe, K, 2010) |
| "These activities compared with those in squamous cell carcinoma." | 1.36 | [Four resected cases with basaloid carcinoma of esophagus--comparison of 5-FU-related enzymes (thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT)) between basaloid carcinoma and squamous cell carcin ( Fujiwara, Y; Morimura, K; Takemura, M; Yoshida, K, 2010) |
| "Frequently advanced or recurrent esophageal cancer was invasive trachea and often causing hemoptysis, stenosis and dyspnea." | 1.36 | [A case of recurrent esophageal cancer with tracheal invasion treated by chemo-radiotherapy (CRT) after placement of tracheal stent that maintained complete response (CR) for two years]. ( Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kawasaki, Y; Kurokawa, T; Nagahama, T; Tei, S; Watayou, Y, 2010) |
| "Of 18 metastatic breast carcinoma patients experienced in our institution from November 2002 to July 2007, all patients had resisted the anthracycline or taxanes therapy before." | 1.35 | [Clinical effect and positioning of capecitabine for metastatic breast carcinoma]. ( Harada, T; Iwamoto, M; Kimura, K; Nohara, T; Sumiyoshi, K; Takahashi, Y; Tanaka, S; Tanigawa, N, 2008) |
| "Mitomycin was the most frequently active agent for the superficial part." | 1.35 | In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA). ( Ahn, KD; Cho, YB; Choi, SH; Chun, HK; Kim, HC; Lee, JM; Lee, WY; Shin, HJ; Song, SY; Yun, SH, 2009) |
| "Metastatic penoscrotal extramammary Paget's disease (EMPD) has seldom been reported in the literature." | 1.35 | Clinicopathological characteristics, management and outcome of metastatic penoscrotal extramammary Paget's disease. ( Dai, B; Mao, HR; Shen, YJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y, 2009) |
| "Early relapse in colorectal cancer (CRC) patients is attributed mainly to the higher malignant entity (such as an unfavorable genotype, deeper tumor invasion, lymph node metastasis and advance cancer stage) and poor response to chemotherapy." | 1.35 | ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. ( Cheng, TL; Fang, WY; Huang, MY; Lee, SC; Lin, SR; Wang, JY, 2008) |
| "Fourteen human cancer cell lines with and without DNA MMR derived from carcinomas of the colon, bladder, ovary and prostate were treated with CAI, vehicle or control drugs (nifedipine and 5-flurouracil)." | 1.35 | Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. ( Friedlander, ML; Kohn, EC; Qu, XJ; Yang, JL; Yu, Y, 2008) |
| " Based on the findings, the antitumor effects of a selected retinoid either alone or in combination with cisplatin were also investigated in a preclinical mouse melanoma model." | 1.35 | Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma. ( Chan, SY; Ho, PC; Liu, X, 2008) |
| "The role of surgery for esophageal squamous cell carcinoma (SCC) with clinical evidence of adjacent organ invasion (cT4) is a debated issue." | 1.34 | Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. ( Bernini, M; Cordiano, C; de Manzoni, G; Giacopuzzi, S; Grandinetti, A; Minicozzi, AM; Pasini, F; Pedrazzani, C, 2007) |
| "A resected case of squamous cell carcinoma associated with ductal carcinoma in the hemilateral breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases is reported with some discussion." | 1.34 | [A resected case of squamous cell carcinoma of the breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases]. ( Akagawa, T; Fujioka, S; Hara, T; Hiramatsu, K; Hirata, A; Ito, T; Kato, K; Kutsuna, Y; Machiki, Y; Matsuba, H; Miyata, T, 2007) |
| "5-fluorouracil (5FU) has traditionally been the drug of choice in combination with radiation therapy." | 1.34 | Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma. ( Amichetti, M; Caraul, B; Casula, G; Deidda, MA; Dessì, M; Farci, D; Farigu, R; Lay, GC; Maxia, L; Murtas, R; Orrù, S, 2007) |
| "Endoscopic findings showed Type 3 gastric cancer with pyloric stenosis." | 1.34 | [A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil]. ( Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E, 2007) |
| "He was diagnosed as advanced sigmoid colon cancer which invaded the rectal colon (Ra) and prostate (SI, N 0, P 0, H 0, M (-), cStage IIIa)." | 1.34 | [A case of advanced colon cancer invading the rectum effectively treated with chemoradiation therapy before surgery]. ( Maezawa, K; Mizukami, H; Nemoto, H; Sanada, Y; Sasaya, S; Yoshizawa, Y, 2007) |
| "101 patients with cervical cancer FIGO IB1-IVB underwent chemoradiation after transperitoneal laparoscopic staging." | 1.34 | Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. ( Bischoff, A; Budach, V; Füller, J; Köhler, C; Marnitz, S; Roth, C; Schneider, A; Wendt, T, 2007) |
| " From March 2002, we started to treat patients with advanced gastric cancer (stage IV) with a new regimen; intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells (intermittent FP ." | 1.34 | [The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamaguchi, K; Yamamitsu, S, 2007) |
| "The 5-year distant metastasis-free survival rate, with and without adjuvant chemotherapy, was 97% and 96%, respectively." | 1.33 | Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. ( Chan, KY; Cheng, SH; Chong, V; Chu, NM; Feng, AC; Hong, CF; Hsieh, CY; Huang, AT; Jian, JJ; Lin, CY; Lin, YC; Tan, TD; Tsai, SY; Yen, KL, 2005) |
| "Patients with rectal cancer treated by preoperative chemoradiation showed a surprisingly low rate of micrometastasis detection (7%), even in high-risk patients (T3 and T4 tumors)." | 1.33 | Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy. ( Coelho Siqueira, SA; Gama-Rodrigues, JJ; Habr-Gama, A; Kiss, DR; Nishida Arazawa, ST; Perez, RO; Rawet, V, 2005) |
| "Thirty invasive breast cancer patients (31 breasts) who received NAC as BCT and needle biopsy before chemotherapy were included in this study." | 1.33 | Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients. ( Ito, S; Kariya, S; Moriki, T; Murata, Y; Nishioka, A; Ogawa, Y; Ohnishi, T; Yoshida, S, 2005) |
| "Unknown primary squamous cell carcinoma in the neck has been treated by combination therapy consisting of chemotherapy, radiation therapy and surgery." | 1.33 | [A case of unknown primary squamous cell carcinoma in the neck showing a high response with combined chemotherapy including nedaplatin, adriamycin and 5-fluorouracil]. ( Fujitani, K; Hirao, M; Ikenaga, M; Kashiwazaki, M; Masuda, N; Mishima, H; Nakamori, S; Sawamura, T; Tsujinaka, T; Yamashita, S, 2005) |
| "The lymph node status of 73 resectable gastric cancer patients was analyzed preoperatively by computed tomography (CT), ultrasonography and magnetic resonance, and the OPRT activity of collected tumor tissue was measured." | 1.33 | Impact of orotate phosphoribosyl transferase activity as a predictor of lymph node metastasis in gastric cancer. ( Futagawa, S; Kitajima, M; Nishimura, K; Noguchi, H; Ochiai, T; Okada, T; Ouchi, M; Sugitani, M; Takahashi, Y; Tsuruoka, Y; Yamada, M, 2005) |
| "Here, we report a case of a male with anal cancer who was treated with 5-FU 1000 mg/m(2), continuous infusion for 5 days q4 weeks." | 1.33 | Intermediate dose 5-fluorouracil-induced encephalopathy. ( Choi, HJ; Chung, HC; Jeung, HC; Kim, YA; Rha, SY; Seong, JS, 2006) |
| "Seventy-seven patients with primary breast cancer who had undergone neoadjuvant anthracycline-based chemotherapy were included in the present study." | 1.33 | Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. ( Alberti, S; Angelucci, D; Cianchetti, E; Ficorella, C; Iacobelli, S; Lattanzio, R; Marchetti, P; Natoli, C; Piantelli, M; Ricevuto, E; Tinari, N, 2006) |
| "Microsatellite instability is a recognised pathway of colorectal carcinogenesis responsible for about 15% of all sporadic colorectal cancers." | 1.33 | 5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer. ( Kaufman, A; Ramanathan, P; Robinson, BG; Schnitzler, M; Warusavitarne, J, 2006) |
| "Patients with locally advanced pancreatic cancer who received gemcitabine chemotherapy or 5-FU-based CCRT showed better survival than those who received supportive care only." | 1.33 | Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. ( Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Yoon, WJ; Yoon, YB, 2006) |
| "As leukopenia was seen after the first cycle, the administration doses were reduced and GTX has been continued for a total 13 cycles." | 1.33 | [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine]. ( Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H, 2006) |
| "An advanced colon cancer of the cecum was found with a colonoscopy." | 1.33 | [A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases]. ( Handa, R; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Miyake, Y; Oshima, K; Oshima, S; Yamamoto, H, 2006) |
| "The murine AT-84 orthotopic model of oral cancer was assessed to find how similar it is to human oral cancer." | 1.32 | Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer. ( Hutchison, R; Kellman, RM; Lou, E; Shillitoe, EJ, 2003) |
| "We report a case of esophageal cancer infiltrating the left main bronchus in which radical esophagectomy with clear surgical margins could be performed after preoperative radiochemotherapy." | 1.32 | [Resection of esophageal cancer infiltrating the left main bronchus following complete response to preoperative radiochemotherapy--a case report]. ( Fujiwara, Y; Fukuhara, K; Kaneko, M; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Taguchi, S; Takemura, M; Tanaka, Y, 2003) |
| "A total of 49 paired of breast cancer tissues and the adjacent normal breast tissues were evaluated in this study." | 1.32 | DPD activity and immunohistochemical DPD expression in human breast cancer. ( Horiguchi, J; Iijima, K; Iino, Y; Koibuchi, Y; Morishita, Y; Ninomiya, J; Takei, H; Yokoe, T; Yoshida, T, 2004) |
| "Etodolac did not increase the inhibitory effect of 5-FU on cell proliferation." | 1.32 | Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer. ( Hirakawa, K; Matsunaga, N; Nishiguchi, Y; Nishino, H; Ohira, M; Seki, S; Tachimori, A; Yamada, N, 2004) |
| "Finally, RhoB inhibits melanoma metastasis to the lung in a mouse model." | 1.32 | Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. ( Cheng, J; Djeu, JY; Jiang, K; Sebti, S; Sun, J; Wei, S, 2004) |
| "Breast cancer has a significant capacity to metastasize to bone." | 1.32 | Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. ( Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U, 2004) |
| "Six patients with gastric cancer, stage IIIA to IV, received intraabdominal cisplatin (CDDP) at laporotomy." | 1.31 | [Postoperative adjuvant immunochemotherapy using Lentinan for advanced gastric carcinoma patients with metastasis in the regional lymph nodes and serosal invasion]. ( Kagawa, R; Nakayama, N; Sakata, S; Tada, M; Yamaguchi, T, 2002) |
| "The median CD4 count at diagnosis of anal cancer was 209 cells/microl (range: 29-380 cells/microl), 5 had prior AIDS defining diagnoses." | 1.31 | Treatment of HIV-associated invasive anal cancer with combined chemoradiation. ( Bower, M; Cleator, S; Fife, K; Gazzard, B; Nelson, M; Phillips, R, 2000) |
| "In stage 3 gastric cancer, the overall survival rates following surgery was significantly (p < 0." | 1.31 | Postsurgical sequential methotrexate, fluorouracil, and leucovorin for stages 3 and 4 gastric carcinoma: A preliminary study. ( Kitaoka, A; Ohsumi, K; Tokuka, A; Tokunaga, Y; Yagi, T, 2000) |
| "We treated a case of unresectable gastric cancer in which peritoneal lavage cytology and the primary tumor responded to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection." | 1.31 | [A case of stage IV gastric cancer responding to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection]. ( Hattori, T; Hirano, K; Kase, H; Kobayashi, K; Ogawa, M; Teramoto, T; Tokura, N; Washizawa, N, 2000) |
| "The prognosis of upper thoracic esophageal cancer is poor when compared with middle and lower thoracic esophageal cancer because the tumor easily infiltrates the respiratory tract and surgical en-bloc resection is difficult." | 1.31 | Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy. ( Doki, Y; Fujiwara, Y; Inoue, M; Monden, M; Shiozaki, H; Tsujinaka, T; Yano, M, 2000) |
| "5-Fluorouracil and cisplatin were administered intraperitoneally on postoperative days 1-4, and this was repeated at 4-week intervals." | 1.31 | Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer. ( Chung, HC; Min, JS; Noh, SH; Roh, JK; Shin, DW; Yoo, CH, 2001) |
| "The expression of TS in the nuclei of pancreatic cancer cells in 72 primary lesions of resectable IDC and 30 distant metastases of unresectable IDC was examined by immunostaining using anti-TS polyclonal antibody and immunoreactivity was classified into three categories: negative (-), low (+) and high (2+)." | 1.31 | Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. ( Dong, M; Itakura, M; Nio, Y; Takamura, M; Yamaguchi, K; Yamasawa, K, 2002) |
| "We performed PMC-CPT-11 therapy (modified pharmacokinetic modulating chemotherapy plus irinotecan, or modified PMC) in a case of sigmoid colon cancer with local invasion and multiple hepatic metastases." | 1.31 | [A case of hepatic metastasis from rectal carcinoma successfully treated with pharmacokinetic modulating chemotherapy (PMC)-CPT-11 therapy]. ( Chang, W; Kondo, Y; Kosaka, H; Maeda, S; Matsusaka, S; Okada, T; Oriyama, T, 2002) |
| "A 57-year-old man suffering from gastric cancer with esophageal invasion and liver and paraaortic lymph nodes metastases was treated with continuous 5-FU injection and intra-hepatic arterial infusion of low-dose cisplatin following non-curative surgery." | 1.30 | [A case of far-advanced gastric cancer treated with continuous 5-fluorouracil injection and intrahepatic arterial infusion of low-dose cisplatin]. ( Oka, M; Ueno, T, 1997) |
| "Chemoradiotherapy combined with hyperthermia was administered to 35 patients with advanced esophageal carcinoma who either required preoperative treatment or had nonresectable disease." | 1.30 | Clinical results of treatment of advanced esophageal carcinoma with hyperthermia in combination with chemoradiotherapy. ( Fujimaki, M; Katoh, H; Sakamoto, T; Shimizu, T; Takemori, S; Tazawa, K; Yamashita, I, 1997) |
| "The mean activity in 37 bladder cancers and in 8 samples of normal bladder epithelial tissue was 108." | 1.30 | Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer. ( Hosaka, M; Kubota, Y; Matsuzaki, J; Miura, T; Moriyama, M; Noguchi, S; Takebayashi, S, 1997) |
| "The human colorectal cancer cell line C170HM2 readily forms liver metastases in vivo." | 1.30 | A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2. ( Jackman, AL; Morris, TM; Page, MJ; Rohlff, C; Skelton, L; Watson, SA, 1999) |
| "A 63-year-old male with an esophageal cancer invading the bronchus was treated with radiation therapy (70 Gy) from November 1995, resulting in the disappearance of the lesion." | 1.30 | [Usefulness of combination therapy with expandable metallic stent replacement and FLEP chemotherapy (consisting of 5-FU, leucovorin, etoposide and cisplatin) for advanced esophageal cancer invading the bronchus: a case report]. ( Hada, T; Kobayashi, I; Kohno, S; Matai, K; Oda, Y; Ohmori, H; Sasaya, K; Yamazaki, Y, 1999) |
| "Three cases of postoperative gastric cancer with peritoneal dissemination were treated by combined administration of CDDP, 5-FU and Lentinan." | 1.29 | [Postoperative immunochemotherapy for gastric carcinoma with peritoneal dissemination--the effects with the combination of CDDP, 5-FU and lentinan]. ( Mio, H; Terabe, K, 1994) |
| "Pancreatic cancer is a disease with essentially no effective treatment." | 1.29 | A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. ( Furukawa, T; Hoffman, RM; Kitajima, M; Kubota, T; Watanabe, M, 1993) |
| "Seventy patients with local squamous cell carcinoma of the esophagus were treated between 1981 and 1990 with preoperative chemotherapy, surgical resection, and possible postoperative radiation therapy and/or chemotherapy." | 1.29 | Long-term follow-up of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and possible postoperative radiotherapy and/or chemotherapy in squamous cell carcinoma of the esophagus. ( Bromberg, C; Carey, RW; Choi, NC; Grillo, HC; Hilgenberg, AD; Logan, DL; Mathisen, DJ; Wain, JC; Wilkins, EW, 1993) |
| "However, the presence of a tracheoesophageal fistula has historically been considered a relative contraindication to radiation therapy." | 1.29 | Irradiation of carcinoma of the esophagus containing a tracheoesophageal fistula. ( Arlington, A; Bohorquez, J, 1993) |
| "The patient was a 44-year-old male with gastric cancer accompanied by pancreatic invasion and metastasis to the periaortic lymph nodes." | 1.29 | [A patient with stage IV gastric cancer responding to combination chemotherapy with 5-FU, leucovorin and CDDP]. ( Kobayashi, O; Motohashi, H; Okada, K; Okugawa, T; Rino, Y; Sairenji, M, 1993) |
| "The ratio of disappearance of bladder tumors after conventional irradiation (i." | 1.28 | [Preoperative radiotherapy with concomitant chemotherapy in the treatment of infiltrating cancers of the bladder]. ( Baillet, F; Chrétien, Y; Dufour, B; Housset, M, 1991) |
| "A 24-year-old man with hepatocellular carcinoma presented with recurrent obstructive jaundice caused by bile duct invasion and distal migration of necrotic tumor fragments." | 1.27 | Recurrent obstructive jaundice caused by fibrolamellar hepatocellular carcinoma. ( Albaugh, JS; Keeffe, EB; Krippaehne, WW, 1984) |
| "Forty patients with advanced squamous cell carcinoma of the esophagus were treated with a combination of cisplatin, 5-FU (by continuous 5-day infusion), and allopurinol; 37 are evaluable for response." | 1.27 | Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer. ( Cartei, G; De Besi, P; Fiorentino, M; Fosser, V; Paccagnella, A; Peracchia, A; Salvagno, L; Sileni, VC; Tremolada, C, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (2.86) | 18.7374 |
| 1990's | 64 (10.76) | 18.2507 |
| 2000's | 167 (28.07) | 29.6817 |
| 2010's | 313 (52.61) | 24.3611 |
| 2020's | 34 (5.71) | 2.80 |
| Authors | Studies |
|---|---|
| Chakravarti, B | 1 |
| Akhtar, T | 1 |
| Rai, B | 1 |
| Yadav, M | 1 |
| Akhtar Siddiqui, J | 1 |
| Dhar Dwivedi, SK | 1 |
| Thakur, R | 1 |
| Singh, AK | 2 |
| Kumar, H | 1 |
| Khan, K | 1 |
| Pal, S | 1 |
| Rath, SK | 1 |
| Lal, J | 1 |
| Konwar, R | 1 |
| Trivedi, AK | 1 |
| Datta, D | 1 |
| Mishra, DP | 1 |
| Godbole, MM | 1 |
| Sanyal, S | 1 |
| Chattopadhyay, N | 1 |
| Kumar, A | 2 |
| Bai, ZT | 1 |
| Wu, ZR | 1 |
| Xi, LL | 1 |
| Li, X | 6 |
| Chen, P | 1 |
| Wang, FQ | 1 |
| Meng, WB | 1 |
| Zhou, WC | 1 |
| Wu, XA | 1 |
| Yao, XJ | 1 |
| Zhang, M | 1 |
| Zhao, TQ | 1 |
| Zhao, YD | 1 |
| Liu, XY | 1 |
| Wang, B | 4 |
| Li, ZH | 1 |
| He, ZX | 1 |
| Zhang, XH | 1 |
| Liang, JJ | 1 |
| Ma, LY | 1 |
| Liu, HM | 1 |
| Dai, H | 1 |
| Huang, M | 1 |
| Qian, J | 1 |
| Liu, J | 4 |
| Meng, C | 1 |
| Li, Y | 5 |
| Ming, G | 1 |
| Zhang, T | 3 |
| Wang, S | 1 |
| Shi, Y | 4 |
| Yao, Y | 1 |
| Ge, S | 1 |
| Zhang, Y | 10 |
| Ling, Y | 1 |
| Gordon, NS | 1 |
| Baxter, LA | 1 |
| Goel, A | 2 |
| Arnold, R | 1 |
| Kaur, B | 1 |
| Liu, W | 1 |
| Pirrie, SJ | 1 |
| Hussain, S | 1 |
| Viney, R | 1 |
| Ford, D | 1 |
| Zarkar, A | 2 |
| Wood, MA | 1 |
| Mitin, T | 3 |
| Thompson, RF | 1 |
| James, ND | 5 |
| Ward, DG | 1 |
| Bryan, RT | 1 |
| Hua, R | 1 |
| Yan, X | 1 |
| Tang, D | 1 |
| Ni, Q | 1 |
| Wang, D | 2 |
| Zhu, J | 1 |
| Mao, G | 1 |
| Mu, Z | 1 |
| Wu, DA | 1 |
| Alati, A | 2 |
| Fabiano, E | 2 |
| Geiss, R | 1 |
| Mareau, A | 1 |
| Charles-Nelson, A | 1 |
| Bibault, JE | 1 |
| Giraud, P | 1 |
| Kreps, S | 1 |
| Méjean, A | 3 |
| Housset, M | 4 |
| Durdux, C | 3 |
| Zhou, Y | 2 |
| Sun, L | 2 |
| Chen, K | 1 |
| Mignot, F | 1 |
| Xylinas, E | 1 |
| Masson-Lecomte, A | 1 |
| Hermieu, JF | 1 |
| Desgrandchamps, F | 1 |
| Hennequin, C | 1 |
| Quéro, L | 1 |
| Liu, Y | 7 |
| Huang, L | 1 |
| Wang, G | 4 |
| Wang, J | 7 |
| Xu, X | 1 |
| Shi, C | 1 |
| Huang, J | 2 |
| Lin, C | 1 |
| Verma, V | 1 |
| Lazenby, A | 1 |
| Ly, QP | 1 |
| Berim, LD | 1 |
| Schwarz, JK | 1 |
| Madiyalakan, M | 1 |
| Nicodemus, CF | 1 |
| Hollingsworth, MA | 1 |
| Meza, JL | 1 |
| Are, C | 1 |
| Padussis, J | 1 |
| Grem, JL | 1 |
| Voskanyan, SE | 1 |
| Shabalin, MV | 1 |
| Artemiyev, AI | 1 |
| Kolyshev, IY | 1 |
| Bogoevich, Z | 1 |
| Kucherov, NN | 1 |
| Bashkov, AN | 1 |
| Naydenov, EV | 1 |
| Muñoz, R | 1 |
| Hileeto, D | 1 |
| Cruz-Muñoz, W | 1 |
| Wood, GA | 1 |
| Xu, P | 1 |
| Man, S | 1 |
| Viloria-Petit, A | 1 |
| Kerbel, RS | 1 |
| Opattova, A | 1 |
| Horak, J | 1 |
| Vodenkova, S | 1 |
| Kostovcikova, K | 1 |
| Cumova, A | 1 |
| Macinga, P | 1 |
| Galanova, N | 1 |
| Rejhova, A | 1 |
| Vodickova, L | 1 |
| Kozics, K | 1 |
| Turnovcova, K | 1 |
| Hucl, T | 1 |
| Sliva, D | 1 |
| Vodicka, P | 1 |
| Dho, SH | 1 |
| Cho, EH | 1 |
| Lee, JY | 2 |
| Lee, SY | 1 |
| Jung, SH | 1 |
| Kim, LK | 1 |
| Lim, JC | 1 |
| Han, L | 1 |
| Cui, D | 1 |
| Li, B | 2 |
| Xu, WW | 2 |
| Lam, AKY | 1 |
| Chan, KT | 2 |
| Zhu, Y | 6 |
| Lee, NPY | 1 |
| Law, SYK | 1 |
| Guan, XY | 2 |
| Qin, YR | 2 |
| Chan, KW | 2 |
| Ma, S | 1 |
| Tsao, SW | 2 |
| Cheung, ALM | 1 |
| Tsang, ES | 1 |
| Spratlin, J | 1 |
| Cheung, WY | 1 |
| Kim, CA | 1 |
| Kong, S | 2 |
| Xu, Y | 2 |
| Gill, S | 1 |
| Igarashi, H | 1 |
| Taniguchi, H | 3 |
| Nosho, K | 1 |
| Ishigami, K | 1 |
| Koide, H | 1 |
| Mitsuhashi, K | 1 |
| Okita, K | 1 |
| Takemasa, I | 1 |
| Imai, K | 2 |
| Nakase, H | 1 |
| Suzuki, T | 2 |
| Okamura, A | 1 |
| Watanabe, M | 2 |
| Mine, S | 1 |
| Imamura, Y | 2 |
| Asari, T | 1 |
| Osumi, H | 1 |
| Nakayama, I | 1 |
| Ichimura, T | 1 |
| Ogura, M | 1 |
| Ooki, A | 1 |
| Takahari, D | 1 |
| Yamaguchi, K | 4 |
| Chin, K | 1 |
| Hashimoto, M | 1 |
| Shirakawa, Y | 1 |
| Maeda, N | 1 |
| Tanabe, S | 1 |
| Noma, K | 2 |
| Sakurama, K | 1 |
| Katsui, K | 2 |
| Nishizaki, M | 2 |
| Fujiwara, T | 1 |
| Sheng, W | 1 |
| Tang, J | 2 |
| Zhou, J | 2 |
| Dong, M | 2 |
| van Roessel, S | 1 |
| Strijker, M | 1 |
| Steyerberg, EW | 1 |
| Groen, JV | 1 |
| Mieog, JS | 1 |
| Groot, VP | 1 |
| He, J | 3 |
| De Pastena, M | 1 |
| Marchegiani, G | 1 |
| Bassi, C | 1 |
| Suhool, A | 1 |
| Jang, JY | 4 |
| Busch, OR | 1 |
| Halimi, A | 1 |
| Zarantonello, L | 1 |
| Groot Koerkamp, B | 1 |
| Samra, JS | 1 |
| Mittal, A | 1 |
| Gill, AJ | 1 |
| Bolm, L | 1 |
| van Eijck, CH | 1 |
| Abu Hilal, M | 1 |
| Del Chiaro, M | 1 |
| Keck, T | 1 |
| Alseidi, A | 1 |
| Wolfgang, CL | 1 |
| Malleo, G | 1 |
| Besselink, MG | 1 |
| Hong, E | 1 |
| Park, S | 2 |
| Ooshima, A | 1 |
| Hong, CP | 1 |
| Park, J | 1 |
| Heo, JS | 3 |
| Lee, S | 4 |
| An, H | 1 |
| Kang, JM | 1 |
| Park, SH | 2 |
| Park, JO | 3 |
| Kim, SJ | 2 |
| Nishibeppu, K | 1 |
| Komatsu, S | 4 |
| Imamura, T | 2 |
| Kiuchi, J | 2 |
| Kishimoto, T | 1 |
| Arita, T | 2 |
| Kosuga, T | 2 |
| Konishi, H | 4 |
| Kubota, T | 5 |
| Shiozaki, A | 6 |
| Fujiwara, H | 8 |
| Okamoto, K | 7 |
| Otsuji, E | 6 |
| Chen, L | 3 |
| Bi, S | 1 |
| Wei, Q | 1 |
| Zhao, Z | 4 |
| Wang, C | 3 |
| Xie, S | 1 |
| Lee, JB | 1 |
| Kim, HS | 3 |
| Jung, I | 1 |
| Shin, SJ | 1 |
| Beom, SH | 1 |
| Chang, JS | 1 |
| Koom, WS | 2 |
| Kim, TI | 1 |
| Hur, H | 3 |
| Min, BS | 2 |
| Kim, NK | 2 |
| Jeong, SY | 2 |
| Baek, JH | 1 |
| Kim, SH | 4 |
| Lim, JS | 1 |
| Lee, KY | 2 |
| Ahn, JB | 3 |
| Tsuchiya, N | 1 |
| Matsuyama, R | 1 |
| Murakami, T | 1 |
| Yabushita, Y | 2 |
| Sawada, Y | 1 |
| Kumamoto, T | 2 |
| Endo, I | 2 |
| Rajan, SAP | 1 |
| Skardal, A | 1 |
| Hall, AR | 1 |
| Pederson, H | 1 |
| Staples, CJ | 1 |
| Housewright, C | 1 |
| Yang, Y | 4 |
| Ma, L | 2 |
| Li, W | 5 |
| Cai, J | 1 |
| Sakr, A | 1 |
| Elsherbiny, M | 1 |
| Abdel Moneim, R | 1 |
| Shaaban, S | 1 |
| Aldaly, M | 1 |
| Kim, EJ | 2 |
| Kim, YJ | 2 |
| Lee, HI | 1 |
| Jeong, SH | 1 |
| Nam, HJ | 1 |
| Cho, JH | 1 |
| Chung, HH | 2 |
| Lee, CT | 2 |
| Hu, JM | 1 |
| Chou, YC | 1 |
| Lin, YW | 1 |
| Shih, YL | 1 |
| Fu, J | 1 |
| Wang, X | 10 |
| Yue, Q | 1 |
| Go, G | 1 |
| Yun, CW | 1 |
| Yoon, YM | 1 |
| Lim, JH | 1 |
| Lee, JH | 5 |
| Lee, SH | 4 |
| Wang, T | 4 |
| Gao, X | 2 |
| Zhou, K | 1 |
| Jiang, T | 1 |
| Gao, S | 1 |
| Liu, P | 2 |
| Zuo, X | 1 |
| Shi, X | 1 |
| Li, N | 2 |
| Miao, F | 1 |
| Cai, S | 1 |
| Yu, Y | 3 |
| Hagen, ER | 1 |
| Cleary, RK | 1 |
| Bigness, A | 1 |
| Imanirad, I | 1 |
| Sahin, IH | 1 |
| Xie, H | 1 |
| Frakes, J | 1 |
| Hoffe, S | 1 |
| Laskowitz, D | 1 |
| Felder, S | 1 |
| Noepel-Duennebacke, S | 1 |
| Juette, H | 1 |
| Schulmann, K | 1 |
| Graeven, U | 1 |
| Porschen, R | 1 |
| Stoehlmacher, J | 1 |
| Hegewisch-Becker, S | 2 |
| Raulf, A | 1 |
| Arnold, D | 1 |
| Reinacher-Schick, A | 1 |
| Tannapfel, A | 1 |
| Voogt, ELK | 1 |
| Schaap, DP | 1 |
| van den Berg, K | 1 |
| Nieuwenhuijzen, GAP | 1 |
| Bloemen, JG | 1 |
| Creemers, GJ | 1 |
| Willems, J | 1 |
| Cnossen, JS | 1 |
| Peulen, HMU | 1 |
| Nederend, J | 1 |
| van Lijnschoten, G | 1 |
| Burger, JWA | 1 |
| Rutten, HJT | 1 |
| Akalovich, S | 1 |
| Portyanko, A | 2 |
| Pundik, A | 1 |
| Mezheyeuski, A | 2 |
| Doroshenko, T | 1 |
| Hao, C | 2 |
| Cui, Y | 2 |
| Lane, J | 1 |
| Jia, S | 1 |
| Ji, J | 3 |
| Jiang, WG | 3 |
| Chang, PM | 1 |
| Lu, HJ | 1 |
| Wang, LW | 1 |
| Tai, SK | 2 |
| Chen, MH | 1 |
| Chu, PY | 2 |
| Yang, MH | 2 |
| Ariza, S | 1 |
| Espinosa, S | 1 |
| Naranjo, M | 1 |
| Chang, GJ | 1 |
| Abdel-Rahman, WM | 1 |
| Al-Khayyal, NA | 1 |
| Nair, VA | 1 |
| Aravind, SR | 1 |
| Saber-Ayad, M | 1 |
| Epelboym, I | 1 |
| Zenati, MS | 1 |
| Hamad, A | 1 |
| Steve, J | 1 |
| Lee, KK | 1 |
| Bahary, N | 1 |
| Hogg, ME | 2 |
| Zeh, HJ | 1 |
| Zureikat, AH | 1 |
| Baik, H | 1 |
| Lee, SM | 1 |
| Seo, SH | 1 |
| An, MS | 1 |
| Kim, KH | 1 |
| Bae, KB | 1 |
| Oh, MK | 1 |
| Hong, KH | 1 |
| Wu, X | 2 |
| Wang, H | 5 |
| Lian, Y | 1 |
| Gu, L | 1 |
| Huang, Y | 2 |
| Deng, M | 1 |
| Gao, Z | 1 |
| Zhang, L | 10 |
| Xing, Y | 1 |
| Gao, Q | 1 |
| Sun, X | 1 |
| Zhang, D | 1 |
| Cao, G | 1 |
| Sasaki, T | 1 |
| Ito, Y | 1 |
| Ohue, M | 2 |
| Kanemitsu, Y | 2 |
| Kobatake, T | 1 |
| Ito, M | 2 |
| Moriya, Y | 2 |
| Saito, N | 2 |
| Lu, Y | 1 |
| Huang, H | 1 |
| Yang, H | 1 |
| Chen, D | 2 |
| Katanyoo, K | 1 |
| Berger, MD | 1 |
| Stintzing, S | 2 |
| Heinemann, V | 3 |
| Yang, D | 1 |
| Cao, S | 1 |
| Sunakawa, Y | 1 |
| Ning, Y | 1 |
| Matsusaka, S | 2 |
| Okazaki, S | 1 |
| Miyamoto, Y | 1 |
| Suenaga, M | 2 |
| Schirripa, M | 1 |
| Soni, S | 1 |
| Zhang, W | 3 |
| Falcone, A | 1 |
| Loupakis, F | 1 |
| Lenz, HJ | 1 |
| Wu, JQ | 1 |
| Zhai, J | 1 |
| Li, CY | 2 |
| Tan, AM | 1 |
| Wei, P | 1 |
| Shen, LZ | 1 |
| He, MF | 1 |
| Shoda, K | 1 |
| Nagahara, H | 1 |
| Nakao, S | 1 |
| Fukuoka, T | 1 |
| Shibutani, M | 1 |
| Maeda, K | 2 |
| Matsutani, S | 1 |
| Doi, Y | 1 |
| Ohtani, H | 1 |
| Yamazaki, T | 1 |
| Amano, R | 1 |
| Tanaka, H | 3 |
| Muguruma, K | 1 |
| Yashiro, M | 1 |
| Hirakawa, K | 3 |
| Ohira, M | 2 |
| Kato, M | 1 |
| Murata, A | 1 |
| Nishikawa, S | 1 |
| Tsutsumi, S | 2 |
| Yokoyama, H | 1 |
| Takahashi, K | 3 |
| Morita, T | 2 |
| Odagiri, K | 1 |
| Yamazaki, M | 1 |
| Tanaka, K | 4 |
| Miyazaki, Y | 1 |
| Makino, T | 1 |
| Takahashi, T | 6 |
| Kurokawa, Y | 1 |
| Nakajima, K | 3 |
| Mori, M | 6 |
| Doki, Y | 5 |
| Cercek, A | 2 |
| Roxburgh, CSD | 1 |
| Strombom, P | 1 |
| Smith, JJ | 1 |
| Temple, LKF | 1 |
| Nash, GM | 1 |
| Guillem, JG | 1 |
| Paty, PB | 1 |
| Yaeger, R | 2 |
| Stadler, ZK | 2 |
| Seier, K | 1 |
| Gonen, M | 2 |
| Segal, NH | 2 |
| Reidy, DL | 1 |
| Varghese, A | 1 |
| Shia, J | 2 |
| Vakiani, E | 1 |
| Wu, AJ | 1 |
| Crane, CH | 1 |
| Gollub, MJ | 1 |
| Garcia-Aguilar, J | 3 |
| Saltz, LB | 1 |
| Weiser, MR | 1 |
| Tselis, N | 1 |
| Prott, FJ | 1 |
| Ott, O | 1 |
| Weiss, C | 1 |
| Rödel, C | 2 |
| Greally, M | 1 |
| Pilson, K | 1 |
| Linehan, A | 1 |
| O'Keane, C | 1 |
| Shields, CJ | 1 |
| Conneely, JB | 1 |
| McCaffrey, JA | 1 |
| Desai, GS | 1 |
| Pande, P | 1 |
| Shah, RC | 1 |
| Jagannath, P | 1 |
| Kawakami, T | 1 |
| Tsushima, T | 1 |
| Omae, K | 1 |
| Ogawa, H | 1 |
| Shirasu, H | 1 |
| Kito, Y | 1 |
| Yoshida, Y | 1 |
| Hamauchi, S | 1 |
| Todaka, A | 1 |
| Machida, N | 1 |
| Yokota, T | 1 |
| Yamazaki, K | 1 |
| Fukutomi, A | 1 |
| Onozawa, Y | 1 |
| Yasui, H | 1 |
| Li, S | 2 |
| Tian, J | 1 |
| Zhang, H | 2 |
| Zhou, S | 1 |
| Yang, J | 2 |
| Zhang, Z | 3 |
| Ji, Z | 1 |
| Wu, DM | 1 |
| Hong, XW | 1 |
| Wang, LL | 1 |
| Cui, XF | 1 |
| Lu, J | 1 |
| Chen, GQ | 1 |
| Zheng, YL | 1 |
| Chen, M | 2 |
| Cao, Y | 1 |
| Li, H | 4 |
| Zhao, J | 2 |
| Zhai, Z | 1 |
| Ren, F | 1 |
| Li, K | 1 |
| Hatano, E | 1 |
| Uemoto, S | 1 |
| Yamaue, H | 1 |
| Yamamoto, M | 1 |
| Barenboim, A | 1 |
| Lahat, G | 1 |
| Geva, R | 1 |
| Nachmany, I | 1 |
| Nakache, R | 1 |
| Goykhman, Y | 1 |
| Brazowski, E | 1 |
| Rosen, G | 1 |
| Isakov, O | 1 |
| Wolf, I | 1 |
| Klausner, JM | 1 |
| Lubezky, N | 1 |
| Polski, A | 1 |
| Sibug Saber, M | 1 |
| Kim, JW | 2 |
| Berry, JL | 1 |
| Marco, MR | 1 |
| Zhou, L | 2 |
| Patil, S | 1 |
| Marcet, JE | 1 |
| Varma, MG | 1 |
| Oommen, S | 1 |
| Cataldo, PA | 1 |
| Hunt, SR | 1 |
| Herzig, DO | 1 |
| Fichera, A | 1 |
| Polite, BN | 1 |
| Hyman, NH | 1 |
| Ternent, CA | 1 |
| Stamos, MJ | 1 |
| Pigazzi, A | 1 |
| Dietz, D | 1 |
| Yakunina, Y | 1 |
| Pelossof, R | 1 |
| Mondaca, S | 1 |
| Chatila, WK | 1 |
| Bates, D | 1 |
| Hechtman, JF | 1 |
| Varghese, AM | 1 |
| Kundra, R | 1 |
| Capanu, M | 2 |
| Schultz, N | 1 |
| Saltz, L | 1 |
| Jin, H | 1 |
| Seo, GS | 1 |
| Zambetti, M | 2 |
| Montemurro, F | 1 |
| Morandi, P | 2 |
| Zamagni, C | 2 |
| Brandes, AA | 1 |
| Bisagni, G | 2 |
| Cagossi, K | 1 |
| Bengala, C | 1 |
| Gori, S | 1 |
| Iannacone, C | 1 |
| Stell, A | 1 |
| Gianni, L | 1 |
| Coen, JJ | 1 |
| Zhang, P | 1 |
| Saylor, PJ | 1 |
| Wu, CL | 2 |
| Parker, W | 1 |
| Lautenschlaeger, T | 1 |
| Zietman, AL | 4 |
| Efstathiou, JA | 1 |
| Jani, AB | 1 |
| Kucuk, O | 1 |
| Souhami, L | 2 |
| Rodgers, JP | 1 |
| Sandler, HM | 2 |
| Shipley, WU | 4 |
| Phelip, JM | 1 |
| Edeline, J | 1 |
| Blanc, JF | 2 |
| Barbier, E | 1 |
| Michel, P | 1 |
| Bourgeois, V | 1 |
| Neuzillet, C | 1 |
| Malka, D | 2 |
| Manfredi, S | 2 |
| Desrame, J | 1 |
| Ito, A | 1 |
| Takata, R | 1 |
| Matsuo, T | 2 |
| Kimura, T | 2 |
| Otsuka, K | 2 |
| Ishii, S | 1 |
| Tokiwa, S | 1 |
| Tanji, S | 1 |
| Sugimura, J | 1 |
| Omori, S | 1 |
| Obara, W | 1 |
| Yang, LY | 1 |
| Shan, YM | 1 |
| Zhou, EH | 1 |
| Chen, XP | 1 |
| Sato, H | 1 |
| Tsukahara, K | 1 |
| Okamoto, I | 1 |
| Katsube, Y | 1 |
| Shimizu, A | 1 |
| Kondo, T | 1 |
| Hanyu, K | 1 |
| Fushimi, C | 1 |
| Okada, T | 4 |
| Miura, K | 1 |
| Akhter, K | 1 |
| Enamur Rashid, M | 1 |
| Liu, Q | 1 |
| Jia, B | 1 |
| Du, X | 1 |
| Dai, G | 1 |
| Liu, H | 4 |
| Chen, J | 3 |
| Zeng, M | 1 |
| Wen, K | 1 |
| Wang, Y | 5 |
| Feng, L | 1 |
| Tanaka, M | 1 |
| Heckler, M | 1 |
| Mihaljevic, AL | 1 |
| Sun, H | 1 |
| Klaiber, U | 1 |
| Heger, U | 1 |
| Büchler, MW | 1 |
| Hackert, T | 1 |
| Ding, XQ | 1 |
| Zhao, S | 1 |
| Wang, JY | 2 |
| Zheng, HC | 1 |
| Ma, CM | 1 |
| Cho, KH | 1 |
| Jeong, BY | 1 |
| Park, CG | 1 |
| Lee, HY | 1 |
| Saeinasab, M | 1 |
| Bahrami, AR | 1 |
| González, J | 1 |
| Marchese, FP | 1 |
| Martinez, D | 1 |
| Mowla, SJ | 1 |
| Matin, MM | 1 |
| Huarte, M | 1 |
| Yu, S | 1 |
| Wu, C | 1 |
| Tan, Q | 1 |
| Suganuma, Y | 1 |
| Nishida, T | 1 |
| Ishimoto, T | 1 |
| Sai, S | 1 |
| Nomi, S | 1 |
| Macedo, FI | 1 |
| Ryon, E | 1 |
| Maithel, SK | 1 |
| Lee, RM | 1 |
| Kooby, DA | 1 |
| Fields, RC | 1 |
| Hawkins, WG | 1 |
| Williams, G | 1 |
| Maduekwe, U | 1 |
| Kim, HJ | 3 |
| Ahmad, SA | 1 |
| Patel, SH | 1 |
| Abbott, DE | 1 |
| Schwartz, P | 1 |
| Weber, SM | 1 |
| Scoggins, CR | 1 |
| Martin, RCG | 1 |
| Dudeja, V | 1 |
| Franceschi, D | 1 |
| Livingstone, AS | 1 |
| Merchant, NB | 1 |
| Hrynchyk, I | 1 |
| Herrera, M | 1 |
| Karlberg, M | 1 |
| Osterman, E | 1 |
| Ragnhammar, P | 1 |
| Edler, D | 1 |
| Ponten, F | 1 |
| Sjöblom, T | 1 |
| Glimelius, B | 3 |
| Östman, A | 1 |
| Akiyama, Y | 1 |
| Iwaya, T | 1 |
| Endo, F | 1 |
| Nikai, H | 1 |
| Baba, S | 2 |
| Chiba, T | 1 |
| Takahara, T | 1 |
| Nitta, H | 2 |
| Mizuno, M | 1 |
| Kimura, Y | 3 |
| Koeda, K | 1 |
| Sasaki, A | 1 |
| Beppu, T | 1 |
| Hayashi, H | 1 |
| Chikamoto, A | 1 |
| Baba, H | 1 |
| Golubovskaya, VM | 1 |
| Sumbler, B | 1 |
| Ho, B | 1 |
| Yemma, M | 1 |
| Cance, WG | 1 |
| Oikonomopoulos, GM | 1 |
| Huber, KE | 1 |
| Syrigos, KN | 1 |
| Saif, MW | 1 |
| Quigley, EA | 1 |
| Halpern, AC | 1 |
| Funke, V | 1 |
| Lehmann-Koch, J | 1 |
| Bickeböller, M | 1 |
| Benner, A | 1 |
| Tagscherer, KE | 1 |
| Grund, K | 1 |
| Pfeifer, M | 1 |
| Herpel, E | 1 |
| Schirmacher, P | 1 |
| Chang-Claude, J | 1 |
| Brenner, H | 1 |
| Hoffmeister, M | 1 |
| Roth, W | 1 |
| Horioka, K | 1 |
| Kaku, K | 1 |
| Jimi, S | 1 |
| Oohata, Y | 1 |
| Kamei, T | 1 |
| Gupta, S | 1 |
| Khan, H | 1 |
| Barik, S | 1 |
| Negi, MP | 1 |
| Kim, K | 4 |
| Min, HS | 1 |
| Chie, EK | 3 |
| Kim, SW | 3 |
| Han, SW | 2 |
| Oh, DY | 4 |
| Im, SA | 5 |
| Kim, TY | 6 |
| Bang, YJ | 4 |
| Jang, JJ | 1 |
| Ha, SW | 4 |
| Morrison, LC | 1 |
| McClelland, R | 1 |
| Aiken, C | 1 |
| Bridges, M | 1 |
| Liang, L | 1 |
| Di Curzio, D | 1 |
| Del Bigio, MR | 1 |
| Taylor, MD | 1 |
| Werbowetski-Ogilvie, TE | 1 |
| Elezkurtaj, S | 1 |
| Moser, L | 1 |
| Budczies, J | 1 |
| Müller, AJ | 1 |
| Bläker, H | 1 |
| Buhr, HJ | 1 |
| Dietel, M | 1 |
| Kruschewski, M | 1 |
| Gogia, A | 1 |
| Pushker, N | 1 |
| Sen, S | 1 |
| Bakhshi, S | 1 |
| Martín, M | 1 |
| Ruiz, A | 1 |
| Ruiz Borrego, M | 1 |
| Barnadas, A | 1 |
| González, S | 1 |
| Calvo, L | 1 |
| Margelí Vila, M | 1 |
| Antón, A | 2 |
| Rodríguez-Lescure, A | 1 |
| Seguí-Palmer, MA | 1 |
| Muñoz-Mateu, M | 1 |
| Dorca Ribugent, J | 1 |
| López-Vega, JM | 1 |
| Jara, C | 1 |
| Espinosa, E | 1 |
| Mendiola Fernández, C | 1 |
| Andrés, R | 1 |
| Ribelles, N | 1 |
| Plazaola, A | 1 |
| Sánchez-Rovira, P | 1 |
| Salvador Bofill, J | 1 |
| Crespo, C | 1 |
| Carabantes, FJ | 1 |
| Servitja, S | 1 |
| Chacón, JI | 1 |
| Rodríguez, CA | 1 |
| Hernando, B | 1 |
| Álvarez, I | 1 |
| Carrasco, E | 1 |
| Lluch, A | 2 |
| Wu, CE | 1 |
| Lin, YC | 2 |
| Hong, JH | 1 |
| Chuang, CK | 1 |
| Pang, ST | 1 |
| Liaw, CC | 1 |
| Hunt, D | 1 |
| Kaufman, DS | 3 |
| Uzzo, R | 1 |
| Buyyounouski, MK | 1 |
| Sandler, H | 1 |
| Nishino, T | 2 |
| Yamamoto, Y | 1 |
| Ikeda, M | 3 |
| Morimoto, M | 1 |
| Furukawa, T | 2 |
| Goto, M | 1 |
| Furukita, Y | 1 |
| Takechi, H | 1 |
| Seike, J | 1 |
| Tangoku, A | 1 |
| Zhong, J | 1 |
| Yang, L | 3 |
| Liu, N | 2 |
| Zheng, J | 1 |
| Lin, CY | 3 |
| Baselga, J | 2 |
| Costa, F | 2 |
| Gomez, H | 1 |
| Hudis, CA | 1 |
| Rapoport, B | 1 |
| Roche, H | 2 |
| Schwartzberg, LS | 1 |
| Petrenciuc, O | 1 |
| Shan, M | 1 |
| Gradishar, WJ | 1 |
| Imanishi, S | 1 |
| Shuto, K | 1 |
| Aoyagi, T | 1 |
| Kono, T | 1 |
| Saito, H | 2 |
| Matsubara, H | 2 |
| Weng, Y | 1 |
| Fei, B | 1 |
| Chi, AL | 1 |
| Cai, M | 1 |
| Huddart, RA | 2 |
| Hall, E | 3 |
| Hussain, SA | 6 |
| Jenkins, P | 2 |
| Rawlings, C | 2 |
| Tremlett, J | 2 |
| Crundwell, M | 2 |
| Adab, FA | 1 |
| Sheehan, D | 1 |
| Syndikus, I | 1 |
| Hendron, C | 3 |
| Lewis, R | 3 |
| Waters, R | 2 |
| Guckenberger, M | 1 |
| Saur, G | 1 |
| Wehner, D | 1 |
| Thalheimer, A | 1 |
| Kim, M | 1 |
| Germer, CT | 1 |
| Flentje, M | 1 |
| Strojan, P | 1 |
| Grašič Kuhar, C | 1 |
| Žumer, B | 1 |
| Kadivec, M | 1 |
| Karner, K | 1 |
| Fajdiga, I | 1 |
| Jančar, B | 1 |
| Gale, N | 1 |
| Poljak, M | 1 |
| Kocjan, BJ | 1 |
| Zakotnik, B | 1 |
| Dunne, PD | 1 |
| McArt, DG | 1 |
| Blayney, JK | 1 |
| Kalimutho, M | 1 |
| Greer, S | 1 |
| Srivastava, S | 1 |
| Ong, CW | 1 |
| Arthur, K | 1 |
| Loughrey, M | 1 |
| Redmond, K | 1 |
| Longley, DB | 1 |
| Salto-Tellez, M | 1 |
| Johnston, PG | 1 |
| Van Schaeybroeck, S | 1 |
| Nakagawa, K | 3 |
| Matsuo, K | 1 |
| Taguri, M | 1 |
| Curtis, NJ | 1 |
| Noble, F | 1 |
| Bailey, IS | 1 |
| Kelly, JJ | 1 |
| Byrne, JP | 1 |
| Underwood, TJ | 1 |
| Jia, Y | 2 |
| Ye, L | 2 |
| Ji, K | 1 |
| Toms, AM | 1 |
| Davies, ML | 1 |
| Ruge, F | 1 |
| Hargest, R | 1 |
| Deng, J | 2 |
| Lei, W | 1 |
| Fu, JC | 1 |
| Li, JH | 1 |
| Xiong, JP | 2 |
| Lévy, A | 1 |
| Blanchard, P | 1 |
| Janot, F | 2 |
| Temam, S | 1 |
| Bourhis, J | 1 |
| Daly-Schveitzer, N | 1 |
| Tao, Y | 1 |
| Senfter, D | 2 |
| Huttary, N | 2 |
| Krupitza, G | 2 |
| Dolznig, H | 2 |
| Mader, RM | 2 |
| Zhang, B | 2 |
| Chen, X | 3 |
| Bae, S | 1 |
| Singh, K | 1 |
| Washington, MK | 1 |
| Datta, PK | 1 |
| Sueda, T | 2 |
| Noura, S | 1 |
| Shingai, T | 1 |
| Gotoh, K | 1 |
| Motoori, M | 1 |
| Takahashi, H | 1 |
| Kishi, K | 1 |
| Marubashi, S | 2 |
| Fujiwara, Y | 7 |
| Ohigashi, H | 5 |
| Yano, M | 3 |
| Tomita, Y | 1 |
| Ishikawa, O | 5 |
| Nakayasu, Y | 1 |
| Yoshimatsu, K | 1 |
| Yokomizo, H | 1 |
| Osawa, G | 1 |
| Yano, Y | 1 |
| Nakayama, M | 2 |
| Sakuma, A | 1 |
| Shiozawa, S | 1 |
| Shimakawa, T | 1 |
| Katsube, T | 1 |
| Naritaka, Y | 1 |
| Kuwabara, H | 1 |
| Watanabe, S | 1 |
| Liu, B | 2 |
| Mitsuoka, A | 1 |
| Sanada, T | 1 |
| Goseki, N | 1 |
| Nako, Y | 1 |
| Morimura, R | 1 |
| Murayama, Y | 2 |
| Ikoma, H | 3 |
| Kuriu, Y | 2 |
| Nakanishi, M | 3 |
| Ichikawa, D | 5 |
| Sakakura, C | 2 |
| Giuliani, J | 1 |
| Marzola, M | 1 |
| Diaz, T | 1 |
| Tejero, R | 1 |
| Moreno, I | 1 |
| Ferrer, G | 1 |
| Cordeiro, A | 1 |
| Artells, R | 1 |
| Navarro, A | 1 |
| Hernandez, R | 1 |
| Tapia, G | 1 |
| Monzo, M | 1 |
| Jiao, S | 1 |
| Shi, Z | 1 |
| Dong, A | 1 |
| Song, X | 1 |
| He, F | 2 |
| Wang, W | 2 |
| Guo, T | 1 |
| Li, P | 1 |
| Zhao, Y | 3 |
| Ji, H | 1 |
| Zhou, Z | 1 |
| Yusup, G | 1 |
| Akutsu, Y | 1 |
| Mutallip, M | 1 |
| Qin, W | 1 |
| Hu, X | 4 |
| Komatsu-Akimoto, A | 1 |
| Hoshino, I | 1 |
| Hanari, N | 1 |
| Akanuma, N | 1 |
| Isozaki, Y | 1 |
| Yin, SY | 1 |
| Chao, YK | 1 |
| Tseng, CK | 1 |
| Chang, HK | 1 |
| Liu, YH | 1 |
| Wu, YC | 1 |
| Chen, TP | 1 |
| Yeh, CH | 1 |
| Suzuki, H | 1 |
| Fujii, T | 2 |
| Asao, T | 2 |
| Wada, S | 1 |
| Araki, K | 1 |
| Kubo, N | 2 |
| Watanabe, A | 1 |
| Tsukagoshi, M | 1 |
| Kuwano, H | 2 |
| Kiseleva, VI | 1 |
| Krikunova, LI | 1 |
| Mkrtchian, LS | 1 |
| Liubina, LV | 1 |
| Beziaeva, GP | 1 |
| Panarina, LV | 1 |
| Saenko, AS | 1 |
| Zamulaeva, IA | 1 |
| Matsuda, N | 1 |
| Hayashi, N | 2 |
| Ohde, S | 1 |
| Yagata, H | 1 |
| Kajiura, Y | 1 |
| Yoshida, A | 1 |
| Suzuki, K | 1 |
| Nakamura, S | 2 |
| Tsunoda, H | 1 |
| Yamauchi, H | 1 |
| Wu, WR | 1 |
| Zhang, R | 2 |
| Shi, XD | 1 |
| Zhu, MS | 1 |
| Xu, LB | 1 |
| Zeng, H | 1 |
| Liu, C | 3 |
| Tao, ZH | 1 |
| Wen, D | 1 |
| Wan, JL | 1 |
| Liu, DL | 1 |
| Zhang, S | 2 |
| Cui, JF | 1 |
| Sun, HC | 1 |
| Wang, L | 3 |
| Fan, J | 1 |
| Wu, WZ | 1 |
| Yoshikawa, K | 1 |
| Kuwata, H | 1 |
| Nakahata, Y | 1 |
| Abdel-Fatah, TM | 1 |
| McArdle, SE | 1 |
| Johnson, C | 1 |
| Moseley, PM | 1 |
| Ball, GR | 1 |
| Pockley, AG | 1 |
| Ellis, IO | 3 |
| Rees, RC | 1 |
| Chan, SY | 2 |
| Baik, SH | 1 |
| Kim, H | 1 |
| Zhou, G | 1 |
| Zhao, M | 1 |
| Xie, TX | 1 |
| Tanaka, N | 2 |
| Sano, D | 1 |
| Patel, AA | 1 |
| Ward, AM | 1 |
| Sandulache, VC | 1 |
| Jasser, SA | 1 |
| Skinner, HD | 1 |
| Fitzgerald, AL | 1 |
| Osman, AA | 1 |
| Wei, Y | 2 |
| Xia, X | 1 |
| Songyang, Z | 1 |
| Mills, GB | 1 |
| Hung, MC | 1 |
| Caulin, C | 1 |
| Liang, J | 3 |
| Myers, JN | 1 |
| Tashiro, J | 1 |
| Yamaguchi, S | 1 |
| Ishii, T | 1 |
| Suzuki, A | 1 |
| Kondo, H | 1 |
| Morita, Y | 1 |
| Hara, K | 2 |
| Koyama, I | 1 |
| Du, T | 1 |
| Qu, Y | 1 |
| Li, J | 6 |
| Su, L | 1 |
| Zhou, Q | 2 |
| Yan, M | 1 |
| Li, C | 1 |
| Zhu, Z | 1 |
| Lee, DW | 1 |
| Kim, KJ | 1 |
| Lee, HJ | 1 |
| Rhee, YY | 1 |
| Bae, JM | 1 |
| Cho, NY | 1 |
| Lee, KH | 3 |
| Park, KJ | 1 |
| Park, JG | 1 |
| Kang, GH | 1 |
| Wang, SS | 1 |
| Xie, X | 2 |
| Wong, CS | 1 |
| Choi, Y | 1 |
| Fung, MC | 1 |
| Xiong, B | 1 |
| Zhang, C | 1 |
| Cheng, Y | 2 |
| Iveson, T | 1 |
| Donehower, RC | 1 |
| Davidenko, I | 1 |
| Tjulandin, S | 1 |
| Deptala, A | 1 |
| Harrison, M | 1 |
| Nirni, S | 1 |
| Lakshmaiah, K | 1 |
| Thomas, A | 1 |
| Jiang, Y | 2 |
| Zhu, M | 1 |
| Tang, R | 1 |
| Anderson, A | 1 |
| Dubey, S | 1 |
| Oliner, KS | 1 |
| Loh, E | 1 |
| Jia, L | 2 |
| Ren, D | 1 |
| Gong, Y | 1 |
| Wang, N | 1 |
| Zhang, X | 3 |
| Andreoli, SC | 1 |
| Gasparini, NJ | 1 |
| de Carvalho, GP | 1 |
| Garicochea, B | 2 |
| Pogue, RE | 1 |
| de Andrade, RV | 1 |
| Sudarshan, M | 1 |
| Alcindor, T | 1 |
| Ades, S | 1 |
| Aloraini, A | 1 |
| van Huyse, M | 1 |
| Asselah, J | 1 |
| David, M | 1 |
| Frechette, D | 1 |
| Brisson, S | 1 |
| Thirlwell, M | 1 |
| Ferri, L | 1 |
| Marthey, L | 1 |
| Sa-Cunha, A | 1 |
| Gauthier, M | 1 |
| Cueff, A | 1 |
| Francois, E | 1 |
| Trouilloud, I | 1 |
| Bachet, JB | 1 |
| Coriat, R | 1 |
| Terrebonne, E | 1 |
| De La Fouchardière, C | 1 |
| Solub, D | 1 |
| Lécaille, C | 1 |
| Thirot Bidault, A | 1 |
| Carbonnel, F | 1 |
| Taieb, J | 2 |
| Yuan, Y | 1 |
| Cai, H | 1 |
| Yang, XJ | 1 |
| Guo, TK | 1 |
| Chen, YR | 1 |
| von Weikersthal, LF | 1 |
| Decker, T | 2 |
| Kiani, A | 1 |
| Vehling-Kaiser, U | 2 |
| Al-Batran, SE | 2 |
| Heintges, T | 1 |
| Lerchenmüller, C | 1 |
| Kahl, C | 1 |
| Seipelt, G | 1 |
| Kullmann, F | 1 |
| Stauch, M | 1 |
| Scheithauer, W | 2 |
| Hielscher, J | 1 |
| Scholz, M | 2 |
| Müller, S | 1 |
| Link, H | 2 |
| Niederle, N | 1 |
| Rost, A | 1 |
| Höffkes, HG | 1 |
| Moehler, M | 3 |
| Lindig, RU | 1 |
| Modest, DP | 1 |
| Rossius, L | 1 |
| Kirchner, T | 1 |
| Jung, A | 1 |
| Mikami, Y | 2 |
| Tamura, N | 1 |
| Akiyama, M | 1 |
| Muraoka, T | 1 |
| Sakurai, U | 1 |
| Sawabe, M | 1 |
| Lindner, K | 1 |
| Borchardt, C | 1 |
| Schöpp, M | 1 |
| Bürgers, A | 1 |
| Stock, C | 1 |
| Hussey, DJ | 1 |
| Haier, J | 1 |
| Hummel, R | 1 |
| Cienfuegos, JA | 2 |
| Rotellar, F | 1 |
| Baixauli, J | 2 |
| Beorlegui, C | 2 |
| Sola, JJ | 2 |
| Arbea, L | 1 |
| Pastor, C | 2 |
| Arredondo, J | 1 |
| Hernández-Lizoáin, JL | 2 |
| Hong, YS | 1 |
| Nam, BH | 1 |
| Kim, KP | 1 |
| Kim, JE | 2 |
| Park, SJ | 2 |
| Park, YS | 2 |
| Kim, SY | 1 |
| Kim, JH | 3 |
| Lim, SB | 1 |
| Yu, CS | 1 |
| Kim, JC | 1 |
| Yun, SH | 2 |
| Park, JH | 1 |
| Park, HC | 2 |
| Jung, KH | 1 |
| Kim, TW | 2 |
| Holck, S | 1 |
| Nielsen, HJ | 1 |
| Hammer, E | 1 |
| Christensen, IJ | 1 |
| Larsson, LI | 1 |
| Miyata, Y | 1 |
| Nomata, K | 1 |
| Ohba, K | 1 |
| Sakamoto, I | 1 |
| Uetani, M | 1 |
| Sakai, H | 1 |
| Zuo, D | 1 |
| Chen, Y | 3 |
| Liu, R | 1 |
| He, Y | 2 |
| Ren, L | 1 |
| Deng, T | 1 |
| Ying, G | 1 |
| Ba, Y | 1 |
| Bilici, A | 1 |
| Selcukbiricik, F | 1 |
| Demir, N | 1 |
| Oven Ustaalioglu, BB | 1 |
| Dikilitas, M | 1 |
| Yildiz, O | 1 |
| Misirlioglu, HC | 1 |
| Coskun-Breuneval, M | 1 |
| Kucukpilakci, B | 1 |
| Ugur, VI | 1 |
| Elgin, Y | 1 |
| Demirkasimoglu, T | 1 |
| Kara, SP | 1 |
| Ozgen, A | 1 |
| Sanri, E | 1 |
| Guney, Y | 1 |
| Ordu, AD | 1 |
| Nieder, C | 1 |
| Geinitz, H | 1 |
| Kup, PG | 1 |
| Deymann, LF | 1 |
| Scherer, V | 1 |
| Combs, SE | 1 |
| Fakhrian, K | 1 |
| Wan, LY | 1 |
| Xiang, XJ | 1 |
| Yu, F | 1 |
| Sun, Z | 2 |
| Feng, M | 2 |
| Kang, Y | 1 |
| Suzuki, R | 1 |
| Li, SQ | 1 |
| Roife, D | 1 |
| Truty, MJ | 1 |
| Chatterjee, D | 1 |
| Thomas, RM | 1 |
| Cardwell, J | 1 |
| Katz, MH | 1 |
| Fleming, JB | 1 |
| Tréhoux, S | 1 |
| Duchêne, B | 1 |
| Jonckheere, N | 2 |
| Van Seuningen, I | 1 |
| Unal, OU | 1 |
| Oztop, I | 3 |
| Kos, T | 1 |
| Turan, N | 1 |
| Kucukoner, M | 2 |
| Helvaci, K | 1 |
| Berk, V | 1 |
| Sevinc, A | 1 |
| Yildiz, R | 1 |
| Cinkir, Hy | 1 |
| Tonyali, O | 1 |
| Demirci, U | 1 |
| Aktas, B | 1 |
| Balakan, O | 1 |
| Yilmaz, AU | 1 |
| Zhang, N | 1 |
| Xu, T | 1 |
| Zhou, M | 1 |
| Peng, L | 1 |
| Miao, R | 1 |
| Sheng, H | 2 |
| Li, L | 1 |
| Atanaskova Mesinkovska, N | 1 |
| Conic, RZ | 1 |
| Kiracofe, EA | 1 |
| Vidimos, AT | 1 |
| Derouet, MF | 1 |
| Liu, G | 3 |
| Darling, GE | 1 |
| Zhao, L | 1 |
| Liu, L | 3 |
| Su, C | 1 |
| Su, R | 1 |
| Chan, E | 1 |
| Kwak, EL | 1 |
| Hwang, J | 1 |
| Heiskala, M | 1 |
| de La Bourdonnaye, G | 1 |
| Mita, M | 1 |
| Baba, K | 2 |
| Oshita, A | 1 |
| Kohyama, M | 1 |
| Inoue, S | 2 |
| Kuroo, Y | 1 |
| Yamaguchi, T | 5 |
| Nakamura, H | 2 |
| Sugiyama, Y | 1 |
| Tazaki, T | 1 |
| Sasaki, M | 2 |
| Daimaru, Y | 1 |
| Ohdan, H | 1 |
| Nakamitsu, A | 1 |
| Suda, K | 1 |
| Kameyama, H | 2 |
| Shimada, Y | 2 |
| Sakata, J | 2 |
| Kobayashi, T | 4 |
| Nogami, H | 1 |
| Minagawa, M | 2 |
| Kosugi, S | 2 |
| Koyama, Y | 2 |
| Wakai, T | 2 |
| Kimura, K | 2 |
| Kagawa, Y | 1 |
| Kato, T | 6 |
| Ishida, T | 1 |
| Morimoto, Y | 2 |
| Matusita, K | 1 |
| Kusama, H | 1 |
| Hashimoto, T | 1 |
| Katura, Y | 1 |
| Nitta, K | 1 |
| Takeno, A | 1 |
| Nakahira, S | 1 |
| Okishiro, M | 1 |
| Sakisaka, H | 1 |
| Egawa, C | 1 |
| Takeda, Y | 3 |
| Tamura, S | 1 |
| Ando, Y | 1 |
| Kadokawa, Y | 1 |
| Aisu, Y | 1 |
| Honda, K | 2 |
| Nishino, H | 5 |
| Nishiuchi, A | 1 |
| Kato, S | 1 |
| Machimoto, T | 1 |
| Asao, Y | 1 |
| Furuyama, H | 1 |
| Yoshimura, T | 1 |
| Yamamoto, K | 2 |
| Fujitani, K | 2 |
| Tsujinaka, T | 3 |
| Hirao, M | 2 |
| Nishikawa, K | 1 |
| Fukuda, Y | 1 |
| Haraguchi, N | 2 |
| Miyake, M | 1 |
| Asaoka, T | 1 |
| Miyamoto, A | 2 |
| Omiya, H | 1 |
| Takami, K | 1 |
| Nakamori, S | 7 |
| Sekimoto, M | 2 |
| Hwang, JE | 1 |
| Hong, JY | 2 |
| Shim, HJ | 1 |
| Bae, WK | 1 |
| Hwang, EC | 1 |
| Jeong, O | 1 |
| Park, YK | 1 |
| Cho, SH | 1 |
| Chung, IJ | 1 |
| Addeo, P | 1 |
| Rosso, E | 1 |
| Fuchshuber, P | 1 |
| Oussoultzoglou, E | 1 |
| De Blasi, V | 1 |
| Simone, G | 1 |
| Belletier, C | 1 |
| Dufour, P | 1 |
| Bachellier, P | 1 |
| Troussier, I | 1 |
| Huguet, F | 1 |
| Servagi-Vernat, S | 1 |
| Benahim, C | 1 |
| Khalifa, J | 1 |
| Darmon, I | 1 |
| Ortholan, C | 1 |
| Krebs, L | 1 |
| Dejean, C | 1 |
| Fenoglietto, P | 1 |
| Vieillot, S | 1 |
| Bensadoun, RJ | 1 |
| Thariat, J | 1 |
| McDonald, AM | 1 |
| Dulaney, CR | 1 |
| López-Araujo, J | 1 |
| Posey, JA | 1 |
| Keene, KS | 1 |
| Christein, JD | 1 |
| Heslin, MJ | 1 |
| Wood, TE | 1 |
| Jacob, R | 1 |
| Onishi, H | 1 |
| Nouso, K | 1 |
| Wada, N | 1 |
| Miyahara, K | 1 |
| Takeuchi, Y | 1 |
| Kuwaki, K | 1 |
| Yasunaka, T | 1 |
| Miyake, Y | 2 |
| Shiraha, H | 1 |
| Takaki, A | 1 |
| Kobayashi, Y | 1 |
| Sakaguchi, K | 1 |
| Kanazawa, S | 1 |
| Hassan, AS | 1 |
| Naicker, M | 1 |
| Yusof, KH | 1 |
| Wan Ishak, WZ | 1 |
| Kucukzeybek, Y | 1 |
| Dirican, A | 1 |
| Demir, L | 1 |
| Yildirim, S | 1 |
| Akyol, M | 1 |
| Yildiz, Y | 1 |
| Bayoglu, IV | 1 |
| Alacacioglu, A | 1 |
| Varol, U | 2 |
| Salman, T | 1 |
| Yildiz, I | 1 |
| Can, H | 1 |
| Tarhan, MO | 1 |
| Holzner, S | 1 |
| Kalipciyan, M | 1 |
| Staribacher, A | 1 |
| Walzl, A | 1 |
| Krieger, S | 1 |
| Brenner, S | 1 |
| Jäger, W | 1 |
| Lund, K | 1 |
| Dembinski, JL | 1 |
| Solberg, N | 1 |
| Urbanucci, A | 1 |
| Mills, IG | 1 |
| Krauss, S | 1 |
| Shakibaei, M | 1 |
| Kraehe, P | 1 |
| Popper, B | 1 |
| Shayan, P | 1 |
| Buhrmann, C | 1 |
| Iwayama, Y | 1 |
| Tsuruma, T | 1 |
| Mizuguchi, T | 1 |
| Furuhata, T | 1 |
| Toyota, N | 1 |
| Matsumura, M | 1 |
| Torigoe, T | 1 |
| Sato, N | 1 |
| Hirata, K | 3 |
| Xie, Q | 1 |
| Rao, Q | 1 |
| Li, R | 1 |
| Zhou, H | 2 |
| Han, J | 1 |
| Yao, T | 1 |
| Lin, Z | 2 |
| Amankwatia, EB | 1 |
| Chakravarty, P | 1 |
| Carey, FA | 1 |
| Weidlich, S | 1 |
| Steele, RJ | 1 |
| Munro, AJ | 1 |
| Wolf, CR | 1 |
| Smith, G | 1 |
| Wattanawongdon, W | 1 |
| Hahnvajanawong, C | 1 |
| Namwat, N | 1 |
| Kanchanawat, S | 1 |
| Boonmars, T | 1 |
| Jearanaikoon, P | 2 |
| Leelayuwat, C | 1 |
| Techasen, A | 1 |
| Seubwai, W | 1 |
| Zheng, W | 1 |
| Xu, YJ | 1 |
| Qiu, SF | 1 |
| Zong, JF | 1 |
| Huang, LL | 1 |
| Huang, CB | 1 |
| Lin, SJ | 1 |
| Pan, JJ | 1 |
| Poschau, M | 1 |
| Dickreuter, E | 1 |
| Singh-Müller, J | 1 |
| Zscheppang, K | 1 |
| Eke, I | 1 |
| Liersch, T | 1 |
| Cordes, N | 1 |
| Doornaert, P | 1 |
| Terhaard, CH | 1 |
| Kaanders, JH | 1 |
| Kawaoka, T | 1 |
| Aikata, H | 1 |
| Hyogo, H | 1 |
| Morio, R | 1 |
| Morio, K | 1 |
| Hatooka, M | 1 |
| Fukuhara, T | 2 |
| Naeshiro, N | 1 |
| Miyaki, D | 1 |
| Hiramatsu, A | 1 |
| Imamura, M | 2 |
| Kawakami, Y | 1 |
| Takahashi, S | 2 |
| Waki, K | 1 |
| Tsuji, K | 1 |
| Kohno, H | 2 |
| Moriya, T | 1 |
| Chayama, K | 1 |
| Chi, JY | 1 |
| Hsiao, YW | 1 |
| Li, CF | 2 |
| Lo, YC | 1 |
| Lin, ZY | 1 |
| Liu, YM | 1 |
| Han, X | 1 |
| Wang, SM | 1 |
| Chen, BK | 1 |
| Tsai, KK | 1 |
| Wang, JM | 1 |
| He, S | 1 |
| O'Connell, D | 1 |
| Oh, S | 1 |
| Ma, B | 2 |
| Varghese, B | 1 |
| Yip, J | 1 |
| Dolatshahi Pirooz, S | 1 |
| Li, M | 1 |
| Li, GM | 1 |
| Ellen Martin, S | 1 |
| Machida, K | 1 |
| Liang, C | 1 |
| Kang, CM | 1 |
| Bang, SM | 1 |
| Choi, JY | 1 |
| Seong, JS | 2 |
| Hwang, HK | 1 |
| Choi, SH | 4 |
| Lee, WJ | 2 |
| Guo, XZ | 1 |
| Ye, XL | 1 |
| Xiao, WZ | 1 |
| Wei, XN | 1 |
| You, QH | 1 |
| Che, XH | 1 |
| Cai, YJ | 1 |
| Chen, F | 1 |
| Yuan, H | 1 |
| Liu, XJ | 1 |
| Yu, MH | 1 |
| Zhang, J | 3 |
| Zheng, H | 1 |
| Nong, Z | 1 |
| Lu, G | 1 |
| Shah, MA | 2 |
| Janjigian, YY | 1 |
| Stoller, R | 1 |
| Shibata, S | 1 |
| Kemeny, M | 1 |
| Krishnamurthi, S | 1 |
| Su, YB | 1 |
| Ocean, A | 1 |
| Mehrotra, B | 1 |
| Ritch, P | 1 |
| Henderson, C | 1 |
| Kelsen, DP | 2 |
| Sawyer, MB | 1 |
| Pituskin, E | 1 |
| Damaraju, S | 1 |
| Bies, RR | 1 |
| Vos, LJ | 1 |
| Prado, CM | 1 |
| Kuzma, M | 1 |
| Scarfe, AG | 1 |
| Clemons, M | 1 |
| Tonkin, K | 1 |
| Au, HJ | 1 |
| Koski, S | 1 |
| Joy, AA | 1 |
| Smylie, M | 1 |
| King, K | 1 |
| Carandang, D | 1 |
| Damaraju, VL | 1 |
| Hanson, J | 1 |
| Cass, CE | 2 |
| Mackey, JR | 2 |
| Altan, B | 1 |
| Yokobori, T | 1 |
| Ide, M | 1 |
| Mochiki, E | 1 |
| Toyomasu, Y | 1 |
| Kogure, N | 1 |
| Kimura, A | 2 |
| Bai, T | 1 |
| Bao, P | 1 |
| Suzuki, M | 1 |
| Ogata, K | 1 |
| Nishiyama, M | 1 |
| Oyama, T | 2 |
| Matsumoto, H | 2 |
| Okumura, H | 1 |
| Murakami, H | 1 |
| Kubota, H | 1 |
| Higashida, M | 1 |
| Tsuruta, A | 1 |
| Tohyama, K | 1 |
| Hirai, T | 1 |
| Wu, S | 1 |
| Liu, F | 1 |
| Xie, L | 1 |
| Peng, Y | 1 |
| Lv, X | 1 |
| He, X | 1 |
| Safran, H | 1 |
| Charpentier, KP | 1 |
| Perez, K | 1 |
| Mantripragada, K | 1 |
| Miner, T | 1 |
| DiPetrillo, T | 1 |
| Kuritzky, B | 1 |
| Apor, E | 1 |
| Bishop, K | 1 |
| Luppe, D | 1 |
| Mitchell, K | 1 |
| Rosati, K | 1 |
| Song, B | 1 |
| Cui, H | 1 |
| Cheng, C | 1 |
| Yang, B | 1 |
| Wang, F | 2 |
| Kong, P | 1 |
| Jia, Z | 1 |
| Bi, Y | 1 |
| Shi, R | 1 |
| Yan, T | 1 |
| Xu, E | 1 |
| Qian, Y | 1 |
| Xi, Y | 1 |
| Guo, S | 2 |
| Li, G | 1 |
| Jia, J | 1 |
| Guo, J | 1 |
| Li, Q | 1 |
| Cheng, X | 1 |
| Zhan, Q | 1 |
| Davis, EJ | 1 |
| Griffith, KA | 1 |
| Ruch, JM | 1 |
| McDonnell, KJ | 1 |
| Zalupski, MM | 1 |
| Lee, NP | 1 |
| Law, S | 1 |
| Cheung, AL | 1 |
| Tato-Costa, J | 1 |
| Casimiro, S | 1 |
| Pacheco, T | 1 |
| Pires, R | 1 |
| Fernandes, A | 1 |
| Alho, I | 1 |
| Pereira, P | 1 |
| Costa, P | 1 |
| Castelo, HB | 1 |
| Ferreira, J | 1 |
| Costa, L | 1 |
| Laurent, M | 1 |
| Des Guetz, G | 1 |
| Bastuji-Garin, S | 1 |
| Culine, S | 2 |
| Caillet, P | 1 |
| Aparicio, T | 2 |
| Audureau, E | 1 |
| Carvahlo-Verlinde, M | 1 |
| Reinald, N | 1 |
| Tournigand, C | 1 |
| Landre, T | 1 |
| LeThuaut, A | 1 |
| Paillaud, E | 1 |
| Canouï-Poitrine, F | 1 |
| Jiang, CF | 1 |
| Li, DM | 2 |
| Ge, X | 1 |
| Shi, ZM | 1 |
| Liu, X | 3 |
| Yin, Y | 1 |
| Zhen, L | 1 |
| Liu, LZ | 1 |
| Jiang, BH | 1 |
| George, A | 1 |
| Heney, NM | 2 |
| Uzzo, RG | 1 |
| Dreicer, R | 1 |
| Wallace, HJ | 1 |
| Dobelbower, MC | 1 |
| Jian, B | 1 |
| Li, Z | 1 |
| Xiao, D | 1 |
| He, G | 1 |
| Bai, L | 2 |
| Yang, Q | 2 |
| Nagamatsu, H | 1 |
| Sumie, S | 1 |
| Niizeki, T | 1 |
| Tajiri, N | 1 |
| Iwamoto, H | 1 |
| Aino, H | 1 |
| Nakano, M | 2 |
| Shimose, S | 1 |
| Satani, M | 1 |
| Okamura, S | 1 |
| Kuromatsu, R | 1 |
| Matsugaki, S | 1 |
| Kurogi, J | 1 |
| Kajiwara, M | 1 |
| Koga, H | 1 |
| Torimura, T | 1 |
| Otani, T | 1 |
| Kaneko, K | 1 |
| Sato, T | 1 |
| Suzuki, S | 2 |
| Aono, T | 1 |
| Muto, I | 1 |
| Hasegawa, M | 1 |
| Kurosaki, I | 1 |
| Takenoya, T | 1 |
| Nishimura, Y | 2 |
| Asayama, M | 1 |
| Takano, M | 1 |
| Mori, Y | 1 |
| Ishikawa, H | 1 |
| Nishizawa, Y | 3 |
| Fukuda, T | 1 |
| Kazama, S | 1 |
| Amikura, K | 1 |
| Kurozumi, M | 1 |
| Kawashima, Y | 1 |
| Tanaka, Y | 3 |
| Sakamoto, H | 1 |
| Zielinski, V | 1 |
| Laban, S | 1 |
| Tribius, S | 1 |
| Schafhausen, P | 1 |
| Veldhoen, S | 1 |
| Knecht, R | 1 |
| Clauditz, T | 1 |
| Muenscher, A | 1 |
| Nair, AG | 1 |
| Kaliki, S | 1 |
| Mishra, DK | 1 |
| Reddy, VA | 1 |
| Naik, MN | 1 |
| Zhu, P | 1 |
| Zhao, N | 1 |
| Sheng, D | 1 |
| Hou, J | 1 |
| Yang, X | 1 |
| Zhu, B | 1 |
| Han, Z | 1 |
| Wei, L | 1 |
| Dos Santos, LV | 1 |
| Faria, TM | 1 |
| Lima, AB | 1 |
| Abdalla, KC | 1 |
| de Moraes, ED | 1 |
| Cruz, MR | 1 |
| Lima, JP | 1 |
| Ock, CY | 1 |
| Keam, B | 1 |
| Kim, TM | 1 |
| Han, DH | 1 |
| Won, TB | 1 |
| Hah, JH | 1 |
| Kwon, TK | 1 |
| Kim, DW | 1 |
| Kim, DY | 1 |
| Rhee, CS | 1 |
| Wu, HG | 2 |
| Sung, MW | 1 |
| Heo, DS | 1 |
| Shao, S | 1 |
| Sun, PH | 1 |
| Satherley, LK | 1 |
| Ji, KE | 1 |
| Feng, YI | 1 |
| Takagi, H | 3 |
| Ariake, K | 1 |
| Takemura, S | 1 |
| Doi, T | 1 |
| Stojanović, N | 1 |
| Brozovic, A | 1 |
| Majhen, D | 1 |
| Bosnar, MH | 1 |
| Fritz, G | 1 |
| Osmak, M | 1 |
| Ambriović-Ristov, A | 1 |
| Ameri, A | 1 |
| Mortazavi, N | 1 |
| Khoshbakht Ahmadi, H | 1 |
| Novin, K | 1 |
| Kang, HR | 1 |
| Choi, HG | 1 |
| Jeon, CK | 1 |
| Lim, SJ | 1 |
| Kim, HY | 1 |
| Cho, Y | 1 |
| Kang, H | 1 |
| Yim, YS | 1 |
| Song, J | 1 |
| Chun, KH | 1 |
| Stanisavljević, L | 1 |
| Myklebust, MP | 1 |
| Leh, S | 1 |
| Dahl, O | 1 |
| Popovtzer, A | 1 |
| Burnstein, H | 1 |
| Stemmer, S | 1 |
| Limon, D | 1 |
| Hili, O | 1 |
| Bachar, G | 1 |
| Sopov, V | 1 |
| Feinmesser, R | 1 |
| Groshar, D | 1 |
| Shvero, J | 1 |
| Kawaguchi, T | 1 |
| Takeshita, H | 1 |
| Miyamae, M | 1 |
| Ohashi, T | 1 |
| Okajima, W | 1 |
| Martínez, P | 1 |
| Rosenstone, S | 1 |
| Rodríguez, J | 1 |
| Ansari, N | 1 |
| Solomon, MJ | 1 |
| Fisher, RJ | 1 |
| Mackay, J | 1 |
| Burmeister, B | 1 |
| Ackland, S | 1 |
| Heriot, A | 1 |
| Joseph, D | 1 |
| McLachlan, SA | 1 |
| McClure, B | 1 |
| Ngan, SY | 1 |
| Lu, YX | 1 |
| Chen, DL | 1 |
| Wang, DS | 1 |
| Chen, LZ | 1 |
| Mo, HY | 1 |
| Wu, QN | 1 |
| Yu, HE | 1 |
| Xie, D | 1 |
| Yun, JP | 1 |
| Zeng, ZL | 1 |
| Ju, HQ | 1 |
| Xu, RH | 1 |
| Weng, M | 1 |
| Yang, C | 1 |
| Ning, N | 1 |
| Zhao, R | 1 |
| Yang, W | 1 |
| Jin, Y | 1 |
| Redpath, RJ | 1 |
| Jin, X | 1 |
| Zhong, Z | 1 |
| Zhang, F | 1 |
| Shen, G | 1 |
| Chen, H | 1 |
| Yang, P | 1 |
| Wu, Q | 1 |
| Wei, J | 1 |
| Chen, Z | 2 |
| Hu, H | 1 |
| Cao, J | 1 |
| Lv, Y | 1 |
| Cai, Y | 1 |
| Wei, W | 1 |
| Yin, C | 1 |
| Hao, Z | 1 |
| Shen, C | 1 |
| Park, M | 1 |
| Sundaramoorthy, P | 1 |
| Sim, JJ | 1 |
| Jeong, KY | 1 |
| Kim, HM | 2 |
| Ni, S | 1 |
| Zhu, X | 1 |
| Wan, C | 1 |
| Xu, J | 1 |
| Lu, C | 1 |
| Xiao, L | 1 |
| Jiang, C | 1 |
| He, Z | 2 |
| Jahani, M | 1 |
| Azadbakht, M | 1 |
| Norooznezhad, F | 1 |
| Mansouri, K | 1 |
| Choudhury, A | 1 |
| West, CM | 1 |
| Porta, N | 1 |
| Denley, H | 1 |
| Huddart, R | 1 |
| James, N | 2 |
| Ishii, Y | 1 |
| Hirano, Y | 1 |
| Munechika, T | 1 |
| Yonemitsu, Y | 1 |
| Nomi, M | 1 |
| Shibata, R | 1 |
| Okamoto, T | 1 |
| Maeno, H | 1 |
| Yanagisawa, J | 1 |
| Kawamoto, S | 1 |
| Noritomi, T | 1 |
| Yu, X | 1 |
| Shi, W | 1 |
| Sun, S | 1 |
| Song, Z | 1 |
| Liu, M | 1 |
| Zeng, Q | 1 |
| Cui, S | 1 |
| Qu, X | 1 |
| Schramm, A | 1 |
| Schochter, F | 1 |
| Friedl, TWP | 1 |
| de Gregorio, N | 1 |
| Andergassen, U | 1 |
| Alunni-Fabbroni, M | 1 |
| Trapp, E | 1 |
| Jaeger, B | 1 |
| Heinrich, G | 1 |
| Camara, O | 1 |
| Ober, A | 1 |
| Mahner, S | 1 |
| Fehm, TN | 1 |
| Pantel, K | 1 |
| Fasching, PA | 1 |
| Schneeweiss, A | 1 |
| Janni, W | 1 |
| Rack, BK | 1 |
| Liang, X | 1 |
| Shi, H | 1 |
| Qiu, C | 1 |
| Lin, S | 1 |
| Qi, Y | 1 |
| Zhao, A | 1 |
| Christou, N | 1 |
| Perraud, A | 1 |
| Blondy, S | 1 |
| Jauberteau, MO | 1 |
| Battu, S | 1 |
| Mathonnet, M | 1 |
| Sun, Y | 1 |
| Hu, S | 1 |
| Yue, J | 1 |
| Xue, X | 1 |
| Xue, L | 1 |
| Kudriavtsev, DV | 1 |
| Kudriavtseva, GT | 1 |
| Mardynskiĭ, IuS | 1 |
| Poortmans, PM | 1 |
| Richaud, P | 1 |
| Collette, L | 1 |
| Ho Goey, S | 1 |
| Pierart, M | 1 |
| Van Der Hulst, M | 1 |
| Bolla, M | 1 |
| Izzo, L | 1 |
| Pietrasanta, D | 1 |
| Izzo, P | 1 |
| Caputo, M | 1 |
| Di Cello, P | 1 |
| Meloni, P | 1 |
| Bolognese, A | 1 |
| Jensen, SA | 1 |
| Vainer, B | 1 |
| Witton, CJ | 1 |
| Jørgensen, JT | 1 |
| Sørensen, JB | 1 |
| Hata, F | 1 |
| Sasaki, K | 1 |
| Yamamitsu, S | 2 |
| Shirasaka, T | 2 |
| Diao, C | 1 |
| Cheng, RC | 1 |
| Zhang, JM | 1 |
| Wei, XP | 1 |
| Su, YJ | 1 |
| Liu, QY | 1 |
| Xu, JB | 1 |
| Tan, YT | 1 |
| Lin, ZQ | 1 |
| Chen, Q | 2 |
| Wang, LJ | 1 |
| Zhang, BZ | 1 |
| Nohara, T | 1 |
| Iwamoto, M | 1 |
| Sumiyoshi, K | 1 |
| Harada, T | 1 |
| Tanaka, S | 1 |
| Takahashi, Y | 3 |
| Tanigawa, N | 1 |
| Trojan, J | 1 |
| Lubomierski, N | 1 |
| Lehnert, T | 1 |
| Engels, K | 1 |
| Zeuzem, S | 1 |
| Bechstein, WO | 1 |
| Kikuchi, M | 1 |
| Kamei, S | 1 |
| Morirama, Y | 1 |
| Tuchiya, T | 1 |
| Miwa, K | 1 |
| Yokoi, S | 1 |
| Ehara, H | 1 |
| Deguchi, T | 1 |
| Hirose, Y | 1 |
| Lyons, JM | 1 |
| Anthony, CT | 1 |
| Thomson, JL | 1 |
| Woltering, EA | 1 |
| Chiarion-Sileni, V | 1 |
| Innocente, R | 1 |
| Cavina, R | 1 |
| Ruol, A | 1 |
| Corti, L | 1 |
| Pigozzo, J | 1 |
| Del Bianco, P | 1 |
| Fumagalli, U | 1 |
| Santoro, A | 2 |
| Ancona, E | 1 |
| Lee, CC | 3 |
| Chu, ST | 2 |
| Chou, P | 2 |
| Chen, LF | 1 |
| Nitsche, M | 1 |
| Horstmann, O | 1 |
| Christiansen, H | 1 |
| Hermann, RM | 1 |
| Hess, CF | 1 |
| Becker, H | 1 |
| Pradier, O | 1 |
| Schmidberger, H | 2 |
| Fernández Sarabia, MT | 1 |
| Rodríguez García, JM | 1 |
| Cardenal Escarcena, A | 1 |
| Serrano Vicente, J | 1 |
| García Bernardo, L | 1 |
| Vliegen, RF | 1 |
| Beets-Tan, RG | 1 |
| Vanhauten, B | 1 |
| Driessen, A | 1 |
| Oellers, M | 1 |
| Kessels, AG | 1 |
| Arens, A | 1 |
| Beets, GL | 1 |
| Buijsen, J | 1 |
| van Baardwijk, A | 1 |
| de Ruysscher, D | 1 |
| Lammering, G | 1 |
| Noda, T | 1 |
| Nagano, H | 4 |
| Kobayashi, S | 1 |
| Murakami, M | 2 |
| Tomimaru, Y | 2 |
| Dono, K | 2 |
| Umeshita, K | 2 |
| Shima, T | 1 |
| Wakasa, K | 2 |
| Monden, M | 4 |
| Nishio, M | 1 |
| Miyashita, A | 1 |
| Nagata, H | 1 |
| Hamada, T | 1 |
| Kubota, K | 1 |
| Kikuchi, S | 2 |
| Ochiai, T | 4 |
| Kokuba, Y | 2 |
| Sonoyama, T | 2 |
| Park, IJ | 1 |
| Choi, GS | 1 |
| Lim, KH | 1 |
| Kang, BM | 1 |
| Jun, SH | 1 |
| Cho, YB | 1 |
| Lee, WY | 1 |
| Song, SY | 1 |
| Shin, HJ | 1 |
| Ahn, KD | 1 |
| Lee, JM | 1 |
| Kim, HC | 1 |
| Chun, HK | 1 |
| Meredith, KL | 1 |
| Hoffe, SE | 1 |
| Shibata, D | 1 |
| Dittmar, Y | 1 |
| Voigt, R | 1 |
| Heise, M | 1 |
| Rabsch, A | 1 |
| Jandt, K | 1 |
| Settmacher, U | 1 |
| Martinez-Balibrea, E | 1 |
| Martínez-Cardús, A | 1 |
| Musulén, E | 1 |
| Ginés, A | 1 |
| Manzano, JL | 1 |
| Aranda, E | 2 |
| Plasencia, C | 1 |
| Neamati, N | 1 |
| Abad, A | 2 |
| Kume, S | 1 |
| Takahashi, M | 1 |
| Hashimoto, D | 1 |
| Hirata, T | 1 |
| Torigoe, Y | 1 |
| Ikeda, O | 1 |
| Jhawer, M | 1 |
| Coit, D | 1 |
| Brennan, M | 1 |
| Qin, LX | 1 |
| Klimstra, D | 1 |
| Tang, L | 1 |
| Shimizu, Y | 2 |
| Inaba, Y | 1 |
| Nakamura, K | 1 |
| Sato, A | 1 |
| Ye, DW | 1 |
| Yao, XD | 1 |
| Zhang, SL | 1 |
| Dai, B | 1 |
| Zhang, HL | 1 |
| Shen, YJ | 1 |
| Mao, HR | 1 |
| Vaishampayan, UN | 1 |
| Marur, S | 1 |
| Heilbrun, LK | 1 |
| Cher, ML | 1 |
| Dickow, B | 1 |
| Smith, DW | 1 |
| Al Hasan, SA | 1 |
| Eliason, J | 1 |
| Popowich, DA | 1 |
| Wang, EC | 1 |
| Kiel, KD | 1 |
| Stryker, SJ | 1 |
| Halverson, AL | 1 |
| Worden, FP | 1 |
| Moyer, J | 1 |
| Lee, JS | 1 |
| Taylor, JM | 1 |
| Urba, SG | 1 |
| Eisbruch, A | 1 |
| Teknos, TN | 1 |
| Chepeha, DB | 1 |
| Prince, ME | 1 |
| Hogikyan, N | 1 |
| Lassig, AA | 1 |
| Emerick, K | 1 |
| Mukherji, S | 1 |
| Hadjiski, L | 1 |
| Tsien, CI | 1 |
| Miller, TH | 1 |
| Wallace, NE | 1 |
| Mason, HL | 1 |
| Bradford, CR | 1 |
| Wolf, GT | 1 |
| You, DD | 1 |
| Lee, HG | 1 |
| Choi, DW | 2 |
| Chakrabarty, S | 2 |
| Tay, E | 1 |
| Cree, IA | 1 |
| Hungerford, J | 1 |
| Franks, W | 1 |
| Viale, G | 2 |
| Giobbie-Hurder, A | 1 |
| Gusterson, BA | 2 |
| Maiorano, E | 2 |
| Mastropasqua, MG | 2 |
| Sonzogni, A | 1 |
| Mallon, E | 1 |
| Colleoni, M | 3 |
| Castiglione-Gertsch, M | 4 |
| Regan, MM | 2 |
| Price, KN | 3 |
| Brown, RW | 1 |
| Golouh, R | 3 |
| Crivellari, D | 3 |
| Karlsson, P | 1 |
| Öhlschlegel, C | 1 |
| Gelber, RD | 4 |
| Goldhirsch, A | 4 |
| Coates, AS | 2 |
| Kersting, S | 1 |
| Konopke, R | 1 |
| Dittert, D | 1 |
| Distler, M | 1 |
| Rückert, F | 1 |
| Gastmeier, J | 1 |
| Baretton, GB | 1 |
| Saeger, HD | 1 |
| Tardío, JC | 1 |
| Nájera, L | 1 |
| Alemany, I | 1 |
| Martín, T | 1 |
| Castaño, A | 1 |
| Pérez-Regadera, JF | 1 |
| Aleskandarany, MA | 1 |
| Green, AR | 1 |
| Rakha, EA | 1 |
| Mohammed, RA | 1 |
| Elsheikh, SE | 1 |
| Powe, DG | 1 |
| Paish, EC | 1 |
| Macmillan, RD | 1 |
| Chan, S | 1 |
| Ahmed, SI | 1 |
| Soto Iglesias, S | 1 |
| Baltar Arias, R | 1 |
| Vázquez Rodríguez, S | 1 |
| Alvarez, M | 1 |
| Gómez Martínez, P | 1 |
| Alvarez Sánchez, MV | 1 |
| Vázquez Astray, E | 1 |
| Boeck, S | 1 |
| Waldschmidt, D | 1 |
| Kettner, E | 2 |
| Märten, A | 1 |
| Winkelmann, C | 1 |
| Klein, S | 1 |
| Kojouharoff, G | 1 |
| Gauler, T | 1 |
| Fischer von Weikersthal, L | 1 |
| Clemens, MR | 1 |
| Geissler, M | 1 |
| Greten, TF | 2 |
| Neugebauer, S | 1 |
| Yi, SY | 1 |
| Jun, HJ | 1 |
| Lee, J | 1 |
| Lee, JK | 2 |
| Lee, KT | 1 |
| Lim, HY | 1 |
| Kang, WK | 1 |
| Lim, DH | 1 |
| Cunningham, D | 5 |
| Chau, I | 3 |
| Stocken, DD | 2 |
| Valle, JW | 1 |
| Smith, D | 1 |
| Steward, W | 1 |
| Harper, PG | 1 |
| Dunn, J | 1 |
| Tudur-Smith, C | 1 |
| West, J | 1 |
| Falk, S | 1 |
| Crellin, A | 1 |
| Adab, F | 1 |
| Thompson, J | 1 |
| Leonard, P | 1 |
| Ostrowski, J | 1 |
| Eatock, M | 1 |
| Herrmann, R | 1 |
| Neoptolemos, JP | 1 |
| Tabernero, J | 2 |
| Macarulla, T | 1 |
| Braun, MS | 1 |
| Richman, SD | 1 |
| Thompson, L | 1 |
| Daly, CL | 1 |
| Meade, AM | 1 |
| Adlard, JW | 1 |
| Allan, JM | 1 |
| Parmar, MK | 1 |
| Quirke, P | 1 |
| Seymour, MT | 1 |
| Starling, N | 1 |
| Watkins, D | 1 |
| Thomas, J | 1 |
| Webb, J | 1 |
| Brown, G | 2 |
| Thomas, K | 1 |
| Oates, J | 2 |
| Hoshino, H | 1 |
| Miyoshi, N | 1 |
| Nagai, K | 1 |
| Ishii, H | 2 |
| Thearle, MS | 1 |
| Freda, PU | 1 |
| Bruce, JN | 1 |
| Isaacson, SR | 1 |
| Lee, Y | 1 |
| Fine, RL | 1 |
| Nakamura, J | 1 |
| Kitajima, Y | 1 |
| Kai, K | 1 |
| Hashiguchi, K | 1 |
| Hiraki, M | 1 |
| Noshiro, H | 1 |
| Miyazaki, K | 1 |
| Montagna, E | 1 |
| Cancello, G | 1 |
| Torrisi, R | 1 |
| Rizzo, S | 1 |
| Scarano, E | 1 |
| Jacot, W | 1 |
| Bibeau, F | 1 |
| Gourgou-Bourgade, S | 1 |
| Gutowski, M | 1 |
| Colombo, PE | 1 |
| Bleuse, JP | 1 |
| Kramar, A | 2 |
| Romieu, G | 1 |
| Fernández-Martos, C | 1 |
| Pericay, C | 1 |
| Aparicio, J | 1 |
| Salud, A | 1 |
| Safont, M | 1 |
| Massuti, B | 1 |
| Vera, R | 1 |
| Escudero, P | 1 |
| Maurel, J | 2 |
| Marcuello, E | 2 |
| Mengual, JL | 1 |
| Saigi, E | 1 |
| Estevan, R | 1 |
| Mira, M | 1 |
| Polo, S | 1 |
| Hernandez, A | 1 |
| Gallen, M | 1 |
| Arias, F | 1 |
| Serra, J | 1 |
| Alonso, V | 1 |
| Seo, YR | 1 |
| Kim, CK | 1 |
| Park, SK | 1 |
| Koh, ES | 1 |
| Hong, DS | 1 |
| Biffi, R | 1 |
| Fazio, N | 1 |
| Luca, F | 1 |
| Chiappa, A | 1 |
| Andreoni, B | 1 |
| Zampino, MG | 1 |
| Roth, A | 1 |
| Schuller, JC | 1 |
| Fiori, G | 1 |
| Orsi, F | 1 |
| Bonomo, G | 1 |
| Crosta, C | 1 |
| Huber, O | 1 |
| Sato, S | 1 |
| Mukai, M | 1 |
| Huh, JW | 1 |
| Kim, HR | 1 |
| Thanasai, J | 1 |
| Limpaiboon, T | 1 |
| Sripa, B | 1 |
| Pairojkul, C | 1 |
| Tantimavanich, S | 1 |
| Miwa, M | 1 |
| Miyata, H | 1 |
| Yamasaki, M | 1 |
| Takiguchi, S | 1 |
| Lagrange, JL | 1 |
| Bascoul-Mollevi, C | 1 |
| Geoffrois, L | 1 |
| Beckendorf, V | 1 |
| Ferrero, JM | 2 |
| Joly, F | 1 |
| Allouache, N | 1 |
| Bachaud, JM | 1 |
| Chevreau, C | 1 |
| Chauvet, B | 3 |
| Beretta, GD | 2 |
| Scartozzi, M | 1 |
| Tondulli, L | 1 |
| Cascinu, S | 2 |
| Plentz, RR | 1 |
| Manns, MP | 1 |
| Dessein, AF | 1 |
| Stechly, L | 1 |
| Dumont, P | 1 |
| Monté, D | 1 |
| Leteurtre, E | 1 |
| Truant, S | 1 |
| Pruvot, FR | 1 |
| Figeac, M | 1 |
| Hebbar, M | 1 |
| Lecellier, CH | 1 |
| Lesuffleur, T | 1 |
| Dessein, R | 1 |
| Grard, G | 1 |
| Dejonghe, MJ | 1 |
| de Launoit, Y | 1 |
| Furuichi, Y | 1 |
| Prévost, G | 1 |
| Porchet, N | 1 |
| Gespach, C | 1 |
| Huet, G | 1 |
| Manterola, C | 1 |
| Vial, M | 1 |
| Roa, JC | 1 |
| Pang, R | 1 |
| Law, WL | 1 |
| Chu, AC | 1 |
| Poon, JT | 1 |
| Lam, CS | 1 |
| Chow, AK | 1 |
| Ng, L | 1 |
| Cheung, LW | 1 |
| Lan, XR | 1 |
| Lan, HY | 1 |
| Tan, VP | 1 |
| Yau, TC | 1 |
| Poon, RT | 1 |
| Wong, BC | 1 |
| Cho, SY | 1 |
| Han, SS | 1 |
| Kim, YK | 1 |
| Lee, KW | 1 |
| Woo, SM | 1 |
| Kim, TH | 1 |
| Xia, Y | 1 |
| Qiu, Y | 1 |
| Shi, L | 1 |
| Wang, K | 1 |
| Xi, T | 1 |
| Shen, F | 1 |
| Yan, Z | 1 |
| Wu, M | 1 |
| Lee, AW | 1 |
| Tung, SY | 2 |
| Chua, DT | 1 |
| Ngan, RK | 1 |
| Chappell, R | 1 |
| Tung, R | 2 |
| Siu, L | 1 |
| Ng, WT | 1 |
| Sze, WK | 1 |
| Au, GK | 1 |
| Law, SC | 1 |
| O'Sullivan, B | 1 |
| Yau, TK | 1 |
| Leung, TW | 1 |
| Au, JS | 1 |
| Sze, WM | 1 |
| Choi, CW | 1 |
| Fung, KK | 1 |
| Lau, JT | 1 |
| Lau, WH | 1 |
| Lordick, F | 1 |
| Grenacher, L | 1 |
| Röcken, C | 1 |
| Ebert, M | 1 |
| Schumacher, G | 1 |
| Fakhry, C | 1 |
| Bajaj, G | 1 |
| Aygun, N | 1 |
| Westra, W | 1 |
| Gillison, M | 1 |
| Tanaka, T | 2 |
| Sugito, M | 1 |
| Kobayashi, A | 1 |
| Minagawa, N | 1 |
| Watanabe, K | 1 |
| Li, SP | 1 |
| Taylor, NJ | 1 |
| Makris, A | 1 |
| Ah-See, ML | 1 |
| Beresford, MJ | 1 |
| Stirling, JJ | 1 |
| d'Arcy, JA | 1 |
| Collins, DJ | 1 |
| Padhani, AR | 1 |
| Kim, YH | 1 |
| Kim, MJ | 1 |
| Park, NH | 2 |
| Song, YS | 2 |
| Kang, SB | 2 |
| Sawai, K | 2 |
| Goi, T | 2 |
| Hirono, Y | 1 |
| Katayama, K | 3 |
| Yamaguchi, A | 2 |
| Murad-Regadas, SM | 1 |
| Regadas, FS | 1 |
| Rodrigues, LV | 1 |
| Crispin, FJ | 1 |
| Kenmoti, VT | 1 |
| Fernandes, GO | 1 |
| Buchen, G | 1 |
| Monteiro, FC | 1 |
| Song, ST | 1 |
| Wang, CJ | 1 |
| Stratmann, J | 1 |
| Zhou, ZG | 1 |
| Sun, XF | 1 |
| Abahssain, H | 1 |
| Afchain, P | 1 |
| Melas, N | 1 |
| Ismaili, N | 1 |
| Rahali, R | 1 |
| Rabti, HM | 1 |
| Errihani, H | 1 |
| Takemura, M | 3 |
| Morimura, K | 1 |
| Yoshida, K | 1 |
| Chang, SY | 1 |
| Chang, YC | 1 |
| Li, WY | 1 |
| Tsai, TL | 1 |
| Wang, YF | 1 |
| Hsieh, SL | 1 |
| Ami, K | 2 |
| Nagahama, T | 2 |
| Ando, M | 2 |
| Watayou, Y | 1 |
| Amagasa, H | 2 |
| Ganno, H | 2 |
| Hataji, K | 1 |
| Kawasaki, Y | 1 |
| Kurokawa, T | 2 |
| Fukuda, A | 2 |
| Tei, S | 2 |
| Arai, K | 3 |
| Oberholzer, K | 1 |
| Menig, M | 1 |
| Kreft, A | 1 |
| Schneider, A | 2 |
| Junginger, T | 1 |
| Heintz, A | 1 |
| Kreitner, KF | 1 |
| Hötker, AM | 1 |
| Hansen, T | 1 |
| Düber, C | 1 |
| Boscolo-Rizzo, P | 1 |
| Muzzi, E | 1 |
| Trabalzini, F | 1 |
| Gava, A | 1 |
| Stellin, M | 1 |
| Da Mosto, MC | 1 |
| Gollins, S | 1 |
| Sun Myint, A | 1 |
| Haylock, B | 1 |
| Wise, M | 1 |
| Saunders, M | 1 |
| Neupane, R | 1 |
| Essapen, S | 1 |
| Samuel, L | 1 |
| Dougal, M | 1 |
| Lloyd, A | 1 |
| Morris, J | 1 |
| Topham, C | 1 |
| Susnerwala, S | 1 |
| Ofner, D | 1 |
| Devries, AF | 1 |
| Schaberl-Moser, R | 1 |
| Greil, R | 1 |
| Rabl, H | 1 |
| Tschmelitsch, J | 1 |
| Zitt, M | 1 |
| Kapp, KS | 1 |
| Fastner, G | 1 |
| Keil, F | 1 |
| Eisterer, W | 1 |
| Jäger, R | 1 |
| Offner, F | 1 |
| Gnant, M | 1 |
| Thaler, J | 1 |
| Bai, J | 1 |
| Kleyser-Sugrue, K | 1 |
| Nerenstone, SR | 1 |
| Welch, JP | 1 |
| Ohkuma, M | 1 |
| Mimori, K | 1 |
| Tanaka, F | 1 |
| Shimomura, M | 1 |
| Hirose, H | 1 |
| Yanaga, K | 1 |
| Chang, HR | 1 |
| Chen, PN | 1 |
| Yang, SF | 1 |
| Sun, YS | 1 |
| Wu, SW | 1 |
| Hung, TW | 1 |
| Lian, JD | 1 |
| Chu, SC | 1 |
| Hsieh, YS | 1 |
| Yoh, T | 1 |
| Yamamichi, K | 1 |
| Oishi, M | 1 |
| Iwaki, R | 1 |
| Motohiro, T | 1 |
| Zhao, G | 2 |
| Cui, J | 1 |
| Zhang, JG | 2 |
| Qin, Q | 2 |
| Yin, T | 1 |
| Deng, SC | 2 |
| Tian, K | 2 |
| Wang, GB | 1 |
| Wang, CY | 3 |
| Mansutti, M | 3 |
| Gomez, P | 2 |
| Dittrich, C | 1 |
| Ciruelos, E | 1 |
| Pavesi, L | 1 |
| Semiglazov, V | 1 |
| De Benedictis, E | 1 |
| Gaion, F | 1 |
| Bari, M | 1 |
| Valagussa, P | 1 |
| Luca, G | 1 |
| Smith, DD | 1 |
| Madoff, RD | 1 |
| Cataldo, P | 1 |
| Marcet, J | 1 |
| Shigaki, N | 1 |
| Yokoyama, S | 1 |
| Yamashita, H | 2 |
| Sugita, H | 1 |
| Arima, N | 1 |
| Huang, B | 1 |
| Cao, K | 1 |
| Mao, X | 1 |
| Wang, Z | 1 |
| Zhuang, J | 1 |
| Pan, J | 1 |
| Mo, C | 1 |
| Qiu, S | 1 |
| Hughes, R | 1 |
| Parry, J | 1 |
| Beynon, J | 1 |
| Jenkins, G | 1 |
| Song, S | 1 |
| Song, C | 1 |
| Itatani, Y | 1 |
| Akiyoshi, T | 1 |
| Kuroyanagi, H | 1 |
| Yamakawa, K | 1 |
| Noaki, R | 1 |
| Konishi, T | 1 |
| Fujimoto, Y | 1 |
| Ueno, M | 1 |
| Oya, M | 1 |
| Kawashima, M | 1 |
| Hayashi, R | 1 |
| Tahara, M | 1 |
| Arahira, S | 1 |
| Miyazaki, M | 1 |
| Sakuraba, M | 1 |
| Zenda, S | 1 |
| Ogino, T | 1 |
| Zheng, G | 1 |
| Pen, B | 1 |
| Yin, J | 1 |
| Hirayama, K | 1 |
| Hayashi, T | 1 |
| Nishiwaki, Y | 1 |
| Kamishima, M | 1 |
| Furuhashi, S | 1 |
| Fukushima, H | 1 |
| Nakata, Y | 1 |
| Tamura, H | 1 |
| Kanai, T | 1 |
| Ikematsu, Y | 1 |
| Mori, H | 1 |
| Ozawa, T | 1 |
| Nakamura, M | 2 |
| Watayo, Y | 1 |
| Okada, Y | 1 |
| Kawasaki, H | 1 |
| Wajima, N | 1 |
| Miyamoto, K | 1 |
| Maruyama, A | 1 |
| Hakamada, K | 2 |
| Gong, L | 1 |
| Lou, JY | 1 |
| Wang, P | 1 |
| Zhang, JW | 1 |
| Peng, ZL | 1 |
| Zhang, JQ | 1 |
| Hooker, CM | 1 |
| Brock, MV | 1 |
| Shin, J | 1 |
| How, R | 1 |
| Franco, N | 1 |
| Prevas, H | 1 |
| Hulbert, A | 1 |
| Yang, SC | 1 |
| Wu, ZM | 1 |
| Teng, RY | 1 |
| Shen, JG | 1 |
| Xie, SD | 1 |
| Xu, CY | 1 |
| Wang, LB | 1 |
| Xia, H | 1 |
| Wang, Q | 1 |
| Jiang, X | 1 |
| Ma, Y | 1 |
| Hu, M | 1 |
| Isikdogan, A | 1 |
| Arpaci, E | 1 |
| Bilici, M | 1 |
| Uncu, D | 1 |
| Cetin, B | 1 |
| Dane, F | 1 |
| Inane, M | 1 |
| Kaplan, MA | 1 |
| Cayir, K | 1 |
| Yetisyigit, T | 1 |
| Ozdemir, N | 1 |
| Inal, A | 1 |
| Aksoy, S | 1 |
| Alkis, N | 1 |
| Tekin, SB | 1 |
| Eroglu, C | 1 |
| Turhal, S | 1 |
| Benekli, M | 1 |
| Buyukberber, S | 1 |
| Segalla, JG | 1 |
| Del Giglio, A | 1 |
| Pinczowski, H | 1 |
| Ciruelos, EM | 1 |
| Filho, SC | 1 |
| Van Eyll, B | 2 |
| Bermejo, B | 1 |
| Llombart, A | 1 |
| Durán, MÁ | 1 |
| Hoff, PM | 2 |
| Espié, M | 1 |
| de Moraes, AA | 1 |
| Ribeiro, RA | 1 |
| Mathias, C | 1 |
| Gil Gil, M | 1 |
| Ojeda, B | 1 |
| Morales, J | 1 |
| Kwon Ro, S | 1 |
| Koca, D | 1 |
| Yavuzsen, T | 1 |
| Ellidokuz, H | 1 |
| Yilmaz, U | 1 |
| Dewdney, A | 1 |
| Capdevila, J | 1 |
| Cervantes, A | 1 |
| Tait, D | 1 |
| Wotherspoon, A | 1 |
| Gonzalez de Castro, D | 1 |
| Chua, YJ | 1 |
| Wong, R | 1 |
| Barbachano, Y | 1 |
| Hofheinz, RD | 1 |
| Wenz, F | 1 |
| Post, S | 1 |
| Matzdorff, A | 1 |
| Laechelt, S | 1 |
| Hartmann, JT | 1 |
| Müller, L | 1 |
| Fritz, E | 1 |
| Hieber, U | 1 |
| Lindemann, HW | 1 |
| Grunewald, M | 1 |
| Kremers, S | 1 |
| Constantin, C | 1 |
| Hipp, M | 1 |
| Hartung, G | 1 |
| Gencer, D | 1 |
| Kienle, P | 1 |
| Burkholder, I | 1 |
| Hochhaus, A | 2 |
| Sizer, B | 1 |
| Sreenivasan, T | 1 |
| Karaca, B | 1 |
| Cakar, B | 1 |
| Sezgin, C | 1 |
| Karabulut, B | 1 |
| Uslu, R | 1 |
| Yoshii, T | 1 |
| Ohkawa, S | 1 |
| Tamai, S | 1 |
| Kameda, Y | 1 |
| Srivastava, J | 1 |
| Siddiq, A | 1 |
| Emdad, L | 1 |
| Santhekadur, PK | 1 |
| Gredler, R | 1 |
| Shen, XN | 1 |
| Robertson, CL | 1 |
| Dumur, CI | 1 |
| Hylemon, PB | 1 |
| Mukhopadhyay, ND | 1 |
| Bhere, D | 1 |
| Shah, K | 1 |
| Ahmad, R | 1 |
| Giashuddin, S | 1 |
| Stafflinger, J | 1 |
| Subler, MA | 1 |
| Windle, JJ | 1 |
| Fisher, PB | 1 |
| Sarkar, D | 1 |
| Iida, A | 1 |
| Guo, ST | 1 |
| Jiang, CC | 1 |
| Wang, GP | 1 |
| Li, YP | 1 |
| Guo, XY | 1 |
| Yang, RH | 1 |
| Feng, Y | 1 |
| Wang, FH | 1 |
| Tseng, HY | 1 |
| Thorne, RF | 1 |
| Jin, L | 1 |
| Zhang, XD | 1 |
| Takanosawa, M | 1 |
| Kawada, K | 1 |
| Kanazawa, T | 3 |
| Ichimura, K | 3 |
| Nakazawa, M | 1 |
| Dellapasqua, S | 1 |
| Bagnardi, V | 1 |
| Rotmensz, N | 1 |
| Sebag-Montefiore, D | 1 |
| Meadows, HM | 1 |
| Plowman, PN | 1 |
| Hurman, DC | 1 |
| Davidson, N | 1 |
| Grieve, R | 1 |
| Levine, E | 1 |
| Glynne-Jones, R | 1 |
| Inada, K | 2 |
| Maeshiro, T | 1 |
| Shida, D | 1 |
| Seyama, Y | 1 |
| Miyamoto, S | 1 |
| Umekita, N | 1 |
| Tsukidate, H | 1 |
| Fukamachi, S | 1 |
| Ikezawa, F | 1 |
| Endo, K | 1 |
| Suzuki, Y | 2 |
| Tezuka, F | 1 |
| Niu, Z | 1 |
| Li, F | 1 |
| Schmoll, HJ | 1 |
| Sobrero, A | 2 |
| Karapetis, CS | 1 |
| Rougier, P | 2 |
| Koski, SL | 2 |
| Kocakova, I | 1 |
| Bondarenko, I | 1 |
| Bodoky, G | 1 |
| Mainwaring, P | 1 |
| Salazar, R | 1 |
| Barker, P | 1 |
| Mookerjee, B | 1 |
| Robertson, J | 1 |
| Van Cutsem, E | 1 |
| Pestalozzi, BC | 1 |
| Tebbutt, NC | 1 |
| Koynov, KD | 1 |
| Kurteva, G | 1 |
| Pintér, T | 1 |
| Pike, L | 1 |
| Fielding, A | 1 |
| Robertson, JD | 1 |
| Saunders, MP | 1 |
| Furusaka, T | 1 |
| Asakawa, T | 1 |
| Tanaka, A | 1 |
| Matsuda, H | 1 |
| Shah, SM | 1 |
| Drage, MG | 1 |
| Lichtman, AH | 1 |
| Haddad, RI | 1 |
| Singh, N | 1 |
| Przybylowska-Sygut, K | 1 |
| Stanczyk, M | 1 |
| Kusinska, R | 1 |
| Kordek, R | 1 |
| Majsterek, I | 1 |
| Guo, R | 1 |
| Cheng, L | 1 |
| Barrick, B | 1 |
| Matthys, B | 1 |
| Fraga, G | 1 |
| Xuan, Y | 1 |
| Kim, YB | 1 |
| Lee, G | 1 |
| Shim, W | 1 |
| Yun, J | 1 |
| Ham, IH | 1 |
| Han, SU | 1 |
| Niu, Y | 1 |
| Perez, RO | 2 |
| Habr-Gama, A | 2 |
| Lynn, PB | 1 |
| São Julião, GP | 1 |
| Bianchi, R | 1 |
| Proscurshim, I | 1 |
| Gama-Rodrigues, J | 1 |
| Fathi, R | 1 |
| Kamalpour, L | 1 |
| Gammon, B | 1 |
| Kamada, Y | 1 |
| Ishikawa, T | 2 |
| Kokura, S | 1 |
| Tian, YF | 1 |
| Chen, TJ | 1 |
| Chen, LT | 1 |
| Lin, LC | 1 |
| Hsing, CH | 1 |
| Lee, SW | 1 |
| Sheu, MJ | 1 |
| Lee, HH | 1 |
| Shiue, YL | 1 |
| Huang, HY | 1 |
| Pan, HY | 1 |
| Chen, SH | 1 |
| Yamada, S | 1 |
| Ritchim, P | 1 |
| Charkrabandhu, T | 1 |
| Jongraksat, W | 1 |
| Chow, LW | 1 |
| Ng, TY | 1 |
| Lee, MH | 1 |
| Yip, AY | 1 |
| Toi, M | 2 |
| Glück, S | 1 |
| Takizawa, M | 1 |
| Hirano, M | 1 |
| Murakami, N | 1 |
| Uno, Y | 1 |
| Kikuchi, T | 1 |
| Nozawa, H | 1 |
| Hara, T | 2 |
| Asaumi, Y | 1 |
| Kikkawa, H | 1 |
| Sakon, M | 2 |
| Kagawa, R | 1 |
| Nakayama, N | 1 |
| Sakata, S | 1 |
| Tada, M | 1 |
| Lin, JC | 1 |
| Jan, JS | 1 |
| Hsu, CY | 1 |
| Jiang, RS | 1 |
| Wang, WY | 1 |
| Nakagoe, T | 1 |
| Yamaguchi, E | 1 |
| Sawai, T | 1 |
| Tsuji, T | 1 |
| Shibasaki, S | 1 |
| Nanashima, A | 1 |
| Yamaguchi, H | 1 |
| Yasutake, T | 1 |
| Ayabe, H | 2 |
| Lorvidhaya, V | 1 |
| Chitapanarux, I | 1 |
| Sangruchi, S | 1 |
| Lertsanguansinchai, P | 1 |
| Kongthanarat, Y | 1 |
| Tangkaratt, S | 1 |
| Visetsiri, E | 1 |
| Reichardt, P | 1 |
| Von Minckwitz, G | 1 |
| Thuss-Patience, PC | 1 |
| Jonat, W | 1 |
| Kölbl, H | 1 |
| Jänicke, F | 1 |
| Kieback, DG | 1 |
| Kuhn, W | 1 |
| Schindler, AE | 1 |
| Mohrmann, S | 1 |
| Kaufmann, M | 1 |
| Lück, HJ | 1 |
| Cocconi, G | 1 |
| Carlini, P | 1 |
| Gamboni, A | 1 |
| Gasperoni, S | 1 |
| Rodinò, C | 1 |
| Zironi, S | 1 |
| Porrozzi, S | 1 |
| Cognetti, F | 1 |
| Di Costanzo, F | 1 |
| Canaletti, R | 1 |
| Ruggeri, EM | 1 |
| Camisa, R | 1 |
| Pucci, F | 2 |
| Droz, JP | 1 |
| Muracciole, X | 1 |
| Mottet, N | 1 |
| Ould Kaci, M | 1 |
| Vannetzel, JM | 1 |
| Albin, N | 1 |
| Rodier, JM | 1 |
| Misset, JL | 1 |
| Mackenzie, S | 1 |
| Cvitkovic, E | 1 |
| Benoit, G | 1 |
| Tachibana, M | 1 |
| Yoshimura, H | 1 |
| Kinugasa, S | 1 |
| Shibakita, M | 1 |
| Dhar, DK | 1 |
| Ueda, S | 1 |
| Nagasue, N | 1 |
| Ito, K | 2 |
| Nakazato, H | 1 |
| Koike, A | 1 |
| Saji, S | 1 |
| Mai, M | 1 |
| Sakamoto, J | 1 |
| Ohashi, Y | 1 |
| Hazama, S | 1 |
| Oka, M | 2 |
| Hinoda, Y | 1 |
| Matsunaga, N | 2 |
| Yamada, N | 2 |
| Lou, E | 1 |
| Kellman, RM | 1 |
| Hutchison, R | 1 |
| Shillitoe, EJ | 1 |
| Osugi, H | 2 |
| Taguchi, S | 1 |
| Kaneko, M | 2 |
| Fukuhara, K | 1 |
| Nishizawa, S | 2 |
| Kinoshita, H | 1 |
| Horiguchi, J | 2 |
| Yoshida, T | 2 |
| Koibuchi, Y | 2 |
| Iijima, K | 1 |
| Ninomiya, J | 1 |
| Takei, H | 2 |
| Yokoe, T | 2 |
| Iino, Y | 2 |
| Morishita, Y | 2 |
| Tachimori, A | 1 |
| Nishiguchi, Y | 1 |
| Seki, S | 1 |
| Peyromaure, M | 1 |
| Slama, J | 1 |
| Beuzeboc, P | 1 |
| Ponvert, D | 1 |
| Debré, B | 1 |
| Zerbib, M | 1 |
| Eifel, PJ | 1 |
| Winter, K | 1 |
| Morris, M | 3 |
| Levenback, C | 1 |
| Grigsby, PW | 1 |
| Cooper, J | 1 |
| Rotman, M | 1 |
| Gershenson, D | 1 |
| Mutch, DG | 1 |
| Peake, DR | 1 |
| Glaholm, JG | 2 |
| Wallace, DM | 2 |
| Jiang, K | 1 |
| Sun, J | 1 |
| Cheng, J | 1 |
| Djeu, JY | 1 |
| Wei, S | 1 |
| Sebti, S | 1 |
| Lerouge, D | 1 |
| Touboul, E | 1 |
| Lefranc, JP | 1 |
| Uzan, S | 1 |
| Jannet, D | 1 |
| Moureau-Zabotto, L | 1 |
| Genestie, C | 1 |
| Antoine, M | 1 |
| Jamali, M | 1 |
| Ema, T | 1 |
| Maeda, Y | 1 |
| Iwasaki, Y | 1 |
| Katayanagi, S | 1 |
| Bujko, K | 1 |
| Nowacki, MP | 1 |
| Nasierowska-Guttmejer, A | 1 |
| Michalski, W | 1 |
| Bebenek, M | 1 |
| Pudełko, M | 1 |
| Kryj, M | 1 |
| Oledzki, J | 1 |
| Szmeja, J | 1 |
| Słuszniak, J | 1 |
| Serkies, K | 1 |
| Kładny, J | 1 |
| Pamucka, M | 1 |
| Kukołowicz, P | 1 |
| Delaunoit, T | 1 |
| Maréchal, R | 1 |
| Hendlisz, A | 1 |
| Eisendrath, P | 1 |
| Legendre, H | 1 |
| Pector, JC | 1 |
| De Becker, D | 1 |
| Bleiberg, H | 1 |
| Iwasaki, H | 1 |
| George, L | 1 |
| Bladou, F | 1 |
| Bardou, VJ | 1 |
| Gravis, G | 1 |
| Tallet, A | 1 |
| Alzieu, C | 1 |
| Serment, G | 1 |
| Salem, N | 1 |
| Tominaga, T | 3 |
| Kimura, M | 1 |
| Asaga, T | 1 |
| Yoshida, M | 1 |
| Awane, H | 1 |
| Koyama, H | 1 |
| Takatsuka, Y | 2 |
| Mitsuyama, S | 1 |
| Ikeda, T | 1 |
| Ogita, M | 1 |
| Aoyama, H | 1 |
| Sano, M | 2 |
| Abe, R | 1 |
| Nishi, T | 1 |
| Wada, T | 1 |
| Danno, M | 1 |
| Takashima, S | 1 |
| Bi, F | 1 |
| Pan, Y | 1 |
| Xue, Y | 1 |
| Yao, X | 1 |
| Zheng, Y | 1 |
| Fan, D | 1 |
| Vogt, U | 1 |
| Bielawski, KP | 1 |
| Bosse, U | 1 |
| Schlotter, CM | 1 |
| Mizushima, T | 1 |
| Sando, K | 1 |
| Ito, T | 2 |
| Mikata, S | 1 |
| Nonaka, K | 1 |
| Ide, H | 1 |
| Michiura, T | 1 |
| Kainuma, S | 1 |
| Yamanaka, H | 1 |
| Iwase, K | 1 |
| Kamoshida, S | 1 |
| Matsuoka, H | 1 |
| Shimomura, R | 1 |
| Tsutsumi, Y | 1 |
| Kobayashi, H | 2 |
| Koike, T | 1 |
| Nakatsuka, A | 1 |
| Kurita, H | 1 |
| Sagara, J | 1 |
| Taniguchi, S | 1 |
| Kurashina, K | 1 |
| Christopoulou, A | 1 |
| Cheng, SH | 1 |
| Tsai, SY | 1 |
| Yen, KL | 1 |
| Jian, JJ | 1 |
| Feng, AC | 1 |
| Chan, KY | 1 |
| Hong, CF | 1 |
| Chu, NM | 1 |
| Tan, TD | 1 |
| Hsieh, CY | 1 |
| Chong, V | 1 |
| Huang, AT | 1 |
| Wenzel, C | 1 |
| Bartsch, R | 1 |
| Locker, GJ | 1 |
| Hussian, D | 1 |
| Pluschnig, U | 1 |
| Sevelda, U | 1 |
| Gnant, MF | 1 |
| Jakesz, R | 1 |
| Zielinski, CC | 1 |
| Steger, GG | 1 |
| Vorob'ëv, GI | 1 |
| Odariuk, TS | 1 |
| Orlova, LP | 1 |
| Nechushkin, MI | 1 |
| Rybakov, EG | 1 |
| Yamagishi, H | 1 |
| Itoi, H | 1 |
| Fuji, N | 1 |
| Ueda, Y | 1 |
| Nishida Arazawa, ST | 1 |
| Rawet, V | 1 |
| Coelho Siqueira, SA | 1 |
| Kiss, DR | 1 |
| Gama-Rodrigues, JJ | 1 |
| Mermershtain, W | 1 |
| Gluzman, A | 1 |
| Gusakova, I | 1 |
| Walfish, S | 1 |
| Cohen, Y | 1 |
| Ariad, S | 1 |
| Grothey, A | 1 |
| Sargent, DJ | 1 |
| Hurwitz, HI | 1 |
| Fehrenbacher, L | 1 |
| Hainsworth, JD | 1 |
| Heim, W | 1 |
| Berlin, J | 1 |
| Holmgren, E | 1 |
| Hambleton, J | 1 |
| Novotny, WF | 1 |
| Kabbinavar, F | 1 |
| Sastre, J | 1 |
| Masutti, B | 1 |
| Navarro, M | 1 |
| Gil, S | 1 |
| Valladares, M | 1 |
| Maestu, I | 1 |
| Carrato, A | 2 |
| Vicent, JM | 1 |
| Díaz-Rubio, E | 1 |
| Gibson, MK | 1 |
| Murphy, B | 1 |
| Hussain, MH | 1 |
| DeConti, RC | 1 |
| Ensley, J | 1 |
| Forastiere, AA | 1 |
| Aguiar, S | 1 |
| Lopes, A | 2 |
| Soares, FA | 1 |
| Rossi, BM | 2 |
| Ferreira, FO | 1 |
| Nakagawa, WT | 2 |
| Carvalho, AL | 1 |
| Filho, WJ | 1 |
| Kariya, S | 1 |
| Ogawa, Y | 1 |
| Nishioka, A | 1 |
| Moriki, T | 1 |
| Ohnishi, T | 1 |
| Ito, S | 1 |
| Murata, Y | 1 |
| Yoshida, S | 1 |
| Green, MC | 1 |
| Buzdar, AU | 1 |
| Smith, T | 1 |
| Ibrahim, NK | 1 |
| Valero, V | 1 |
| Rosales, MF | 1 |
| Cristofanilli, M | 1 |
| Booser, DJ | 1 |
| Pusztai, L | 1 |
| Rivera, E | 1 |
| Theriault, RL | 1 |
| Carter, C | 1 |
| Frye, D | 1 |
| Hunt, KK | 2 |
| Symmans, WF | 1 |
| Strom, EA | 1 |
| Sahin, AA | 1 |
| Sikov, W | 1 |
| Hortobagyi, GN | 1 |
| Yamashita, S | 1 |
| Sawamura, T | 1 |
| Mishima, H | 2 |
| Ikenaga, M | 2 |
| Kashiwazaki, M | 1 |
| Masuda, N | 1 |
| Sugitani, M | 1 |
| Nishimura, K | 1 |
| Noguchi, H | 1 |
| Ouchi, M | 1 |
| Yamada, M | 1 |
| Kitajima, M | 2 |
| Tsuruoka, Y | 1 |
| Futagawa, S | 1 |
| Sorscher, SM | 1 |
| Gruber, G | 1 |
| Bonetti, M | 1 |
| Nasi, ML | 1 |
| Rudenstam, CM | 2 |
| Holmberg, SB | 1 |
| Lindtner, J | 2 |
| Collins, J | 1 |
| Carbone, A | 1 |
| Thürlimann, B | 1 |
| Simoncini, E | 2 |
| Fey, MF | 1 |
| Kamikonya, N | 1 |
| Inoue, T | 1 |
| Koishi, K | 1 |
| Yoshikawa, R | 1 |
| Nakao, K | 1 |
| Yagyu, R | 1 |
| Nishiwaki, M | 1 |
| Fujiwara, M | 1 |
| Kojima, S | 1 |
| Yamamura, T | 1 |
| Cunningham, SC | 1 |
| Cusnir, M | 1 |
| Burdick, RK | 1 |
| Van Echo, DA | 1 |
| Moesinger, R | 1 |
| Schilsky, RL | 1 |
| Izzo, JG | 1 |
| Malhotra, U | 1 |
| Wu, TT | 1 |
| Ensor, J | 1 |
| Luthra, R | 1 |
| Swisher, SG | 1 |
| Liao, Z | 1 |
| Chao, KS | 1 |
| Hittelman, WN | 1 |
| Aggarwal, BB | 1 |
| Ajani, JA | 1 |
| Kim, YA | 1 |
| Chung, HC | 2 |
| Choi, HJ | 1 |
| Rha, SY | 1 |
| Jeung, HC | 1 |
| Katayose, Y | 1 |
| Oda, A | 1 |
| Oikawa, M | 1 |
| Rikiyama, T | 1 |
| Unno, M | 1 |
| Tinari, N | 1 |
| Lattanzio, R | 1 |
| Natoli, C | 1 |
| Cianchetti, E | 1 |
| Angelucci, D | 1 |
| Ricevuto, E | 1 |
| Ficorella, C | 1 |
| Marchetti, P | 1 |
| Alberti, S | 1 |
| Piantelli, M | 1 |
| Iacobelli, S | 1 |
| Warusavitarne, J | 1 |
| Ramanathan, P | 1 |
| Kaufman, A | 1 |
| Robinson, BG | 1 |
| Schnitzler, M | 1 |
| Besova, NS | 1 |
| Orel, NF | 1 |
| Borisova, TA | 1 |
| Markovich, AA | 1 |
| Zaguzina, NN | 1 |
| Gorbunova, VA | 1 |
| Adelstein, DJ | 1 |
| Leblanc, M | 1 |
| Chamorey, E | 1 |
| Oudard, S | 1 |
| Dides, S | 1 |
| Lesbats, G | 1 |
| Cavaglione, G | 1 |
| Nouyrigat, P | 1 |
| Foa, C | 2 |
| Kaphan, R | 1 |
| Zorzi, D | 1 |
| Abdalla, EK | 1 |
| Pawlik, TM | 1 |
| Brown, TD | 1 |
| Vauthey, JN | 1 |
| Park, JK | 1 |
| Ryu, JK | 1 |
| Yoon, WJ | 1 |
| Kim, YT | 1 |
| Yoon, YB | 1 |
| Kojima, Y | 1 |
| Kushihata, F | 1 |
| Kobayashi, N | 1 |
| Handa, R | 1 |
| Oshima, K | 1 |
| Oshima, S | 1 |
| Iijima, S | 1 |
| Yamamoto, H | 1 |
| Kurokawa, E | 1 |
| Kikkawa, N | 2 |
| Platell, C | 2 |
| McCaul, K | 1 |
| Millward, M | 1 |
| van Hazel, G | 1 |
| Bayliss, E | 1 |
| Trotter, J | 1 |
| Ransom, D | 1 |
| Iacopetta, B | 2 |
| Gaui, MF | 1 |
| Amorim, G | 1 |
| Arcuri, RA | 1 |
| Pereira, G | 1 |
| Moreira, D | 1 |
| Djahjah, C | 1 |
| Biasoli, I | 1 |
| Spector, N | 1 |
| Jäger, E | 1 |
| de Manzoni, G | 1 |
| Pedrazzani, C | 1 |
| Pasini, F | 1 |
| Bernini, M | 1 |
| Minicozzi, AM | 1 |
| Giacopuzzi, S | 1 |
| Grandinetti, A | 1 |
| Cordiano, C | 1 |
| Shen, J | 1 |
| Gilcrease, MZ | 1 |
| Babiera, GV | 1 |
| Ross, MI | 1 |
| Meric-Bernstam, F | 1 |
| Feig, BW | 1 |
| Kuerer, HM | 1 |
| Francis, A | 1 |
| Ames, FC | 1 |
| Hiramatsu, K | 1 |
| Kato, K | 2 |
| Hirata, A | 1 |
| Matsuba, H | 1 |
| Miyata, T | 1 |
| Akagawa, T | 1 |
| Kutsuna, Y | 1 |
| Machiki, Y | 1 |
| Fujioka, S | 1 |
| Labianca, R | 1 |
| Barone, C | 1 |
| Carnaghi, C | 1 |
| Cassano, A | 1 |
| Catalano, V | 1 |
| Bertetto, O | 1 |
| Barni, S | 1 |
| Frontini, L | 1 |
| Aitini, E | 1 |
| Rota, S | 1 |
| Torri, V | 1 |
| Floriani, I | 1 |
| Pozzo, C | 1 |
| Rimassa, L | 1 |
| Mosconi, S | 1 |
| Giordani, P | 1 |
| Ardizzoia, A | 1 |
| Foa, P | 1 |
| Rabbi, C | 1 |
| Chiara, S | 1 |
| Gasparini, G | 1 |
| Nardi, M | 1 |
| Arnoldi, E | 1 |
| Piazza, E | 1 |
| Cortesi, E | 1 |
| Silva, RR | 1 |
| Ravaioli, A | 1 |
| Lay, GC | 1 |
| Caraul, B | 1 |
| Dessì, M | 1 |
| Orrù, S | 1 |
| Murtas, R | 1 |
| Deidda, MA | 1 |
| Farigu, R | 1 |
| Farci, D | 1 |
| Maxia, L | 1 |
| Casula, G | 1 |
| Amichetti, M | 1 |
| Yamada, E | 1 |
| Ninomiya, M | 1 |
| Sasaki, H | 1 |
| Takakura, N | 1 |
| Mizukami, H | 1 |
| Yoshizawa, Y | 1 |
| Sasaya, S | 1 |
| Nemoto, H | 1 |
| Maezawa, K | 1 |
| Sanada, Y | 1 |
| Specenier, PM | 1 |
| Vermorken, JB | 1 |
| Marnitz, S | 1 |
| Köhler, C | 1 |
| Roth, C | 1 |
| Füller, J | 1 |
| Bischoff, A | 1 |
| Wendt, T | 1 |
| Budach, V | 1 |
| Terzi, C | 1 |
| Canda, AE | 1 |
| Sagol, O | 1 |
| Atila, K | 1 |
| Sonmez, D | 1 |
| Fuzun, M | 1 |
| Gorken, IB | 1 |
| Obuz, F | 1 |
| Bajetta, E | 1 |
| Celio, L | 1 |
| Ferrario, E | 1 |
| Di Bartolomeo, M | 1 |
| Denaro, A | 1 |
| Dotti, K | 1 |
| Mancin, M | 1 |
| Bajetta, R | 1 |
| Colombo, A | 1 |
| Pusceddu, S | 1 |
| Kimura, H | 1 |
| Yamada, Y | 2 |
| Inui, N | 1 |
| Hiyama, S | 1 |
| Rivera, F | 1 |
| Vega-Villegas, ME | 1 |
| López-Brea, M | 1 |
| Isla, D | 1 |
| Mayorga, M | 1 |
| Galdós, P | 1 |
| Rubio, A | 1 |
| Del Valle, A | 1 |
| García-Reija, F | 1 |
| García-Montesinos, B | 1 |
| Rodríguez-Iglesias, J | 1 |
| Mayordomo, J | 1 |
| Rama, J | 1 |
| Saiz-Bustillo, R | 1 |
| Sanz-Ortiz, J | 1 |
| Murakami, Y | 1 |
| Uemura, K | 1 |
| Sudo, T | 1 |
| Hayashidani, Y | 1 |
| Hashimoto, Y | 1 |
| Ohge, H | 1 |
| Motoyama, S | 1 |
| Hosono, Y | 1 |
| Maruyama, K | 1 |
| Okuyama, M | 1 |
| Saito, R | 1 |
| Liang, LJ | 1 |
| Hu, WJ | 1 |
| Yin, XY | 1 |
| Peng, BG | 1 |
| Lu, MD | 1 |
| Huang, MY | 1 |
| Fang, WY | 1 |
| Lee, SC | 1 |
| Cheng, TL | 1 |
| Lin, SR | 1 |
| Gallego-Plazas, J | 1 |
| Guillén-Ponce, C | 1 |
| Puig, PL | 1 |
| Bedenne, L | 2 |
| Yamada, T | 1 |
| Yokoi, K | 1 |
| Seya, T | 1 |
| Kanazawa, Y | 1 |
| Koizumi, M | 1 |
| Ohaki, Y | 1 |
| Tajiri, T | 1 |
| Puglisi, F | 1 |
| Cardellino, GG | 1 |
| Di Loreto, C | 1 |
| Magri, MD | 1 |
| Minisini, AM | 1 |
| Andreetta, C | 1 |
| Russo, S | 1 |
| Lombardi, D | 1 |
| Perin, T | 1 |
| Damante, G | 1 |
| Veronesi, A | 1 |
| Yang, JL | 1 |
| Qu, XJ | 1 |
| Kohn, EC | 1 |
| Friedlander, ML | 1 |
| Ho, PC | 1 |
| Chauffert, B | 1 |
| Mornex, F | 1 |
| Bonnetain, F | 1 |
| Mariette, C | 1 |
| Bouché, O | 1 |
| Bosset, JF | 1 |
| Mineur, L | 1 |
| Azzedine, A | 1 |
| Hammel, P | 1 |
| Butel, J | 1 |
| Stremsdoerfer, N | 1 |
| Maingon, P | 1 |
| Albaugh, JS | 1 |
| Keeffe, EB | 1 |
| Krippaehne, WW | 1 |
| Höche, D | 1 |
| Fink, R | 1 |
| Anger, G | 1 |
| Hartenstein, R | 1 |
| Ehrhart, H | 1 |
| Possinger, K | 1 |
| Gerbie, MV | 1 |
| Storme, G | 2 |
| Mareel, MM | 2 |
| Mareel, M | 1 |
| De Bruyne, G | 1 |
| Loré, JM | 1 |
| Diaz-Ordaz, E | 1 |
| Spaulding, M | 1 |
| Chary, K | 1 |
| Kaufman, S | 1 |
| Lawrence, W | 1 |
| Hong, F | 1 |
| Gerold, T | 1 |
| Sundquist, N | 1 |
| Barrali, RA | 1 |
| Marsh, RW | 1 |
| Agaliotis, D | 1 |
| Killeen, R | 1 |
| Yasuda, T | 2 |
| Kabuto, T | 4 |
| Ishiguro, S | 1 |
| Nakano, H | 2 |
| Hiratsuka, M | 3 |
| Kameyama, M | 3 |
| Sasaki, Y | 4 |
| Knysh, VI | 1 |
| Kim, FP | 1 |
| Goldobenko, GV | 1 |
| Tsariuk, VF | 1 |
| Barsukov, IuA | 1 |
| Furukawa, H | 3 |
| Imaoka, S | 3 |
| Iwanaga, T | 1 |
| Kobayashi, K | 2 |
| Tamaki, Y | 1 |
| Touno, T | 1 |
| Shin, E | 1 |
| Yagyu, T | 1 |
| Frasci, G | 1 |
| Leone, F | 1 |
| Monaco, M | 1 |
| Cremone, L | 1 |
| Sapio, U | 1 |
| Faiella, F | 1 |
| Espinosa, A | 1 |
| Persico, G | 1 |
| Jessup, JM | 1 |
| Steele, G | 1 |
| Mayer, RJ | 1 |
| Posner, M | 1 |
| Busse, P | 1 |
| Cady, B | 1 |
| Stone, M | 1 |
| Jenkins, R | 1 |
| Osteen, R | 1 |
| Mio, H | 1 |
| Terabe, K | 1 |
| Graham, RA | 1 |
| Atkins, MB | 1 |
| Karp, DD | 1 |
| Wazer, DE | 1 |
| Hackford, AW | 1 |
| Maulard, C | 1 |
| Chretien, Y | 3 |
| Dufour, B | 3 |
| Delanian, S | 1 |
| Huart, J | 1 |
| Colardelle, F | 1 |
| Brunel, P | 1 |
| Baillet, F | 3 |
| Reboul, F | 2 |
| Hoffman, RM | 1 |
| Masutani, S | 1 |
| Carey, RW | 1 |
| Hilgenberg, AD | 1 |
| Wilkins, EW | 1 |
| Choi, NC | 1 |
| Mathisen, DJ | 1 |
| Grillo, HC | 1 |
| Wain, JC | 1 |
| Logan, DL | 1 |
| Bromberg, C | 1 |
| Arlington, A | 1 |
| Bohorquez, J | 1 |
| Okugawa, T | 1 |
| Rino, Y | 1 |
| Okada, K | 1 |
| Kobayashi, O | 1 |
| Sairenji, M | 1 |
| Motohashi, H | 1 |
| Kume, K | 1 |
| Ono, E | 1 |
| Wakasugi, K | 1 |
| Matsuzaka, T | 1 |
| Fujinaga, H | 1 |
| Maurer, U | 1 |
| Härle, M | 1 |
| Jungius, KP | 1 |
| Brasnu, D | 3 |
| Laccourreye, O | 3 |
| Bassot, V | 1 |
| Laccourreye, L | 1 |
| Naudo, P | 1 |
| Roux, FX | 2 |
| Kodaira, S | 2 |
| Sakabe, T | 1 |
| Hamano, K | 1 |
| Yasutomi, M | 2 |
| Ogawa, N | 1 |
| van Slooten, HJ | 1 |
| Clahsen, PC | 1 |
| van Dierendonck, JH | 1 |
| Duval, C | 1 |
| Pallud, C | 1 |
| Mandard, AM | 1 |
| Delobelle-Deroide, A | 1 |
| van de Velde, CJ | 1 |
| van de Vijver, MJ | 1 |
| Kondo, K | 1 |
| Murase, M | 1 |
| Yokoyama, Y | 1 |
| Kato, J | 1 |
| Hibi, K | 1 |
| Kasai, Y | 1 |
| Akiyama, S | 1 |
| Dimpfl, T | 1 |
| Stumpfe, M | 1 |
| Baltzer, J | 1 |
| Genz, T | 1 |
| Ueyama, N | 1 |
| Ishikawa, K | 2 |
| Miyata, M | 2 |
| Kitamura, K | 1 |
| Seino, K | 1 |
| Sugoh, T | 1 |
| Mikami, K | 1 |
| Endoh, M | 1 |
| Konn, M | 1 |
| Hojo, K | 1 |
| Ogawa, M | 2 |
| Ichihashi, H | 1 |
| Tamada, R | 1 |
| Kunii, Y | 1 |
| Kikuchi, K | 1 |
| Aoyama, N | 1 |
| Koizumi, H | 1 |
| Sawamura, A | 1 |
| Kim, R | 1 |
| Takashima, I | 1 |
| Miyahara, E | 1 |
| Aogi, K | 1 |
| Yamaguchi, Y | 1 |
| Hihara, J | 1 |
| Toge, T | 1 |
| Murata, K | 1 |
| Fujita, M | 1 |
| Ueno, T | 1 |
| Sakamoto, T | 1 |
| Katoh, H | 1 |
| Shimizu, T | 1 |
| Yamashita, I | 1 |
| Takemori, S | 1 |
| Tazawa, K | 1 |
| Fujimaki, M | 1 |
| Matsubara, T | 1 |
| Ueda, M | 1 |
| Nagao, N | 1 |
| Nakajima, T | 2 |
| Nishi, M | 1 |
| Maemura, M | 1 |
| Nagaoka, H | 1 |
| Novaes, PE | 1 |
| Filho, WD | 1 |
| Bandealy, MT | 1 |
| Gonin, R | 1 |
| Loehrer, PJ | 1 |
| Monaco, F | 1 |
| Einhorn, LH | 1 |
| Félix-Faure, C | 1 |
| Davin, JL | 1 |
| Berger, C | 1 |
| Vincent, P | 1 |
| Schmitt, T | 1 |
| Armand, C | 1 |
| Mille, D | 1 |
| Favrel-Tchakamian, V | 1 |
| Gilloz, A | 1 |
| Kuniyasu, T | 1 |
| Nakamura, T | 1 |
| Tabuchi, Y | 1 |
| Kuroda, Y | 2 |
| Maeda, M | 1 |
| Nagawa, H | 1 |
| Maeda, T | 1 |
| Koike, H | 1 |
| Kasai, H | 1 |
| Pinder, SE | 1 |
| Murray, S | 1 |
| Trihia, H | 1 |
| Elston, CW | 1 |
| Cortés-Funes, H | 1 |
| Byrne, MJ | 1 |
| Zehr, EM | 1 |
| Althausen, AF | 1 |
| McGovern, FJ | 1 |
| Kitsukawa, S | 1 |
| Kinn, T | 1 |
| Yonese, J | 1 |
| Izutami, T | 1 |
| Fukui, I | 1 |
| Ishikawa, Y | 1 |
| Kubota, Y | 1 |
| Miura, T | 1 |
| Moriyama, M | 1 |
| Noguchi, S | 1 |
| Matsuzaki, J | 1 |
| Takebayashi, S | 1 |
| Hosaka, M | 1 |
| Matiakin, EG | 1 |
| Uvarov, AA | 1 |
| Kropotov, MA | 1 |
| Azizian, RI | 1 |
| Suwa, H | 1 |
| Hosotani, R | 1 |
| Okino, T | 1 |
| Monden, K | 1 |
| Arii, S | 1 |
| Inoue, K | 1 |
| Kogire, M | 1 |
| Ohshio, G | 1 |
| Fukumoto, M | 1 |
| Murakami, K | 1 |
| Matsuura, T | 1 |
| Hashimoto, A | 1 |
| Yonekura, K | 1 |
| Sakukawa, R | 1 |
| Saiki, I | 1 |
| Rohlff, C | 1 |
| Watson, SA | 1 |
| Morris, TM | 1 |
| Skelton, L | 1 |
| Jackman, AL | 1 |
| Page, MJ | 1 |
| Fasolini, F | 1 |
| Kohno, S | 1 |
| Hada, T | 1 |
| Oda, Y | 1 |
| Kobayashi, I | 1 |
| Ohmori, H | 1 |
| Sasaya, K | 1 |
| Matai, K | 1 |
| Yamazaki, Y | 1 |
| Okamoto, Y | 1 |
| Mizowaki, T | 1 |
| Kusumi, F | 1 |
| Hajiro, K | 1 |
| Nishimura, S | 1 |
| Matsusue, S | 1 |
| Takeda, H | 1 |
| Oh, WK | 1 |
| Manola, J | 1 |
| Richie, JP | 1 |
| Loughlin, KR | 1 |
| Kantoff, PW | 1 |
| Tsujitani, S | 1 |
| Oka, S | 1 |
| Kondo, A | 1 |
| Ikeguchi, M | 1 |
| Maeta, M | 1 |
| Kaibara, N | 1 |
| Shimizu, J | 1 |
| Kishimoto, S | 1 |
| Eguchi, H | 1 |
| Kondo, M | 1 |
| Haie-Meder, C | 1 |
| Fervers, B | 1 |
| Chauvergne, J | 1 |
| Fondrinier, E | 1 |
| Lhommé, C | 1 |
| Guastalla, JP | 1 |
| Resbeut, M | 1 |
| Cleator, S | 1 |
| Fife, K | 1 |
| Nelson, M | 1 |
| Gazzard, B | 1 |
| Phillips, R | 1 |
| Bower, M | 1 |
| Wang, WS | 1 |
| Lin, JK | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Fan, FS | 1 |
| Yen, CC | 1 |
| Lin, TC | 1 |
| Jiang, JK | 1 |
| Yang, SH | 1 |
| Wang, HS | 1 |
| Chen, PM | 1 |
| Droller, MJ | 1 |
| Cameron, DA | 1 |
| Gregory, WM | 1 |
| Bowman, A | 1 |
| Anderson, ED | 1 |
| Levack, P | 1 |
| Forouhi, P | 1 |
| Leonard, RC | 1 |
| Evans, C | 1 |
| Cockerell, CJ | 1 |
| Mizutani, S | 1 |
| Inada, T | 1 |
| Fukutomi, K | 1 |
| Igarashi, S | 1 |
| Ogata, Y | 1 |
| Tokunaga, Y | 1 |
| Kitaoka, A | 1 |
| Yagi, T | 1 |
| Tokuka, A | 1 |
| Ohsumi, K | 1 |
| Morita, M | 1 |
| Washizawa, N | 1 |
| Tokura, N | 1 |
| Kase, H | 1 |
| Hattori, T | 1 |
| Teramoto, T | 1 |
| Hirano, K | 1 |
| Shiozaki, H | 1 |
| Inoue, M | 1 |
| Noh, SH | 1 |
| Yoo, CH | 1 |
| Roh, JK | 1 |
| Shin, DW | 1 |
| Min, JS | 1 |
| Bondiau, PY | 1 |
| Largillier, R | 1 |
| Milano, G | 1 |
| Magné, N | 1 |
| Naitoh, M | 1 |
| Hara, F | 1 |
| Mitunaga, S | 1 |
| Ikeda, E | 1 |
| Moriyama, S | 1 |
| Tuji, T | 1 |
| Furutani, S | 1 |
| Nawa, S | 1 |
| Ohtuka, K | 1 |
| Kashiyama, Y | 1 |
| Myerson, RJ | 1 |
| Valentini, V | 1 |
| Birnbaum, EH | 1 |
| Cellini, N | 1 |
| Coco, C | 1 |
| Fleshman, JW | 1 |
| Gambacorta, MA | 1 |
| Genovesi, D | 1 |
| Kodner, IJ | 1 |
| Picus, J | 1 |
| Ratkin, GA | 1 |
| Read, TE | 1 |
| Corry, J | 1 |
| Rischin, D | 1 |
| Leong, T | 1 |
| Peters, LJ | 1 |
| Moffitt, DD | 1 |
| Peake, D | 1 |
| Veivers, D | 1 |
| Hans, S | 1 |
| Ménard, M | 2 |
| Laccourreye, H | 1 |
| Jennings, LL | 1 |
| Clarke, ML | 1 |
| Santos, CL | 1 |
| Dabbagh, L | 1 |
| Vsianska, M | 1 |
| Coupland, RW | 1 |
| Baldwin, SA | 1 |
| Young, JD | 1 |
| Barbareschi, M | 1 |
| Mori, I | 1 |
| Mauri, F | 1 |
| Muscarà, M | 1 |
| Nakamura, Y | 1 |
| Yoshimura, G | 1 |
| Sakurai, T | 1 |
| Caffo, O | 1 |
| Galligioni, E | 1 |
| Dalla Palma, P | 1 |
| Kakudo, K | 1 |
| Yabusaki, H | 1 |
| Nashimoto, A | 1 |
| Tanaka, O | 1 |
| Hirota, M | 1 |
| Kimura, J | 1 |
| Eguchi, T | 1 |
| Kanazumi, N | 1 |
| Ishii, M | 1 |
| Grabenbauer, GG | 1 |
| Kühn, R | 1 |
| Dunst, J | 1 |
| Papadopoulos, T | 1 |
| Schrott, KM | 1 |
| Sauer, R | 1 |
| Takamura, M | 1 |
| Nio, Y | 1 |
| Yamasawa, K | 1 |
| Itakura, M | 1 |
| Oriyama, T | 1 |
| Chang, W | 1 |
| Maeda, S | 1 |
| Kondo, Y | 1 |
| Kosaka, H | 1 |
| Nibu, K | 1 |
| Sugasawa, M | 1 |
| Asai, M | 1 |
| Mochiki, M | 1 |
| Terahara, A | 1 |
| Kawahara, N | 1 |
| Asato, H | 1 |
| Yachida, S | 1 |
| Fukushima, N | 1 |
| Sakamoto, M | 1 |
| Matsuno, Y | 1 |
| Kosuge, T | 1 |
| Hirohashi, S | 1 |
| Nishimura, R | 1 |
| Nagao, K | 1 |
| Miyayama, H | 1 |
| Matsuda, M | 1 |
| Matsuoka, Y | 1 |
| Fukuda, M | 1 |
| Nguyen, TH | 1 |
| Ho, DQ | 1 |
| Ryan, DP | 1 |
| Willett, CG | 1 |
| Ratto, C | 1 |
| Ricci, R | 1 |
| Rossi, C | 1 |
| Morelli, U | 1 |
| Vecchio, FM | 1 |
| Doglietto, GB | 1 |
| Möschl, P | 1 |
| Lubec, G | 1 |
| De Brabander, MJ | 1 |
| Hartwich, G | 1 |
| Betzler, M | 1 |
| Schlag, P | 1 |
| Schreml, W | 1 |
| Herfarth, C | 1 |
| Frykholm, G | 1 |
| Hemmingsson, A | 1 |
| Nyman, R | 1 |
| Påhlman, L | 1 |
| Aoki, H | 1 |
| Mieno, K | 1 |
| Amino, K | 1 |
| Miura, S | 1 |
| Ohtaki, K | 1 |
| Satoi, Y | 1 |
| Shikata, J | 1 |
| Schwaab, G | 1 |
| Lacau St-Guily, J | 1 |
| Trotoux, J | 1 |
| Solsona, E | 1 |
| Iborra, I | 1 |
| Ricós, JV | 1 |
| Monrós, JL | 1 |
| Dumont, R | 1 |
| Guillem, V | 1 |
| Teshima, H | 1 |
| Fujimoto, I | 1 |
| Hasumi, K | 1 |
| Masubuchi, K | 1 |
| De Besi, P | 1 |
| Sileni, VC | 1 |
| Salvagno, L | 1 |
| Tremolada, C | 1 |
| Cartei, G | 1 |
| Fosser, V | 1 |
| Paccagnella, A | 1 |
| Peracchia, A | 1 |
| Fiorentino, M | 1 |
| Saiga, T | 1 |
| Kashu, I | 1 |
| Tabuchi, K | 1 |
| Midorikawa, O | 1 |
| Patterson, JM | 1 |
| Ray, EH | 1 |
| Mendiondo, OA | 1 |
| Medina, WD | 1 |
| Gee, WF | 1 |
| Amiel, J | 1 |
| Quintens, H | 1 |
| Thyss, A | 1 |
| Caldani, C | 1 |
| Schneider, M | 1 |
| Toubol, J | 1 |
| Mizusawa, H | 1 |
| Meyer, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adjuvant Chemotherapy With FOLFOX After Total Mesorectal Excision for Locally Advanced Rectal Cancer; an Open-label, Multicenter, Prospective, Randomized Phase 3 Trial[NCT02167321] | Phase 2 | 90 participants (Actual) | Interventional | 2014-12-31 | Active, not recruiting | ||
| Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial[NCT05496491] | 84 participants (Anticipated) | Interventional | 2022-08-30 | Recruiting | |||
| National Phase IIIb Prospective Two-Cohort Non-Randomized, Multi-centre, Open Label Study to Assess the Safety of Subcutaneous Trastuzumab and Molecular Biomarkers in Patients With Early and Locally Advanced HER2-Positive Breast Cancer[NCT01940497] | Phase 3 | 240 participants (Actual) | Interventional | 2013-11-15 | Completed | ||
| Phase II Study of Neoadjuvant Folfirinox Chemotherapy Followed by Pembrolizumab Followed by Surgery for Patients With Localized, Resectable Adenocarcinoma of the Pancreas[NCT05132504] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-08-31 | Recruiting | ||
| Hepatic Arterial Infusion Chemotherapy as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma(HCC): A Prospective Randomized Controlled Clinical Trial[NCT02767375] | Phase 2/Phase 3 | 192 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| Multicenter Randomized Phase III Trial to Compare 6 FAC Cycles vs 4 FAC Cycles Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Negative Operable Breast Cancer Patients[NCT00129389] | Phase 3 | 1,925 participants (Actual) | Interventional | 2003-09-19 | Completed | ||
| A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabi[NCT00055601] | Phase 2 | 97 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer[NCT01234337] | Phase 3 | 537 participants (Actual) | Interventional | 2011-02-21 | Completed | ||
| Preoperative Short-course Radiotherapy With Local Boost Versus Conventional Preoperative Short-course Radiotherapy for Rectal Cancer[NCT02498353] | 100 participants (Anticipated) | Interventional | 2015-07-31 | Not yet recruiting | |||
| A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects With Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment With Epirubicin, Cisplatin, an[NCT00719550] | Phase 1/Phase 2 | 130 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| A Prospective, Multicenter, Open-label, Phase II Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Canc[NCT04659382] | Phase 2 | 52 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
| Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.[NCT00433927] | Phase 3 | 568 participants (Anticipated) | Interventional | 2007-01-31 | Active, not recruiting | ||
| Evaluation of Individual Peripheral Blood Circulating Tumor Cells Combined With Tumor Marker Detection of Efficacy of Chemotherapy in Patients With Advanced Colorectal Cancer: A Observational Clinical Trial[NCT02948985] | 100 participants (Anticipated) | Observational [Patient Registry] | 2017-01-31 | Not yet recruiting | |||
| Randomized Phase II Study of Adjuvant Chemotherapy With 5-FU/Leucovorin vs. Oxaliplatin/5-FU/Leucovorin After Preoperative Chemoradiotherapy With Fluoropyrimidines Followed by Surgery in Patients With Locally Advanced Rectal Cancer[NCT00807911] | Phase 2 | 320 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)[NCT02843191] | Phase 3 | 358 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| The Utility of Circulating Tumour Cells and Plasma microRNA Detection to Predict the Response to Treatment in Patients With Esophageal Adenocarcinoma[NCT02812680] | 200 participants (Anticipated) | Observational | 2016-06-30 | Active, not recruiting | |||
| Open-label Phase 1b Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer Who Have Progressed Following Chemotherapy for Advanced or Metastatic Disease[NCT00719199] | Phase 1 | 21 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Sponsor will discontinue further development of EMD 1201081) | ||
| Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473] | 200 participants (Actual) | Interventional | 2011-08-31 | Active, not recruiting | |||
| A Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Patients With Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma[NCT00515411] | Phase 2 | 111 participants (Actual) | Interventional | 2006-10-23 | Completed | ||
| A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum[NCT00145769] | Phase 3 | 326 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| A Phase II Feasibility Study of Combined Accelerated External Radiation and Chemotherapy With 5FU and CDDP Following Transurethral Resection in Patients With Muscle Invasive Transitional Carcinoma of the Bladder - T2-T3, N0, M0 (UICC 1992)[NCT00003642] | Phase 2 | 43 participants (Anticipated) | Interventional | 1998-10-31 | Terminated (stopped due to low accrual) | ||
| Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial[NCT02604615] | Phase 3 | 60 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| A Phase III Multicenter Randomized Clinical Trial Comparing Gemcitabine Alone Or In Combination With Capecitabine For The Treatment Of Patients With Advanced Pancreatic Cancer[NCT00032175] | Phase 3 | 508 participants (Anticipated) | Interventional | 2002-04-30 | Completed | ||
| Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing: A Randomized Trial to Assess the Role of Irinotecan and Oxaliplatin in Advanced Colorectal Cancer[NCT00008060] | Phase 3 | 0 participants | Interventional | 2000-05-31 | Completed | ||
| Induction Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan) Followed by Short Course Radiotherapy in Locally Advanced Rectal Cancer[NCT05868317] | Phase 2 | 70 participants (Anticipated) | Interventional | 2020-11-01 | Active, not recruiting | ||
| Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147] | Phase 2 | 25 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer[NCT01495676] | 69 participants (Actual) | Interventional | 2011-07-06 | Active, not recruiting | |||
| Preoperative Combined Radiochemotherapy for Patients With Newly Diagnosed, Primary Operable and Locally Advanced Rectal Carcinoma (cT3, Nx, M0) of the Lower and Middle Rectum[NCT00297141] | Phase 2 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694] | Phase 3 | 49 participants (Actual) | Interventional | 2019-05-11 | Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.) | ||
| Timing of Rectal Cancer Response to Chemoradiation[NCT00335816] | Phase 2 | 248 participants (Anticipated) | Interventional | 2008-08-31 | Active, not recruiting | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| Multicenter Randomized Controlled Phase III Trial Comparing Ileostomy Closure Before or After Adjuvant Therapy in Patients Operated for Rectal Cancer[NCT04372992] | 14 participants (Actual) | Interventional | 2020-09-01 | Terminated (stopped due to Low accrual - no restart after pandemic suspension) | |||
| Low-dose Versus Standard-dose Capecitabine Adjuvant Chemotherapy for Chinese Elderly Patients With Stage II/III Colorectal Cancer: A Randomized, Phase 3 Non-inferiority Study[NCT02316535] | Phase 3 | 710 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| 5-Fluorouracil Versus Capecitabine as Perioperative Treatment for Locally Advanced Rectal Cancer. a Randomized Phase III Trial[NCT01500993] | Phase 3 | 401 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| 2X2 Factorial Randomized Phase III Study Comparing Standard Versus Reduced Volume Radiotherapy With and Without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer[NCT00024349] | Phase 3 | 350 participants (Anticipated) | Interventional | 2001-06-30 | Completed | ||
| Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer (Study ATEZOBLADDERPRESERVE)[NCT04186013] | Phase 2 | 39 participants (Anticipated) | Interventional | 2019-09-18 | Active, not recruiting | ||
| Long-term Results of Plasma Epstein-Barr Virus DNA Monitoring In Nasopharyngeal Carcinoma After Curative Treatment[NCT03973723] | 441 participants (Actual) | Observational | 2011-08-01 | Completed | |||
| Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer[NCT04409860] | 120 participants (Anticipated) | Interventional | 2020-05-26 | Recruiting | |||
| Phase II Trial of Weekly Carboplatin-Paclitaxel Adjuvant Chemotherapy After Intensity Modulated Extended-field Chemoradiation in the Treatment of Locally Advanced Cervical Cancer With Para-aortic Positive Nodes[NCT04016142] | Phase 2 | 21 participants (Actual) | Interventional | 2020-07-15 | Active, not recruiting | ||
| Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression[NCT02309658] | Phase 2 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A RANDOMIZED PHASE III EVALUATION OF PACLITAXEL + G-CSF + CISPLATIN VERSUS CISPLATIN + 5-FU IN ADVANCED HEAD AND NECK CANCER[NCT00002888] | Phase 3 | 0 participants | Interventional | 1997-03-31 | Completed | ||
| Adjuvant Dose-dense Sequential Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study[NCT04829890] | 89 participants (Actual) | Observational | 2004-02-29 | Completed | |||
| Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation[NCT01049100] | 250 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | |||
| Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab[NCT00265811] | Phase 3 | 2,559 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Non Resectable But Non Metastatic Adenocarcinoma of the Exocrine Pancreas Non Resecables. Randomised Phase III: Initial Radiochimiotherapy (5-FU, Cisplatine, 60 GY Radiotherapy) Followed by Gemcitabine Versus Gemcitabine Alone[NCT00416507] | Phase 3 | 190 participants (Anticipated) | Interventional | 2000-03-31 | Completed | ||
| Sintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer: a Single-arm, Exploratory, Phase II Trial[NCT06050317] | Phase 2 | 25 participants (Anticipated) | Interventional | 2023-08-18 | Recruiting | ||
| A Phase II Trial of Gemcitabine, Herceptin, and Radiation for Regionally Confined Adenocarcinoma of the Pancreas[NCT00005926] | Phase 2 | 50 participants | Interventional | 2000-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Actual dose (mg) administered = (sum over all cycles of actual dose received [mg] divided by number of cycles). Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up last dose of trastuzumab (up to approximately 1 year)
| Intervention | mg (Mean) |
|---|---|
| Trastuzumab (Vial): Adjuvant | 599.7 |
| Trastuzumab (Vial): Neoadjuvant | 600.00 |
| Trastuzumab (SID): Adjuvant | 593.3 |
| Trastuzumab (SID): Neoadjuvant | 595.9 |
DFS was defined as the time from the first treatment to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Kaplan-Meier estimates were used for analysis. Participants who were disease-free were censored at the data cut off date. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])
| Intervention | Months (Median) |
|---|---|
| Trastuzumab (Vial): Adjuvant | NA |
| Trastuzumab (Vial): Neoadjuvant | NA |
| Trastuzumab (SID): Adjuvant | NA |
| Trastuzumab (SID): Neoadjuvant | NA |
Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up last dose of trastuzumab (up to approximately 1 year)
| Intervention | days (Mean) |
|---|---|
| Trastuzumab (Vial): Adjuvant | 346 |
| Trastuzumab (Vial): Neoadjuvant | 352.2 |
| Trastuzumab (SID): Adjuvant | 340.1 |
| Trastuzumab (SID): Neoadjuvant | 351.9 |
Overall survival was defined as the time from the first treatment to death from any cause. Kaplan-Meier estimates were used for analysis. Participants who did not die were censored on the date they were last known to be alive. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to death due to any cause (up to approximately 4.5 years)
| Intervention | Months (Median) |
|---|---|
| Trastuzumab (Vial): Adjuvant | NA |
| Trastuzumab (Vial): Neoadjuvant | NA |
| Trastuzumab (SID): Adjuvant | NA |
| Trastuzumab (SID): Neoadjuvant | NA |
Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to death due to any cause (up to approximately 4.5 years)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Trastuzumab (Vial): Adjuvant | 5.2 |
| Trastuzumab (Vial): Neoadjuvant | 4.5 |
| Trastuzumab (SID): Adjuvant | 0.0 |
| Trastuzumab (SID): Neoadjuvant | 5.26 |
(NCT01940497)
Timeframe: Screening (Day -28 to -1) up to 2.5 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Trastuzumab (Vial) | 100 |
| Trastuzumab (SID) | 100 |
A participant was considered as disease free if the participant was free from local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Percentage of participants with event at the cut off date were reported. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])
| Intervention | Percentage of Participants (Number) |
|---|---|
| Trastuzumab (Vial): Adjuvant | 18.5 |
| Trastuzumab (Vial): Neoadjuvant | 33.3 |
| Trastuzumab (SID): Adjuvant | 6.6 |
| Trastuzumab (SID): Neoadjuvant | 11.1 |
In the neoadjuvant setting, the activity of two sequential drug regimens, doxorubicin-containing chemotherapy followed by paclitaxel or docetaxel chemotherapy in combination with trastuzumab, was assessed as the percentage of participants with pCR in breast and nodes using mammography. pCR was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after preoperative treatment. Data for this outcome measure were analyzed and reported only for neoadjuvant groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to 24 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Trastuzumab (Vial): Neoadjuvant | 40.9 |
| Trastuzumab (SID): Neoadjuvant | 15.8 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were the AEs occurring from starting on the day of or after first administration of trastuzumab and within 28 days after last dose of trastuzumab. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to 28 days after last dose of trastuzumab (up to approximately 1 year)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Trastuzumab (Vial): Adjuvant | 98.9 |
| Trastuzumab (Vial): Neoadjuvant | 100.0 |
| Trastuzumab (SID): Adjuvant | 89.1 |
| Trastuzumab (SID): Neoadjuvant | 95.2 |
Percentage of HCPs providing responses to various questions related to overall ease of study drug administration was reported in different categories, where categories indicate all possible responses to such questions. (NCT01940497)
Timeframe: After at least 4 participants completed 5 cycles of adjuvant treatment (1 cycle = 21 days; maximum up to 1 year)
| Intervention | Percentage of HCPs (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialization: Oncologist | Specialization: Specialist nurse | Specialization: Other | Specialization: Missing | Personally administered/supervised: Always | Personally administered/supervised: Sometimes | Personally administered/supervised: Never | If 'Never', who administered: Specialist nurse | Syringe prepared at: Pharmacy | Syringe prepared at: Oncology ward | Syringe prepared at: Missing | Time to fill syringe: less than (<) 5 minutes | Time to fill syringe: 6-10 minutes | Time to fill syringe: 11-15 minutes | Time to fill syringe: Unknown | Total time for vial administration: <3 minutes | Total time for vial administration: <5 minutes | Total time for vial administration: 6-15 minutes | Time to prepare SID: <5 minutes | Time to prepare SID: 6-10 minutes | Time to prepare SID: 11-15 minutes | Time to prepare SID: 16-20 minutes | Time to prepare SID: >20 minutes | Total time for SID administration: <3 minutes | Total time for SID administration: <5 minutes | Total time for SID administration: 6-15 minutes | Injection site: Irritation: A lot | Injection site: Irritation: A few | Injection site: Irritation: None | Injection site: Bruising: A few | Injection site: Bruising: None | Injection site: Infection: None | Fever,shivering,flu-like,rash,swelling:A few | Fever,shivering,flu-like,rash,swelling:None | Time at hospital for administration: <2 hours | Time at hospital for administration: >2, <3 hours | Time at hospital for administration: >3, <4 hours | Time at hospital for administration: >4 hours | Time at hospital for administration: Missing | Anxiety to participants: None | Anxiety to participants: A fair amount | Ease of vial administration: None | Ease of vial administration: A fair amount | Ease of vial administration: A lot | Subcutaneous route may simplify management: Yes | Subcutaneous route may simplify management: No | Would recommend SID to intravenous route: Yes | Would recommend SID to intravenous route: No | Would recommend subcutaneous route to medics: Yes | Would recommend subcutaneous route to medics: No | Would recommend subcutaneous to medics:Missing | Convenience of using SID by participants: Yes | Convenience of using SID by participants: No | Convenience of using SID by participants: Missing | |
| HCPs: Trastuzumab (SID) | 16.0 | 76.0 | 8.0 | 0.0 | 48.0 | 48.0 | 4.0 | 4.0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 72.0 | 14.0 | 4.0 | 2.0 | 8.0 | 26.0 | 30.0 | 44.0 | 4.0 | 36.0 | 60.0 | 10.0 | 90.0 | 100.0 | 14.0 | 86.0 | 44.0 | 34.0 | 12.0 | 10.0 | 0.0 | 90.0 | 10.0 | NA | NA | NA | 100.0 | 0.0 | 96.0 | 4.0 | 90.0 | 8.0 | 2.0 | 96.0 | 4.0 | 0.0 |
| HCPs: Trastuzumab (Vial) | 17.3 | 69.2 | 11.5 | 1.9 | 40.4 | 51.9 | 7.7 | 7.7 | 55.8 | 40.4 | 3.8 | 67.3 | 13.5 | 5.8 | 13.5 | 1.9 | 59.6 | 38.5 | NA | NA | NA | NA | NA | NA | NA | NA | 1.9 | 46.2 | 51.9 | 7.7 | 92.3 | 100.0 | 15.4 | 84.6 | 44.2 | 23.1 | 23.1 | 7.7 | 1.9 | 82.7 | 17.3 | 5.8 | 38.5 | 55.8 | 94.2 | 5.8 | 96.2 | 3.8 | 100.0 | 0.0 | 0.0 | 94.2 | 0.0 | 5.8 |
"Participants were asked the following 5 questions: (1) Following the first injection given by the physician/nurse and training on how to use the SID, I felt comfortable injecting the study drug by myself; (2) The SID was convenient and easy to use; (3) I am confident giving myself an injection in the thigh with the SID; (4) Taking all things into account, I find self-administration using the SID satisfactory; (5) If given the opportunity, I would choose to continue self-injecting the study drug using the SID at home. Response to each question was recorded as either of the following options: Unknown, Strongly Disagree, Disagree, Unsure, Agree, Strongly Agree. Percentage of participants who provided responses to above questions was reported. Data for this outcome measure were analyzed and reported only for Trastuzumab (SID) arm." (NCT01940497)
Timeframe: After at least 14 cycles (1 cycle = 21 days; maximum up to 1 year)
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Comfortable: Unknown | Comfortable: Strongly Disagree | Comfortable: Disagree | Comfortable: Unsure | Comfortable: Agree | Comfortable: Strongly Agree | Convenient: Unknown | Convenient: Strongly Disagree | Convenient: Disagree | Convenient: Unsure | Convenient: Agree | Convenient: Strongly Agree | Confident: Unknown | Confident: Strongly Disagree | Confident: Disagree | Confident: Unsure | Confident: Agree | Confident: Strongly Agree | Satisfactory: Unknown | Satisfactory: Strongly Disagree | Satisfactory: Disagree | Satisfactory: Unsure | Satisfactory: Agree | Satisfactory: Strongly Agree | Would continue: Unknown | Would continue: Strongly Disagree | Would continue: Disagree | Would continue: Unsure | Would continue: Agree | Would continue: Strongly Agree | |
| Trastuzumab (SID) | 0.0 | 0.0 | 0.0 | 6.7 | 40 | 53.3 | 0.0 | 0.0 | 0.0 | 6.7 | 33.3 | 60 | 0.0 | 0.0 | 0.0 | 6.7 | 40.0 | 53.3 | 0.0 | 0.0 | 0.0 | 6.7 | 33.3 | 60 | 0.0 | 0.0 | 13.3 | 6.7 | 20 | 60 |
DFS is defined as the evidence of local, regional or metastatic recurrence, second primary cancer (with the exception of carcinoma of squamous cells or basal cells of the skin, cervical carcinoma in situ or lobular or ductal carcinoma in situ of the breast) or death for any reason. (NCT00129389)
Timeframe: Up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FAC | 98 |
| Arm B: FAC-wP | 71 |
OS event is defined as the death from any cause. (NCT00129389)
Timeframe: Up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FAC | 40 |
| Arm B: FAC-wP | 31 |
Bladder-intact survival was measured from the date of randomization to occurrence of cystectomy or death. Five-year rates were estimated using the Kaplan-Meier method. (NCT00055601)
Timeframe: From the date of randomization to five years.
| Intervention | percentage of participants (Number) |
|---|---|
| Pelvic RT + Paclitaxel + Cisplatin | 67 |
| Pelvic RT + Fluorouracil + Cisplatin | 71 |
Complete response requires the absence of any tumor in the tumor-site biopsy specimen or elsewhere and a bimanual exam that does not indicate the presence of a tumor mass. (NCT00055601)
Timeframe: From randomization to eight weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Pelvic RT + Paclitaxel + Cisplatin | 72 |
| Pelvic RT + Fluorouracil + Cisplatin | 62 |
Radiation therapy and chemotherapy per protocol or within acceptable variation guidelines based on central review. The study was designed for a two-sided binomial test with 87% power and a significance level of 0.05 with a null hypothesis of a 70% completion rate against the alternative 90% completion rate. For each arm, more than 34 out of 43 evaluable patients completing the treatment, would indicate to reject the null hypothesis for a better treatment completion rate. Fewer than 24 out 43 evaluable patients completing the treatment would indicate to reject the null hypothesis for a worse treatment completion rate. Otherwise, the conclusion would be that there is not enough evidence to reject the null hypothesis of a 70% completion rate in either direction. (NCT00055601)
Timeframe: From randomization to 11 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Pelvic RT + Paclitaxel + Cisplatin | 67 |
| Pelvic RT + Fluorouracil + Cisplatin | 53 |
DCR was defined as the proportion of participants whose best response was CR, PR, stable disease (SD) or Non-CR/Non-PD. Per RECIST version 1.1, CR=all target lesions disappeared, any pathological lymph node, target/non-target, a reduction in short axis to <10 mm. PR=at least 30% decrease in the sum of diameters of target lesions taking as reference baseline sum diameters. PD=at least 20% increase in the sum of diameters of the target lesions, taking as a reference smallest sum on study. Appearance of new lesions and unequivocal progression of existing non-target lesions. SD=neither sufficient shrinkage qualified for PR nor sufficient increase qualified for PD, taking smallest sum of diameters as a reference. Non-CR/Non-PD=persistence of 1/more non-target lesion(s) and/or maintenance of tumor marker level above normal limits. DCR=CR+PR+SD or Non-CR/Non-PD. CR and PR confirmed by another scan at least 4 weeks later. SD and Non-CR/Non-PD documented at least 6 weeks after randomization. (NCT01234337)
Timeframe: From randomization of the first participant until approximately 3 years later or until disease radiological progression
| Intervention | percentage (%) of participants (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + Capecitabine | 60.5 |
| Placebo + Capecitabine | 58.3 |
DOR was defined as the time from date of first response (CR or PR) to the date when PD is first documented, or to the date of death, whichever occurred first according to RECIST version 1.1. CR=all target lesions disappeared, and any pathological lymph node, whether target or non-target, had a reduction in short axis to <10 mm. If any residual lesion was present, cyto-histology was made available to unequivocally document benignity. PR=at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants still having CR or PR and have not died at the time of analysis were censored at their last date of tumor evaluation. DOR defined for confirmed responders only (that is, CR or PR). 'NA' indicates that value could not be estimated due to censored data. Median and 95% CIs were computed using Kaplan-Meier estimates. (NCT01234337)
Timeframe: From randomization of the first participant until approximately 3 years later or until disease radiological progression
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + Capecitabine | 313 |
| Placebo + Capecitabine | 290 |
ORR was defined as the best tumor response (Complete Response [CR] or Partial Response [PR]) observed during treatment or within 30 days after termination of study treatment, assessed according to the RECIST version 1.1. CR=all target lesions disappeared, and any pathological lymph node, whether target or non-target, had a reduction in short axis to <10 mm. If any residual lesion was present, cyto-histology was made available to unequivocally document benignity. PR=at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR=CR+PR. CR and PR were confirmed by another scan at least 4 weeks later. (NCT01234337)
Timeframe: From randomization of the first participant until approximately 3 years later or until disease radiological progression
| Intervention | Percentage (%) of participants (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + Capecitabine | 13.5 |
| Placebo + Capecitabine | 15.5 |
OS was defined as the time from date of randomization to death due to any cause. Participants still alive at the time of analysis were censored at their last known alive date. Median and other 95% CIs computed using Kaplan-Meier estimates. (NCT01234337)
Timeframe: From randomization of the first participant until approximately 3 years later
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + Capecitabine | 575 |
| Placebo + Capecitabine | 616 |
The EQ-5D was a generic Quality of life (QoL) based instrument validated in cancer populations. EQ-5D questionnaire contained a 5-item descriptive system of health states (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and visual analogue scale (VAS). A single HRQoL score ranging from -0.59 to 1 was generated from standard scoring algorithm developed by the EuroQoL was the EQ-5D index score, higher scores represent better health status. A change of at least 0.10 to 0.12 points was considered clinically meaningful. The results on the ANCOVA of time-adjusted AUC for the EQ-5D - Index Score were reported. The time-adjusted AUC was calculated by dividing the AUC by duration (in days) over the period of interest, and reported as 'scores on a scale'. (NCT01234337)
Timeframe: Day 1 of Cycles 1, 3, 5, 7, 9, 11, 13, 16, 19, 22, 25, 28, and EOT (21 days after last dose of study drug)
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + Capecitabine | 0.665 |
| Placebo + Capecitabine | 0.69 |
The EQ-5D was a generic QoL preference based instrument and has been validated in the cancer populations. VAS was generated from 0 (worst imaginable health state) to 100 (best imaginable health state). This VAS score was referred to as the EQ-5D self-reported health status score. The results on ANCOVA of time-adjusted AUC were reported. The time-adjusted AUC was calculated by dividing the AUC by duration (in days) over the period of interest, and reported as 'scores on a scale'. (NCT01234337)
Timeframe: Day 1 of Cycles 1, 3, 5, 7, 9, 11, 13, 16, 19, 22, 25, 28, and EOT (21 days after last dose of study drug)
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + Capecitabine | 67.532 |
| Placebo + Capecitabine | 69.228 |
The FBSI-8 was an 8-item questionnaire. Participants responded to each item using a 5-point Likert-type scale ranging from 0 (not at all) to 4 (very much). A total scale score was calculated (range from 0 to 32), with higher scores indicating low symptomatology and reflecting a better Health-Related Quality of Life (HRQoL). The results on the analysis of covariance (ANCOVA) of time-adjusted area under curve (AUC) for the FBSI-8 score were reported. The time-adjusted AUC was calculated by dividing the AUC by duration (in days) over the period of interest, and reported as 'scores on a scale'. (NCT01234337)
Timeframe: Day 1 of Cycles 1, 3, 5, 7, 9, 11, 13, 16, 19, 22, 25, 28, 31, 34, 37, and end of treatment (EOT, 21 days after last dose of study drug)
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + Capecitabine | 20.915 |
| Placebo + Capecitabine | 21.356 |
PFS was defined as the time from date of randomization to disease progression, radiological or death due to any cause, whichever occurs first. Per RECIST version 1.1, progressive disease was determined when there was at least 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study (this included the baseline sum if that was the smallest sum on trial). In addition to a relative increase of 20%, the sum had demonstrated an absolute increase of at least 5 mm. Appearance of new lesions and unequivocal progression of existing non-target lesions was also interpreted as progressive disease. Participants without progression or death at the time of analysis were censored at their last date of evaluable tumor evaluation. Median and other 95% confidence intervals (CIs) computed using Kaplan-Meier estimates. (NCT01234337)
Timeframe: From randomization of the first participant until approximately 3 years or until disease radiological progression
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + Capecitabine | 166 |
| Placebo + Capecitabine | 165 |
TTP was defined as the time from date of randomization to disease radiological progression by central review. Per RECIST version 1.1, progressive disease was determined when there was at least 20% increase in the sum of diameters of the target lesions, taking as a reference the smallest sum on study (this included the baseline sum if that was the smallest sum on trial). In addition to a relative increase of 20%, the sum had demonstrated an absolute increase of at least 5 mm. Appearance of new lesions and unequivocal progression of existing non-target lesions was also interpreted as progressive disease. Participants without progression or death at the time of analysis were censored at their last date of evaluable tumor evaluation. Median and other 95% confidence intervals (CIs) computed using Kaplan-Meier estimates. (NCT01234337)
Timeframe: From randomization of the first participant until approximately 3 years later or until disease radiological progression
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + Capecitabine | 168 |
| Placebo + Capecitabine | 165 |
AUC(0-tlast) is defined as AUC from time 0 to the last data point, calculated up by linear trapezoidal rule, down by logarithmic trapezoidal rule. Geometric mean and percentage geometric coefficient of variation (%CV) were reported. In the listed categories below, 'N' signifies the number of evaluable participants for the drug administered. (NCT01234337)
Timeframe: Pre-dose and 0.5, 1, 2, and 4 hours after capecitabine dosing at Cycle 2, Day 14
| Intervention | milligram*hour per liter (Geometric Mean) | |
|---|---|---|
| Capecitabine | 5-fluorouracil | |
| Placebo + Capecitabine | 5.13 | 0.557 |
| Sorafenib (Nexavar, BAY43-9006) + Capecitabine | 7.12 | 0.621 |
Maximum observed drug concentration, directly taken from analytical data. Geometric mean and percentage geometric coefficient of variation (%CV) were reported. In the listed categories below, 'N' signifies the number of evaluable participants for the drug administered. (NCT01234337)
Timeframe: Pre-dose and 0.5, 1, 2, and 4 hours after capecitabine dosing at Cycle 2, Day 14
| Intervention | milligram per liter (Geometric Mean) | |
|---|---|---|
| Capecitabine | 5-fluorouracil | |
| Placebo + Capecitabine | 4.68 | 0.382 |
| Sorafenib (Nexavar, BAY43-9006) + Capecitabine | 6.05 | 0.434 |
Hematological (anemia, hemoglobin, international normalized ratio [INR], lymphocyte, neutrophil, platelet, white blood cell [WBC]), biochemical (ALT [alanine aminotransferase], AST [aspartate aminotransferase], GGT [gamma-glutamyl-transferase], lipase, hypoalbuminemia, hypocalcemia, hyperglycemia, hyperuricemia) evaluations were done. Common terminology criteria for adverse events (CTCAE) version 4-Grade 3: Severe or medically significant; hospitalization or prolongation of hospitalization and CTCAE version 4-Grade 4: life-threatening consequences; urgent intervention were indicated. (NCT01234337)
Timeframe: From the start of study treatment up to 30 days after the last dose
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia (grade 3) | Hemoglobin increased (grade 3) | INR increased (grade 3) | Lymphocyte count decreased (grade 3) | Neutrophil count decreased (grade 3) | Platelet count decreased (grade 3) | WBC decreased (grade 3) | ALT increased (grade 3) | AST increased (grade 3) | Alkaline phosphatase increased (grade 3) | Bilirubin increased (grade 3) | GGT increased (grade 3) | Lipase increased (grade 3) | Serum amylase increased (grade 3) | Hypoalbuminemia (grade 3) | Hypocalcemia (grade 3) | Hypokalemia (grade 3) | Hyponatremia (grade 3) | Hypophosphatemia (grade 3) | Hyperglycemia (grade 3) | Lymphocyte count decreased (grade 4) | Neutrophil count decreased (grade 4) | Platelet count decreased (grade 4) | WBC decreased (grade 4) | ALT increased (grade 4) | GGT increased (grade 4) | Lipase increased (grade 4) | Hypokalemia (grade 4) | Hyponatremia (grade 4) | Hypophosphatemia (grade 4) | Hyperuricemia (grade 4) | |
| Placebo + Capecitabine | 7 | 3 | 9 | 17 | 19 | 2 | 13 | 5 | 5 | 13 | 1 | 21 | 12 | 4 | 2 | 6 | 11 | 7 | 15 | 10 | 2 | 7 | 7 | 3 | 0 | 2 | 1 | 4 | 0 | 0 | 0 |
| Sorafenib (Nexavar, BAY43-9006) + Capecitabine | 12 | 0 | 9 | 20 | 11 | 6 | 15 | 4 | 10 | 12 | 9 | 22 | 19 | 8 | 4 | 9 | 20 | 9 | 47 | 9 | 3 | 7 | 1 | 2 | 3 | 6 | 5 | 2 | 4 | 5 | 5 |
"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, or similar definition as accurate and appropriate" (NCT00515411)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months
| Intervention | percentage of paticipants (Mean) |
|---|---|
| Arm A, - Modified DCF | 63 |
| ARM B - Parent DCF With G-CSF | 53 |
| Arm C - Modified DCF+ Trastuzumab | 73 |
Overall survival measured in months (NCT00515411)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 43 months
| Intervention | months (Median) |
|---|---|
| Arm A, - Modified DCF | 18.8 |
| ARM B - Parent DCF With G-CSF | 12.6 |
| Arm C - Modified DCF+ Trastuzumab | 24.9 |
40 reviews available for fluorouracil and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Nonsurgical Therapies for Basal Cell Carcinoma: A Review.
Topics: Administration, Cutaneous; Aminoquinolines; Anilides; Antineoplastic Agents; Biphenyl Compounds; Car | 2017 |
[Radiochemotherapy for invasive bladder cancer : An update].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Biopsy; Carcinoma, Transitional Cell; Chemoradio | 2018 |
Pancreaticoduodenectomy with Replaced Common Hepatic Artery and Portal Vein Reconstruction in Primary Carcinoma Duodenum: a Case Report and Literature Review.
Topics: Adenocarcinoma; Aged; Angioplasty; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2019 |
Locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase | 2013 |
Microinvasive melanoma: cutaneous pharmacotherapeutic approaches.
Topics: Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Ne | 2013 |
Use of microRNAs in directing therapy and evaluating treatment response in colorectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Chemoradiotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidin | 2014 |
Management of sinonasal undifferentiated carcinoma with intracerebral invasion: Clinical experience at a single institution and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Chemoradiotherapy | 2016 |
[Primary clear cell carcinoma of the cervix: report of five cases and review of the literature].
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; C | 2008 |
The multidisciplinary management of rectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Diagnostic Imaging; Digestive System Surgic | 2009 |
[Virchow's node as the form of onset of squamous cell carcinoma of the pancreas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplat | 2009 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
[Diagnosis and treatment of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Signet Ring Cell; Cisplatin; Endo | 2010 |
[Chemotherapy in gallbladder carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Cisplatin; Deoxyc | 2010 |
[A case of effective neoadjuvant chemoradiotherapy with capecitabine for locally advanced sigmoid colon cancer].
Topics: Adenocarcinoma; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Male; | 2011 |
[A case of locally advanced sigmoid colon cancer invading the bladder and seminal vesicle effectively treated with preoperative mFOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Fluorouraci | 2011 |
Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dia | 2012 |
[A case of sigmoid colon cancer invading urinary bladder treated with preoperative mFOLFOX6 and urinary bladder conserving surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Liver Neopla | 2012 |
[Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Inf | 2002 |
Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2003 |
[Polymorphism in colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genetic Predisposition to D | 2003 |
Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carbopl | 2004 |
Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2004 |
Chemotherapy in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop | 2004 |
Management of muscle invasive bladder cancer--British approaches to organ conservation.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
[Multimodal therapy for unresectable upper and hilar bile duct carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts; Brachytherapy; Cisp | 2006 |
Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2006 |
Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2007 |
Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, | 2008 |
[Concomitant radiotherapy and chemotherapy for infiltrating cancers of bladder. Conservative treatment with very promising perspectives].
Topics: Cisplatin; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Invasiveness; Preoperative Care | 1993 |
[Neoadjuvant chemotherapy and concurrent radiochemotherapy for advanced esophageal carcinoma potentially invading adjacent structures].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials a | 1997 |
[Esophagectomy combined resection of invaded neighboring organs for T4 esophageal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Esop | 1997 |
[Concurrent radio-chemotherapy in infiltrating cancer of the bladder: a new therapeutic approach?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin | 1998 |
[Successful multidisciplinary treatment for bladder cancer with priapism. A case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Comb | 1998 |
[Rectal carcinoma. Optimizing treatment by neoadjuvant and adjuvant therapy?].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Hu | 1999 |
[Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1999 |
Combined modality treatment for locally advanced squamous-cell carcinoma of the oropharynx in a woman with Bloom's syndrome: a case report and review of the literature.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bloom Syndro | 2001 |
Invasive bladder cancer: organ preservation by radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2002 |
Nonmelanoma skin cancer.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Diet Therapy; Fluorouracil; Humans; Life Style; Neo | 2002 |
Management of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2002 |
[Combined approach to malignant tumors of the ethmoid and other paranasal sinuses. Principles and results].
Topics: Actuarial Analysis; Adult; Aged; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Ethmo | 1991 |
112 trials available for fluorouracil and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemoth | 2019 |
Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical | 2020 |
Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Flu | 2020 |
Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ch | 2017 |
Treatment of Locally Advanced Rectal Cancer: Turning Good Rationale Into Good Evidence?
Topics: Antineoplastic Agents; Camptothecin; Chemoradiotherapy; Colectomy; Dose-Response Relationship, Drug; | 2017 |
Postoperative Chemoradiotherapy After Local Resection for High-Risk T1 to T2 Low Rectal Cancer: Results of a Single-Arm, Multi-Institutional, Phase II Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Colectomy | 2017 |
Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplas | 2017 |
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colore | 2017 |
Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Dis | 2018 |
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cis | 2019 |
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinom | 2019 |
Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2019 |
Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2013 |
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2013 |
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2013 |
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
Topics: Administration, Oral; Algorithms; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Prot | 2013 |
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2014 |
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2014 |
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2014 |
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2014 |
Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2015 |
Prognostic value of HLA class I expression in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2015 |
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Dis | 2015 |
FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Disease-Free | 2016 |
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2018 |
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2016 |
Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cispl | 2016 |
LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Topics: AC133 Antigen; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Co | 2016 |
Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04).
Topics: Adenocarcinoma; Adult; Aged; Cause of Death; Chemoradiotherapy; Colectomy; Disease-Free Survival; Do | 2017 |
The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).
Topics: Adult; Aged; Chemoradiotherapy; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Neoplasm | 2017 |
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brea | 2017 |
Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Ad | 2008 |
Efficacy of a continuous venous infusion of fluorouracil and daily divided dose cisplatin as adjuvant therapy in resectable colorectal cancer: a prospective randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colo | 2008 |
[Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2008 |
Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2009 |
Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2009 |
A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Dis | 2009 |
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence In | 2009 |
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2010 |
Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2009 |
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cross-Over Studies; Deoxy | 2010 |
Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine | 2010 |
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2009 |
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2009 |
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doce | 2010 |
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, l
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2010 |
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, l
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2010 |
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, l
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2010 |
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, l
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2010 |
Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2010 |
Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 2011 |
Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; C | 2010 |
Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2010 |
Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2011 |
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2012 |
Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2011 |
Prospective trial of chemotherapy-enhanced accelerated radiotherapy for larynx preservation in patients with intermediate-volume hypopharyngeal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Chem | 2012 |
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates | 2012 |
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, H | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv | 2012 |
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv | 2012 |
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv | 2012 |
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Surviv | 2012 |
Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2012 |
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2012 |
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclophosphamide | 2013 |
Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2003 |
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2003 |
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Confidence I | 2003 |
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Disease-Free Survival; Dose-Response Relationship, Dru | 2003 |
Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cis | 2003 |
Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Administration, Oral; Aged; Antimetabolites, Antineoplastic; | 2004 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Modalit | 2004 |
[Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Cisplatin; Di | 2004 |
Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2004 |
1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Ch | 2004 |
Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitab | 2005 |
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2005 |
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2005 |
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2005 |
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Ca
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2005 |
Chemoradiotherapy for T3 and T4 squamous cell carcinoma of the esophagus using low-dose FP and radiation: a preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2005 |
Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modal | 2006 |
[Study on efficacy and toxicity of new combined regimen "taxoter + cisplatin + 5-fluorouracil" in disseminated and locally-spread stomach cancer. Comparative analysis of tolerance and efficacy in patients younger and older than 65 years].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2006 |
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2006 |
A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemot | 2007 |
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Surv | 2007 |
Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptotheci | 2007 |
Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2008 |
Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2008 |
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; | 2008 |
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; | 2008 |
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; | 2008 |
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; | 2008 |
[The so-called partial synchronization in the treatment of malignant lymphomas. A clinical study].
Topics: Bleomycin; Cell Division; Clinical Trials as Topic; Cytarabine; Doxorubicin; Fluorouracil; Hodgkin D | 1980 |
Improved survival with preoperative chemotherapy followed by resection uncompromised by tumor response for advanced squamous cell carcinoma of the head and neck.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1995 |
Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 1995 |
[Definition, classification and combined treatment of locally invasive rectal neoplasms].
Topics: Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Humans; Neoplasm Invasiveness; Neoplasm | 1994 |
5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Colonic Neoplasms; Confidence | 1994 |
Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1996 |
Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma in Situ; Carcino | 1996 |
[Neoadjuvant chemotherapy in high-grade advanced gastric cancer with protracted infusional 5-fluorouracil and consecutive low-dose cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1996 |
[Prospective controlled study on the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi | 1997 |
Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protoc | 1998 |
The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 1998 |
A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 1998 |
A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 1999 |
A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colectomy; Combined | 2001 |
A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2001 |
[Stage T4 bladder cancer. Impact of neoadjuvant chemotherapy on T4b tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1990 |
Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Humans; Male; Middle A | 1985 |
443 other studies available for fluorouracil and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzhydryl Compounds; Cell Cycle; Cell Line, Tumor; Cell | 2014 |
Inhibition of invasion by N-trans-feruloyloctopamine via AKT, p38MAPK and EMT related signals in hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Coumaric Acids; Epithelial-Mesenchymal Transition; Huma | 2017 |
Discovery of 6-chloro-2-(propylthio)-8,9-dihydro-7H-purines containing a carboxamide moiety as potential selective anti-lung cancer agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Discover | 2018 |
Excellent antitumor and antimetastatic activities based on novel coumarin/pyrazole oxime hybrids.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Coumarins; Epithelial-Mesenchymal Transition | 2019 |
Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Chemoradiotherapy; Cli | 2022 |
Syndecan-2, negatively regulated by miR-20b-5p, contributes to 5-fluorouracil resistance of colorectal cancer cells via the JNK/ERK signaling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Base Pairin | 2021 |
Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance.
Topics: A549 Cells; Adenocarcinoma of Lung; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell | 2021 |
Bladder preservation in older adults with muscle-invasive bladder cancer: A retrospective study with concurrent chemotherapy and twice-daily hypofractionated radiotherapy schedule.
Topics: Aged; Combined Modality Therapy; Cystectomy; Fluorouracil; Humans; Muscles; Neoplasm Invasiveness; O | 2022 |
Micro ribonucleic acid-448 regulates zinc finger e-box binding homeobox 1 to inhibit the growth of breast cancer cells and increase their sensitivity to chemotherapy.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Fluorouracil; Gene Ex | 2022 |
Clinical outcomes of adapted hypofractionated radiotherapy for bladder cancer in elderly patients.
Topics: Aged; Combined Modality Therapy; Cystectomy; Fluorouracil; Humans; Neoplasm Invasiveness; Retrospect | 2023 |
Anticancer Action of Psilostachyin-A in 5-Fluorouracil-Resistant Human Liver Carcinoma are Mediated Through Autophagy Induction, G2/M Phase Cell Cycle Arrest and Inhibiting Extracellular-Signal-Regulated Kinase/Mitogen Activated Protein Kinase (ERK/MAPK)
Topics: Antineoplastic Agents; Autophagy; Beclin-1; Cell Proliferation; Extracellular Signal-Regulated MAP K | 2019 |
[Pure laparoscopic DP-CAR procedure with portal vein resection].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Fluorouracil; | 2019 |
Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cycloph | 2019 |
Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line, Tumor; Colorecta | 2019 |
A novel therapeutic anti‑CD55 monoclonal antibody inhibits the proliferation and metastasis of colorectal cancer cells.
Topics: Antibodies, Monoclonal; CD55 Antigens; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Comp | 2019 |
MicroRNA-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id-1.
Topics: Adult; Aged; Animals; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Esophageal Neoplas | 2019 |
Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; C | 2019 |
PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; | 2020 |
Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophage | 2020 |
Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.
Topics: Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2020 |
Cooperation of SRPK2, Numb and p53 in the malignant biology and chemosensitivity of colorectal cancer.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Colorectal Neoplasms; Disease Progre | 2020 |
International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradi | 2020 |
Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Lin | 2020 |
Plasma microRNA profiles: identification of miR-1229-3p as a novel chemoresistant and prognostic biomarker in gastric cancer.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Survival; Disease-Free Survival; D | 2020 |
Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Down-Regulation; | 2020 |
Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycyti | 2020 |
Multi-Domain Photopatterned 3D Tumor Constructs in a Micro-Physiological System for Analysis, Quantification, and Isolation of Infiltrating Cells.
Topics: Caco-2 Cells; Cell Separation; Colonic Neoplasms; Fluorouracil; HCT116 Cells; Humans; Hydrogels; Hyd | 2020 |
Topical Fluorouracil Therapy for Residual Superficial Basal Cell Carcinoma Following Mohs Micrographic Surgery.
Topics: Administration, Cutaneous; Aged; Carcinoma, Basal Cell; Chemotherapy, Adjuvant; Female; Fluorouracil | 2020 |
Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Color | 2020 |
NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression.
Topics: Antioxidants; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transpor | 2020 |
NKX6.1 Represses Tumorigenesis, Metastasis, and Chemoresistance in Colorectal Cancer.
Topics: Animals; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Transformation, Ne | 2020 |
Functional loss of TAGLN inhibits tumor growth and increases chemosensitivity of non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithe | 2020 |
Role of PrP
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Colon; Colonic Neoplasms; Drug Resistance, Neop | 2020 |
Role of ARID1A in epithelial‑mesenchymal transition in breast cancer and its effect on cell sensitivity to 5‑FU.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; DNA-Binding | 2020 |
Silencing of long non-coding RNA LINC01270 inhibits esophageal cancer progression and enhances chemosensitivity to 5-fluorouracil by mediating GSTP1methylation.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Cell Proliferation; | 2021 |
Organ Preservation in the Treatment of Stage II and III Rectal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colectomy; | 2020 |
Locally advanced rectal adenocarcinoma: Treatment sequences, intensification, and rectal organ preservation.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryonic | 2021 |
Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and witho
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Biomarkers, Tumor; Clini | 2021 |
Improved response rate in patients with prognostically poor locally advanced rectal cancer after treatment with induction chemotherapy and chemoradiotherapy when compared with chemoradiotherapy alone: A matched case-control study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Case-Control Studie | 2021 |
5-FU resistant colorectal cancer cells possess improved invasiveness and β
Topics: Antineoplastic Agents; Cell Adhesion; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; | 2021 |
Distinctive Prognostic Value and Cellular Functions of Osteopontin Splice Variants in Human Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Alternative Splicing; Amino Acid Sequence; Cell Adhesion; Cell Line, | 2021 |
Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations.
Topics: Animals; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Surviv | 2017 |
Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; | 2017 |
Prognostic value of positron emission tomography/computed tomography for adjuvant chemotherapy of colon cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coh | 2018 |
GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neo | 2017 |
Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells.
Topics: Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Fluoro | 2017 |
Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carbopla | 2017 |
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer.
Topics: Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; China; Di | 2017 |
Effects of Neoadjuvant 5-Fluorouracil and Cisplatin Therapy in Patients with Clinical Stage II/III Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2018 |
[A Case of Laparoscopic Surgery Performed for Locally Advanced Rectal Cancer Suspected of Invasion to Prostate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Laparoscopy; Leucovorin; Male; | 2017 |
[A Case of Effective Neoadjuvant Chemotherapy for Transverse Colon Cancer with Extensive Abdominal Wall Invasion].
Topics: Abdominal Wall; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms | 2017 |
[Three-Year Survival after Lymphadenectomy for Residual Lymph Node Metastasis of Esophageal Cancer with Invasion into the Trachea and Carotid Artery after Chemoradiotherapy - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carotid Arteries; Chemoradiotherapy; Cisplatin | 2017 |
Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2018 |
Indolent Nodal Relapse of Colon Carcinoma with Associated Tumor Thrombus Invading the Superior Mesenteric Vein.
Topics: Adenocarcinoma, Mucinous; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2019 |
Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Case-Control Studie | 2018 |
Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Lin | 2018 |
MicroRNA-17 inhibition overcomes chemoresistance and suppresses epithelial-mesenchymal transition through a DEDD-dependent mechanism in gastric cancer.
Topics: Apoptosis; Cell Movement; Cisplatin; Death Domain Receptor Signaling Adaptor Proteins; DNA-Binding P | 2018 |
Bcl-2-associated athanogene 3(BAG3) is associated with tumor cell proliferation, migration, invasion and chemoresistance in colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antimetabolites, Antineoplastic; Apoptosis Regulatory Pr | 2018 |
Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Jap
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoth | 2018 |
Extending far and wide: the role of biopsy and staging in the management of ocular surface squamous neoplasia.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Squamous Cell; Conjunctival Neoplasms; Corneal Disea | 2019 |
FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biom | 2019 |
A new chalcone derivative, 3-phenyl-1-(2,4,6-tris(methoxymethoxy)phenyl)prop-2-yn-1-one), inhibits phorbol ester-induced metastatic activity of colorectal cancer cells through upregulation of heme oxygenase-1.
Topics: Cell Movement; Cell Proliferation; Chalcone; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor | 2018 |
[COMPLETE RESECTION OF URACHAL CARCINOMA WITH SIGMOID COLON INVASION AFTER FOLFOX CHEMOTHERAPY: A CASE REPORT].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colon, Sigmoid; Combined | 2018 |
Aurora kinase A induces chemotherapy resistance through revival of dormant cells in laryngeal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Aurora Kinase A; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell M | 2019 |
Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Cohort Studies; D | 2019 |
Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; | 2019 |
CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Car | 2019 |
Inhibitory effects and molecular mechanisms of pentagalloyl glucose in combination with 5-FU on aggressive phenotypes of HepG2 cells.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Fluorouracil | 2021 |
The YB-1/EZH2/amphiregulin signaling axis mediates LPA-induced breast cancer cell invasion.
Topics: Amphiregulin; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breas | 2019 |
SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF.
Topics: Animals; Apoptosis Inducing Factor; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; CRIS | 2019 |
Long noncoding RNA H19 promotes chemotherapy resistance in choriocarcinoma cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Choriocarcinoma; Drug | 2019 |
[A Case of Curatively Resected Rectosigmoid Colon Cancer That Invaded the Urinary Bladder after Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Male; Neoadj | 2019 |
Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pa | 2019 |
Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Neoplasm In | 2019 |
Safety of thoracoscopic esophagectomy after induction chemotherapy for locally advanced unresectable esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Ca | 2020 |
Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 2013 |
MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells.
Topics: 3' Untranslated Regions; Aniline Compounds; Animals; Antineoplastic Agents; Doxorubicin; Female; Flu | 2014 |
The PEA-15/PED protein regulates cellular survival and invasiveness in colorectal carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; A | 2013 |
[A case of locally advanced sigmoid colon cancer curatively resected after neoadjuvant chemotherapy with FOLFIRI plus panitumumab].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluoro | 2013 |
CD24 expression predicts distant metastasis in extrahepatic bile duct cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Ex | 2013 |
Deconstruction of medulloblastoma cellular heterogeneity reveals differences between the most highly invasive and self-renewing phenotypes.
Topics: Adult; Animals; Antimetabolites, Antineoplastic; CD24 Antigen; Cell Line, Tumor; Cell Movement; Cell | 2013 |
Histopathological regression grading matches excellently with local and regional spread after neoadjuvant therapy of rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Chi-Square Distributio | 2013 |
Avoidance of exenteration in orbital sebaceous gland carcinoma with neoadjuvant chemotherapy.
Topics: Adenocarcinoma, Sebaceous; Cisplatin; Eye Evisceration; Eyelid Neoplasms; Fluorouracil; Humans; Male | 2013 |
Prognostic value of complete response in patients with muscle-invasive bladder cancer undergoing concurrent chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemorad | 2013 |
[Pathological complete response in a case of advanced esophageal cancer invading aorta treated by preoperative chemotherapy with docetaxel and cisplatin plus 5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Combined Modality Therapy; Docetax | 2013 |
Knockdown of inhibitor of growth protein 2 inhibits cell invasion and enhances chemosensitivity to 5-FU in human gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Fluorouracil; Gene Ex | 2013 |
Diffusion-weighted magnetic resonance imaging for predicting and detecting the early response to chemoradiotherapy of advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, A | 2013 |
Inhibition of gastric cancer cell growth in vivo by overexpression of adeno-associated virus-mediated survivin mutant C84A.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Dependovirus; | 2013 |
Long-term quality-of-life after neoadjuvant short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Cross-Sectional Studies; Disease-Free Survival; F | 2013 |
TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Biomarkers, Tumor; Cell L | 2014 |
Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2013 |
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemothera | 2014 |
Death associated protein 1 is correlated with the clinical outcome of patients with colorectal cancer and has a role in the regulation of cell death.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Mo | 2014 |
Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro.
Topics: 3' Untranslated Regions; Apoptosis; Base Sequence; Cell Cycle; Cell Proliferation; Chemoradiotherapy | 2014 |
[Results of definitive radiotherapy for squamous cell carcinomas of the larynx patients with subglottic extension].
Topics: Adult; Aged; Aged, 80 and over; Airway Obstruction; Antibodies, Monoclonal, Humanized; Antineoplasti | 2014 |
Drug resistance mediated changes in lymphendothelial tumor cell intravasation.
Topics: Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Endothelium, Lymphatic; Epithelial-M | 2014 |
Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Cell L | 2014 |
[A case of pathological complete response with neoadjuvant mFOLFOX6 chemotherapy for advanced lower rectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovor | 2013 |
[Two cases of locally advanced colorectal cancer curatively resected after neoadjuvant chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin plus panitumumab].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans | 2013 |
[A case of locally advanced colorectal cancer with abscess responding to 5-fluorouracil, leucovorin, and oxaliplatin plus bevacizumab].
Topics: Abscess; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2013 |
[A case of esophageal squamous cell carcinoma with submucosal tumor-like tumor due to direct invasion of the gastric wall].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; E | 2013 |
Is there a real need of adjuvant chemotherapy for locally advanced nasopharyngeal carcinoma?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2014 |
Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines.
Topics: Aged; Cell Line, Tumor; Colorectal Neoplasms; Disease-Free Survival; Epithelial-Mesenchymal Transiti | 2014 |
A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Case-Control Studies; Cell Cycle Proteins; Cell Survival; | 2014 |
A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; C | 2014 |
Bronchoscopic finding determined outcome after chemoradiotherapy in esophageal cancer patients with airway invasion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Chemoradiotherapy; Cisplatin; Esophage | 2014 |
Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
[The significance of physical status of human papillomavirus type 16 for predicting the effectiveness of invasive cervical cancer treatment].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Comparative Effectiv | 2013 |
A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2014 |
Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Movement; Cell Proliferation; Cholangiocar | 2014 |
MiR-612 suppresses the stemness of liver cancer via Wnt/β-catenin signaling.
Topics: Animals; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cisplatin; D | 2014 |
[A case of curatively resected sigmoid colon cancer after mFOLFOX6 plus panitumumab neoadjuvant chemotherapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucov | 2014 |
HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2014 |
Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiotherapy for rectal cancer?
Topics: Adenocarcinoma; Adult; Aged; Biomarkers, Tumor; Biopsy; Chemoradiotherapy; Combined Modality Therapy | 2014 |
Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Car | 2014 |
Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2014 |
Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway.
Topics: Actin Cytoskeleton; Aged; Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Prolife | 2014 |
KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2015 |
HepG2 cells recovered from apoptosis show altered drug responses and invasiveness.
Topics: Ablation Techniques; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Dos | 2014 |
Characterization of side population cells isolated from the colon cancer cell line SW480.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Drug Resistance, Neop | 2014 |
Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Drug Resis | 2014 |
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2015 |
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2015 |
Liposome-mediated induction of apoptosis of human hepatoma cells by c-myc antisense phosphorothioate oligodeoxynucleotide and 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolif | 2014 |
[A case of pathologically complete response in a patient with locally advanced sigmoid colon cancer after chemotherapy including bevacizumab/FOLFOX4].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Ce | 2014 |
Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy | 2015 |
IQGAP1 in rectal adenocarcinomas: localization and protein expression before and after radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2015 |
Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: a single-centre study of 163 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Tra | 2015 |
Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Wester | 2014 |
Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2014 |
Radio(chemo)therapy for locally advanced squamous cell carcinoma of the esophagus: long-term outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2015 |
miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1.
Topics: 3' Untranslated Regions; Apoptosis; Base Sequence; Cell Cycle; Cell Movement; Cell Proliferation; Ch | 2015 |
Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype.
Topics: Animals; Blotting, Western; Cell Culture Techniques; Cell Cycle; Cell Proliferation; Colony-Forming | 2015 |
The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ducta | 2015 |
Prognostic factors and adjuvant treatments for surgically treated cancers of the biliary tract: a multicentre study of the Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2014 |
Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Proto | 2014 |
Upregulation of CD147 promotes cell invasion, epithelial-to-mesenchymal transition and activates MAPK/ERK signaling pathway in colorectal cancer.
Topics: Basigin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mesenchymal T | 2014 |
Treatment of invasive squamous cell carcinomas in an open Clagett window.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Debride | 2015 |
MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance.
Topics: Adenocarcinoma; Anoikis; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cell Proliferati | 2014 |
Nanoparticles inhibit cancer cell invasion and enhance antitumor efficiency by targeted drug delivery via cell surface-related GRP78.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell | 2015 |
Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2015 |
[Surgical resection after chemotherapy for advanced rectal cancer - report of a case].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
[A case of neoadjuvant chemotherapy for locally advanced rectal cancer, which had a invasion into the vagina followed by curative resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Laparoscopy; Leucovori | 2014 |
[A case of stage IV rectal cancer successfully resected after chemotherapy (mFOLFOX6 plus panitumumab)].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther | 2014 |
[A case of HER2-positive advanced gastric cancer with extensive lymph node metastasis treated via chemotherapy with a trastuzumab-containing regimen followed by conversion surgery].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cis | 2014 |
Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2015 |
Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2015 |
[Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2015 |
Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combin | 2015 |
Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2015 |
Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2015 |
Adjuvant chemotherapy and prognostic factors in stage II colon cancer--Izmir Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2015 |
Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro.
Topics: Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Endothelial Cells; Fluorouracil; Hom | 2015 |
Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment.
Topics: Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial | 2015 |
Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer.
Topics: Alginates; Animals; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Curcumin; Drug Synergism; F | 2015 |
Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
Topics: Adult; Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2016 |
MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.
Topics: Adenoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colorectal Neoplas | 2015 |
Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Topics: Bile Duct Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Deoxycytidi | 2015 |
Analysis on clinical characteristics and influencing factors of patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2015 |
EGFR and β1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; ErbB R | 2015 |
Treatment of T3 laryngeal cancer in the Netherlands: a national survey.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Carboplatin; Ca | 2015 |
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carci | 2015 |
Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; C-Reactive Protein; CCAAT-Enhancer-Binding Protein-delta; | 2015 |
Truncating mutation in the autophagy gene UVRAG confers oncogenic properties and chemosensitivity in colorectal cancers.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Autophagy; Carcinogenesis; Cell Line, Tumor; | 2015 |
The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ch | 2015 |
Downregulation of VMP1 confers aggressive properties to colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colore | 2015 |
Autophagy in human skin squamous cell carcinoma: Inhibition by 3-MA enhances the effect of 5-FU-induced chemotherapy sensitivity.
Topics: Adenine; Apoptosis; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proli | 2015 |
Correlation Between Nuclear Factor E2-Related Factor 2 Expression and Gastric Cancer Progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antioxidants; Carcinoma; Drug Resistance, Neo | 2015 |
A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cy | 2016 |
Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Biomarke | 2016 |
Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2015 |
miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer.
Topics: Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Female; Fl | 2015 |
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Wester | 2016 |
Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2016 |
Therapy-Induced Cellular Senescence Induces Epithelial-to-Mesenchymal Transition and Increases Invasiveness in Rectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cellular Senescence; Doxorubicin; Epithelial- | 2016 |
Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort St | 2018 |
MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Movement; Cell Prolifer | 2016 |
Downregulation of microRNA-193-3p inhibits tumor proliferation migration and chemoresistance in human gastric cancer by regulating PTEN gene.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug | 2016 |
[A Case of Long-Term Survival of a Patient with Liver Metastasis of Colon Cancer and Suspected Inferior Vena Cava Invasion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorouracil; Hum | 2015 |
[Recurrence of Rectal Cancer with Submucosal Invasion in the Bone and Lymph Nodes 89 Months after Surgery--A Case Report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptot | 2015 |
Neoadjuvant chemotherapy for invasive squamous cell carcinoma of the conjunctiva: A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Conjunct | 2015 |
Inhibition of Growth and Metastasis of Colon Cancer by Delivering 5-Fluorouracil-loaded Pluronic P85 Copolymer Micelles.
Topics: AC133 Antigen; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Colonic Neoplasms; D | 2016 |
Timing of adjuvant chemotherapy in colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brazil; Chemotherapy, Adjuvant; | 2016 |
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Reduced RanBPM Expression Is Associated with Distant Metastasis in Gastric Cancer and Chemoresistance.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Adhesion | 2016 |
[A Case of an Unresectable Locally Advanced Rectal Cancer with Surrounding Organ Invasion Successfully Resected after Chemotherapy with mFOLFOX6 plus Cetuximab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Fluorouracil; Humans; Leucovorin; Male; M | 2016 |
Integrin αvβ3 expression in tongue squamous carcinoma cells Cal27 confers anticancer drug resistance through loss of pSrc(Y418).
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cisplatin; Dasatin | 2016 |
ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplat | 2016 |
Butyrate-mediated acquisition of chemoresistance by human colon cancer cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter | 2016 |
Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell M | 2016 |
Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Esophageal | 2016 |
Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Chemotherapy, A | 2017 |
Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway.
Topics: Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Syne | 2016 |
Comparison of the expression and function of Lin28A and Lin28B in colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Cell Prol | 2016 |
Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression.
Topics: Animals; Antimetabolites, Antineoplastic; beta Catenin; Cell Movement; Cell Proliferation; Colorecta | 2016 |
Hyperthermic carbon dioxide pneumoperitoneum reinforces the inhibition of 5-FU on the proliferation and invasion of colon cancer.
Topics: Animals; Carbon Dioxide; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Combined Modality | 2017 |
Synergistically Anti-metastatic Effect of 5-Flourouracil on Colorectal Cancer Cells via Calcium-mediated Focal Adhesion Kinase Proteolysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Calcium Compounds; Cell Death; Ce | 2017 |
CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line | 2017 |
l-arginine alters the effect of 5-fluorouracil on breast cancer cells in favor of apoptosis.
Topics: Apoptosis; Arginine; Breast Neoplasms; Cell Movement; Cell Survival; Chemokine CXCL12; Female; Fluor | 2017 |
[A Case of Locally Far-Advanced Colon Cancer Resected by Laparoscopic Surgery after Colonic Stent Insertion and Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Hum | 2016 |
CXCL12/CXCR4 axis induced miR-125b promotes invasion and confers 5-fluorouracil resistance through enhancing autophagy in colorectal cancer.
Topics: Adenomatous Polyposis Coli Protein; Animals; Apoptosis; Autophagy; Base Sequence; Cell Line, Tumor; | 2017 |
Inhibition of polypyrimidine tract-binding protein 3 induces apoptosis and cell cycle arrest, and enhances the cytotoxicity of 5- fluorouracil in gastric cancer cells.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Cycle C | 2017 |
The extracellular domain of E cadherin linked to invasiveness in colorectal cancer: a new resistance and relapses monitoring serum-bio marker?
Topics: Adult; Aged; Antigens, CD; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cadherins; C | 2017 |
Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2017 |
[Adjuvant chemotherapy as a component of complex treatment for skin melanoma].
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2008 |
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, An | 2008 |
Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, | 2008 |
[Clinical effect and positioning of capecitabine for metastatic breast carcinoma].
Topics: Aged; Breast Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Middle Aged; Neoplasm Inv | 2008 |
Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2008 |
[Case of urachal cancer treated by neoadjuvant chemotherapy with FOLFOX4 (oxaliplatin, 5-FU and leukovolin)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluorouracil; Huma | 2008 |
A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer.
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2008 |
The prognostic influence of prevertebral space involvement in nasopharyngeal carcinoma.
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brai | 2008 |
Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-alpha in pancreatic and periampullary cancer: results of a feasibility study.
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Feasibility Studies; Female; Fluorourac | 2008 |
Adrenal metastasis of breast cancer with involvement of the inferior vena cava.
Topics: Adrenal Gland Neoplasms; Adult; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2008 |
Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer?
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fasci | 2008 |
[A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chola | 2008 |
[A case of huge advanced rectal cancer invaded into the surrounding organs resected successfully after preoperative chemotherapy with mFOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Male; Neoadj | 2008 |
Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod | 2009 |
In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Screening Assays, Antit | 2009 |
[Indications and results of palliative gastric resection in advanced gastric carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chemotherapy, Adjuvant; Female; Flu | 2009 |
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Antineoplastic Combined C | 2009 |
[A case of locally advanced rectal cancer responding to FOLFOX].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Magnetic Resonance | 2009 |
Concurrent chemoradiotherapy with adjuvant chemotherapy for high-risk nasopharyngeal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Clinicopathological characteristics, management and outcome of metastatic penoscrotal extramammary Paget's disease.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Docetaxel; Female; Fluorouracil; Genital | 2009 |
HIV and anal cancer outcomes: a single institution's experience.
Topics: Antineoplastic Agents; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvan | 2009 |
Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cartilage; Ci | 2009 |
Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2009 |
Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Cell Division; Cell Line, | 2010 |
Recurrence of treated ciliary body melanoma following trabeculectomy.
Topics: Aged; Brachytherapy; Ciliary Body; Combined Modality Therapy; Conjunctival Neoplasms; Eye Enucleatio | 2009 |
Rectal angiosarcoma after adjuvant chemoradiotherapy for adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fatal Outcome; Fluorouracil | 2009 |
Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2010 |
Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Cl | 2009 |
Epithelial-mesenchymal transition with expression of SNAI1-induced chemoresistance in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelium; Fluoro | 2009 |
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitab | 2011 |
Is duodenal invasion a relevant prognosticator in patients undergoing adjuvant chemoradiotherapy for distal common bile duct cancer?
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Chemotherapy, Ad | 2010 |
HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Apoptosis; | 2010 |
Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Papillary | 2010 |
Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease Progression; F | 2010 |
Significance of occult neoplastic cells on tumor metastasis: a case report of gastric cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Signet Ring Cell; Cell Differentiation; Chemothe | 2010 |
Prognostic value of perineural invasion in patients with stage II colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2010 |
Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Cell Line | 2010 |
Pre- and post-therapy nodal status equally affects survival of patients with oesophageal squamous cell carcinoma receiving preoperative chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Chemotherapy-free intervals in patients with metastatic colorectal cancer: a tale of two cities?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free S | 2010 |
Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells.
Topics: Animals; Colonic Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Pr | 2010 |
Survival of a cohort of patients with intermediate and advanced gall bladder cancer treated with a prospective therapeutic protocol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Chile; Cho | 2010 |
A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Carcinoma; Cell Migration Assays; Cell Transformation, Neopla | 2010 |
Adjuvant chemoradiation therapy in gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplati | 2010 |
Long-term survival of a patient with leptomeningeal involvement by nasopharyngeal carcinoma after treatment with high-dose intravenous methotrexate.
Topics: Adult; Antimetabolites, Antineoplastic; Cisplatin; Fluorouracil; Humans; Infusions, Intravenous; Mag | 2012 |
Preliminary experience with bladder preservation for lower rectal cancers involving the lower urinary tract.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Feasibility | 2010 |
Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biop | 2010 |
Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemotherapy, Adj | 2011 |
Survivin-3B gene decreases the invasion-inhibitory effect of colon cancer cells with 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Fluorouracil; Humans; Inhibito | 2010 |
Criteria for three-dimensional anorectal ultrasound assessment of response to chemoradiotherapy in rectal cancer patients.
Topics: Adenocarcinoma; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, | 2011 |
[Practice and consideration on neoadjuvant therapy for early breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Re | 2010 |
Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Movement; Cell Prol | 2010 |
[Four resected cases with basaloid carcinoma of esophagus--comparison of 5-FU-related enzymes (thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT)) between basaloid carcinoma and squamous cell carcin
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dihydrouraci | 2010 |
Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell | 2011 |
[A case of recurrent esophageal cancer with tracheal invasion treated by chemo-radiotherapy (CRT) after placement of tracheal stent that maintained complete response (CR) for two years].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2010 |
Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma | 2012 |
Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2011 |
Synchronous colonic adenocarcinoma and pelvic schwannoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carcinoembryoni | 2011 |
Absence of CD71 transferrin receptor characterizes human gastric adenosquamous carcinoma stem cells.
Topics: Animals; Antigens, CD; Biomarkers, Tumor; Carcinogenicity Tests; Carcinoma, Adenosquamous; Drug Resi | 2012 |
Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumo | 2011 |
Role of adjuvant chemoradiotherapy for duodenal cancer: a single center experience.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy, Adj | 2012 |
SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Fluorouracil; Gene Expression Regu | 2011 |
[A resected case of locally invasive rectal cancer successfully treated with neoadjuvant capecitabine, oxaliplatin, bevacizumab and radiation therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcin | 2011 |
Molecular changes consistent with increased proliferation and invasion are common in rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Case-Control Stu | 2011 |
20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Cisplatin; | 2012 |
Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chem | 2012 |
Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epit | 2012 |
[A case of colon cancer with long-term survival treated by resection of recurrence on the rectum and chemotherapy for lung metastasis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Fluorouracil; Humans; Leucov | 2011 |
[A case of advanced esophageal cancer invaded to the trachea with PCR after preoperative chemoradiotherapy, which relapsed at the time of three years and seven months after resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; | 2011 |
Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S | 2012 |
Reduced lymph node harvest after neoadjuvant chemotherapy in gastric cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Demog | 2011 |
Loss of E-cadherin promotes the growth, invasion and drug resistance of colorectal cancer cells and is associated with liver metastasis.
Topics: Active Transport, Cell Nucleus; Antimetabolites, Antineoplastic; beta Catenin; Cadherins; Cell Adhes | 2012 |
Adjuvant chemoradiation for gastric cancer: multicentric study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, A | 2012 |
Evaluation of the efficacy of modified De Gramont and modified FOLFOX4 regimens for adjuvant therapy of locally advanced rectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2011 |
Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorecta | 2013 |
Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradiotherap | 2013 |
Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Cell Transformat | 2012 |
[A case of response to panitumumab as third-line chemotherapy for multiple liver metastases and portal venal tumor embolus of rectal cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Embol | 2012 |
MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.
Topics: 3' Untranslated Regions; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; | 2013 |
Multidisciplinary therapy consisting of minimally invasive resection, irradiation, and intra-arterial infusion of 5-fluorouracil for maxillary sinus carcinomas.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Female; Fluorouracil; Follow-Up Studies; Humans; Infusio | 2013 |
A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2012 |
[A case of small intestinal cancer with peritoneal metastases treated with FOLFOX regimen].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Jejunal Neoplasms; Leuc | 2012 |
[A case of huge advanced rectal cancer resected successfully after chemotherapy with mFOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Female; Flu | 2012 |
Clinicopathological significance of mesothelin expression in invasive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 2012 |
Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread.
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biomarkers, Tumor; Carb | 2012 |
Isolation and characterization of calcium sensing receptor null cells: a highly malignant and drug resistant phenotype of colon cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Calcium; Cell Adhe | 2013 |
Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2013 |
Glycogenes mediate the invasive properties and chemosensitivity of human hepatocarcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement | 2013 |
Ulcerated plaques in the pelvic region of an adult female.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, D | 2012 |
Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Blotting, Western; | 2013 |
miR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKα1.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle C | 2013 |
Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution.
Topics: Adenocarcinoma; Aged; Anal Canal; Brazil; Chemoradiotherapy; Female; Fluorouracil; Humans; Male; Mic | 2013 |
A novel treatment approach for extensive, eruptive, cutaneous squamous cell carcinomas in a patient receiving BRAF inhibitor therapy for metastatic melanoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorour | 2013 |
[A case of advanced colon cancer resected successfully after neoadjuvant chemotherapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Fluorouraci | 2012 |
SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; | 2013 |
Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; F | 2012 |
[A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr | 2002 |
[Postoperative adjuvant immunochemotherapy using Lentinan for advanced gastric carcinoma patients with metastasis in the regional lymph nodes and serosal invasion].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2002 |
Distal intramural spread is an independent prognostic factor for distant metastasis and poor outcome in patients with rectal cancer: a multivariate analysis.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluoroura | 2003 |
[Combined treatment with fluorinated pyrimidines and selective cyclooxygenase-2 inhibitors for liver metastasis of colon cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colonic Neoplasms; Cyclooxyg | 2003 |
Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Models | 2003 |
[Resection of esophageal cancer infiltrating the left main bronchus following complete response to preoperative radiochemotherapy--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cispl | 2003 |
DPD activity and immunohistochemical DPD expression in human breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Lin | 2004 |
Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Line, Tumor; Cell Movem | 2004 |
Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Transformation, Neoplastic; Down-Regulation; Female; | 2004 |
[A case of curatively resected gastric cancer through an effective response to chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 2004 |
Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ci | 2004 |
[Choice of chemotherapeutic drugs for colorectal cancers by DPD and OPRT activities in cancer tissues].
Topics: Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female | 2004 |
Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity.
Topics: Agar; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2004 |
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2004 |
[A case of advanced colon cancer responding completely to systemic 5-fluorouracil/l-leucovorin therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colostomy; | 2004 |
Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; C | 2004 |
Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Squam | 2005 |
Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fl | 2005 |
[Prognosis of epidermoid anal carcinoma regression after conservative treatment].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2004 |
Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2005 |
Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2005 |
Preoperative radio-chemotherapy treatment in locally advanced rectal carcinoma. Results of 8-year follow-up.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Disease-Free Survival; Dose Fractionat | 2005 |
FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; | 2005 |
Prognostic and predictive value of the thymidylate synthase expression in patients with non-metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colonic Neoplasms; | 2005 |
Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Topics: Adult; Aged; Analysis of Variance; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; B | 2005 |
[A case of unknown primary squamous cell carcinoma in the neck showing a high response with combined chemotherapy including nedaplatin, adriamycin and 5-fluorouracil].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
Impact of orotate phosphoribosyl transferase activity as a predictor of lymph node metastasis in gastric cancer.
Topics: Aged; Antineoplastic Agents; Cell Proliferation; Female; Fluorouracil; Humans; Lymphatic Metastasis; | 2005 |
Predicting recurrence risk for synchronous primary colon cancers.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Case Management; Cecal N | 2004 |
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bac | 2003 |
First-line treatment options for patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2004 |
Intermediate dose 5-fluorouracil-induced encephalopathy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasm | 2006 |
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2006 |
5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer.
Topics: Animals; Cell Count; Cell Survival; Colorectal Neoplasms; Disease Models, Animal; Flow Cytometry; Fl | 2006 |
Subtotal hepatectomy following neoadjuvant chemotherapy for a previously unresectable hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Hepa | 2006 |
Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidi | 2006 |
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2006 |
[A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases].
Topics: Adenocarcinoma; Cecal Neoplasms; Chemotherapy, Adjuvant; Colectomy; Fluorouracil; Hepatectomy; Human | 2006 |
Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting.
Topics: Adult; Age Distribution; Age Factors; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; | 2007 |
Chemotherapy for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Fluorouracil; Humans | 2007 |
Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Bronchi; Carcinoma, Sq | 2007 |
Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Fine-Needle; Breast Neo | 2007 |
[A resected case of squamous cell carcinoma of the breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamous Cell; C | 2007 |
Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; | 2007 |
[A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedul | 2007 |
[A case of advanced colon cancer invading the rectum effectively treated with chemoradiation therapy before surgery].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi | 2007 |
Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinom | 2007 |
Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Digestive Syst | 2008 |
[The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 2007 |
Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Injecti | 2008 |
[A case of thoracic esophageal cancer with invasion of the main bronchus in which long-term survival with high quality of life was achieved through chemoradiotherapy, esophageal bypass and then additional chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Cisplatin; Combined Modality Th | 2007 |
Adjuvant intraportal venous chemotherapy for patients with hepatocellular carcinoma and portal vein tumor thrombi following hepatectomy plus portal thrombectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju | 2008 |
ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Chemotherapy, Adjuvant; Colectomy; Color | 2008 |
Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy.
Topics: Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Stud | 2008 |
Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasm | 2008 |
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
Topics: Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Cell Cycle; Cell Line, Tumor; Chromosome | 2008 |
Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma.
Topics: Acitretin; Alitretinoin; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2008 |
Recurrent obstructive jaundice caused by fibrolamellar hepatocellular carcinoma.
Topics: Adult; Carcinoma, Hepatocellular; Cholestasis, Extrahepatic; Combined Modality Therapy; Doxorubicin; | 1984 |
[Current status of chemotherapy of gastric and colorectal cancer].
Topics: Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm Invasivene | 1981 |
Malignant tumors of the vagina. Classification and approach to treatment.
Topics: Adenocarcinoma; Adolescent; Adult; Carcinoma in Situ; Carcinoma, Squamous Cell; Child; Diethylstilbe | 1983 |
Effect of anticancer agents on invasion of mouse fibrosarcoma cells in vitro.
Topics: Animals; Benzimidazoles; Carbamates; Chick Embryo; Fibrosarcoma; Fluorouracil; Mice; Microtubules; M | 1981 |
Influence of cells number on directional migration of MO4 cells in vitro.
Topics: Animals; Benzimidazoles; Carbamates; Cell Line; Cell Movement; Fibroblasts; Fluorouracil; Mice; Mice | 1981 |
Treatment of invasive squamous cell carcinoma complicating anal Buschke-Löwenstein tumor: a case history.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Diseases; Anus Neoplasms; Carcinoma, Squamous C | 1995 |
[Preoperative neoadjuvant chemotherapy with a combination of 5-fluorouracil, adriamycin and cisplatin (FAP) for advanced esophageal cancer invading trachea or main bronchus].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Chemotherapy, Adjuvant; C | 1995 |
[Promotion of hematogenous metastasis in relation to endothelial cell injury by treatment with anticancer drugs].
Topics: Animals; Antineoplastic Agents; Cell Division; Doxorubicin; Endothelium; Fluorouracil; Humans; Mitom | 1994 |
[A case of advanced gastric cancer successfully treated with resection after FEP (5-FU, epirubicin, CDDP) combined chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; D | 1994 |
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil; Humans; Inf | 1993 |
[Postoperative immunochemotherapy for gastric carcinoma with peritoneal dissemination--the effects with the combination of CDDP, 5-FU and lentinan].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cel | 1994 |
Local excision of rectal carcinoma. Early results with combined chemoradiation therapy using 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1994 |
Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 1993 |
A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice.
Topics: Animals; Disease Models, Animal; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Liver Neopl | 1993 |
[Evaluation of intra-arterial infusion chemotherapy and radical pancreatectomy in patients with locally advanced pancreatic cancer].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; | 1993 |
Long-term follow-up of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and possible postoperative radiotherapy and/or chemotherapy in squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1993 |
Irradiation of carcinoma of the esophagus containing a tracheoesophageal fistula.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1993 |
[A patient with stage IV gastric cancer responding to combination chemotherapy with 5-FU, leucovorin and CDDP].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio | 1993 |
[A case of giant advanced breast cancer responding remarkably to CEFT therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1993 |
[5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antimetabolites, Antineoplastic; Fatal Outcome; Female; Flu | 1996 |
Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1996 |
[Results of adjuvant chemotherapy of operated high risk cervix carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 1996 |
[Continuous infusion high-dose leucovorin with cisplatin and 5-fluorouracil for a recurrent oropharynx carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administra | 1997 |
[A case of unresectable pancreatic cancer successfully treated with continuous venous daily infusion of 5-FU and low-dose CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Cisplatin; Drug Administr | 1997 |
[A case of advanced hepatocellular carcinoma with portal invasion effectively treated by continuous intra-arterial chemotherapy with 5-fluorouracil].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, I | 1997 |
[A case of huge liver metastasis from colon cancer successfully treated by hepatic intraarterial infusion of low-dose 5-FU].
Topics: Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil | 1997 |
[A case of far-advanced gastric cancer treated with continuous 5-fluorouracil injection and intrahepatic arterial infusion of low-dose cisplatin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasm | 1997 |
Clinical results of treatment of advanced esophageal carcinoma with hyperthermia in combination with chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 1997 |
Surgical treatment for carcinoma of the thoracic esophagus with major involvement in the neck or upper mediastinum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neo | 1998 |
Angiogenesis and stromal fibronectin expression in invasive breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1998 |
Radiation and chemotherapy instead of surgery for low infiltrative rectal adenocarcinoma: a prospective trial.
Topics: Abdomen; Adenocarcinoma; Adjuvants, Immunologic; Anal Canal; Antidotes; Antimetabolites, Antineoplas | 1998 |
[Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cel | 1998 |
[Concurrent chemotherapy and hyperfractionated radiotherapy for non-operable carcinoma of the bladder].
Topics: Aged; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiat | 1998 |
Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies; Antimetabolites, Antineoplastic; Carcino | 1998 |
Alcohol consumption enhances liver metastasis in colorectal carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Analysis of Variance; Antineoplastic Agents; Blood | 1998 |
Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer.
Topics: Epithelial Cells; Floxuridine; Fluorouracil; Humans; Kinetics; Neoplasm Invasiveness; Neoplasm Stagi | 1997 |
[Results of organ-preserving and reconstructive surgery of the mandible in patients with cancer of the oral cavity].
Topics: Adult; Alveolar Process; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; H | 1998 |
Detection of multiple hepatic micrometastases in pancreatic adenocarcinoma with a solitary liver metastasis by direct sequencing of the K-ras gene: a case report.
Topics: Adenocarcinoma; Aged; Base Sequence; Combined Modality Therapy; Dose Fractionation, Radiation; Femal | 1999 |
4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoates; Body Weight | 1998 |
A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Asialoglycoprotein Receptor; Cell Membrane; Co | 1999 |
[Usefulness of combination therapy with expandable metallic stent replacement and FLEP chemotherapy (consisting of 5-FU, leucovorin, etoposide and cisplatin) for advanced esophageal cancer invading the bronchus: a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cispl | 1999 |
Comparison between chemoradiation protocol intended for organ preservation and conventional surgery for clinical T1-T2 esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Cisp | 1999 |
The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 1999 |
[A case report of hepatocellular carcinoma with hepatic and portal venous tumor thrombus and multiple intrahepatic metastasis who survived over 1 year after the operation with combined locoregional chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined | 1999 |
Treatment of HIV-associated invasive anal cancer with combined chemoradiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therapy; Fl | 2000 |
Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience.
Topics: Adenocarcinoma; Age Factors; Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoembryonic | 2000 |
A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Fluor | 2000 |
Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Chemotherapy, A | 2000 |
Actinic keratosis: time to call a spade a spade.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Epidermis; Fluorouracil; Humans; Keratino | 2000 |
[A patient with gastric cancer with para-aortic lymph node metastases surviving for 9 years after effective preoperative chemotherapy and radical operation].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aorta; Fluorouracil; Gastrectomy; Humans; Lymph Nod | 2000 |
Postsurgical sequential methotrexate, fluorouracil, and leucovorin for stages 3 and 4 gastric carcinoma: A preliminary study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Sc | 2000 |
Combined therapy with conservative surgery, radiotherapy, and regional chemotherapy for maxillary sinus carcinoma.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Maxi | 2000 |
[A case of stage IV gastric cancer responding to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 2000 |
Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2001 |
[Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dihydrouracil Dehydr | 2000 |
[A case of advanced hepatocellular carcinoma with portal invasion resected after treatment by continuous intra-arterial chemotherapy with cisplatin and 5-fluorouracil].
Topics: Aged; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Fluorouracil; Hepatitis C, Ch | 2001 |
Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Therapy, Combination; F | 2001 |
[Clinical study on the expression level of lymphocyte function-related antigen of breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dru | 2000 |
Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers.
Topics: Affinity Labels; Animals; Antibodies, Monoclonal; Antibody Formation; Antimetabolites, Antineoplasti | 2002 |
Prognostic value of thymidine phosphorylase expression in breast carcinoma.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2002 |
[A complete response after neoadjuvant chemotherapy for advanced gastric cancer with esophageal invasion].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dihydrouracil Dehydrogenase (NADP); | 2002 |
[A patient with advanced gastric cancer surviving for more than 5 years after neoadjuvant chemotherapy and curative resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Duodenal Ne | 2002 |
Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemo | 2002 |
[A case of hepatic metastasis from rectal carcinoma successfully treated with pharmacokinetic modulating chemotherapy (PMC)-CPT-11 therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality | 2002 |
Results of multimodality therapy for squamous cell carcinoma of maxillary sinus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2002 |
An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cyclo | 2002 |
Mesorectal microfoci adversely affect the prognosis of patients with rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
[5-fluorouracil inhibits the collagenolytic activity of invasive colonic adenocarcinomas in vitro].
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Microbial Colla | 1978 |
Effect of microtubule inhibitors on malignant invasion in vitro.
Topics: Benzimidazoles; Carbamates; Colchicine; Culture Techniques; Demecolcine; Fluorouracil; Microtubules; | 1978 |
Chemotherapy of gastrointestinal cancer.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Fluorouracil; Gastrointestinal Neoplasms; Humans; Ne | 1979 |
[Breast neoplasms. Staging, therapy and after care].
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immunot | 1978 |
Nonresectable adenocarcinoma of the rectum assessed by MR imaging before and after chemotherapy and irradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1992 |
[Problems with topical therapies for extensive squamous cell carcinoma of the buttocks].
Topics: Administration, Topical; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Buttocks; Carcin | 1991 |
[Preoperative radiotherapy with concomitant chemotherapy in the treatment of infiltrating cancers of the bladder].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1991 |
[Effective continuous intraarterial chemotherapy for a patient with FIGO stage IIIb cervical adenocarcinoma invasing the bladder wall].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Hum | 1990 |
Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1986 |
Increased contraenvironmental-pressure cell division capability: a decisive force in metastasis and invasion of mouse lung adenocarcinoma cell lines.
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line; Clone Cells; Fluorouracil; Lung Neoplasms; Mice; | 1989 |
A new treatment for invasive squamous cell bladder cancer: the Nigro regimen: preoperative chemotherapy and radiation therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1988 |
[Combination transurethral resection and systematic chemotherapy as primary treatment of infiltrating bladder tumors (pT2-pT4 NxM0)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 1988 |
Preoperative irradiation and 5-fluorouracil suppository for carcinoma of the rectum.
Topics: Aged; Combined Modality Therapy; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neop | 1988 |
Cell kinetics in selection and stratification of patients for adjuvant therapy of breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma in Situ; Cell Cy | 1986 |